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Riassunto 
I vaccini glicoconiugati sono uno degli strumenti più efficaci per la prevenzione delle infezioni 
batteriche. Sono composti da un antigene saccaridico scarsamente immunogenico, che viene 
covalentemente legato ad una proteina carrier non solo per aumentarne l’immunogenicità, ma anche 
per convertirne la risposta immunitaria da T-indipendente a T-dipendente, garantendo memoria 
immunologica. Tipicamente tali vaccini sono ottenuti come miscele eterogenee e complesse di poli 
o oligosaccaridi estratti dalle colture batteriche. 
La sintesi chimica è un nuovo approccio per sviluppare vaccini glicoconiugati che presenta diversi 
vantaggi tra cui evitare la contaminazione con impurezze batteriche e introdurre un linker per la 
coniugazione all’estremità riducente dell’oligomero.  
Nuove tecniche come la sintesi automatizzata in fase solida e la sintesi chemo-enzimatica hanno 
inoltre permesso di ridurre i tempi di sintesi e diminuire l’utilizzo di gruppi protettivi durante i vari 
step sintetici, permettendo una produzione di oligomeri su scala industriale. 
Negli ultimi anni, l’utilizzo di nanoparticelle è stato proposto come delivery systems anche per i 
vaccini a base saccaridica. Le nanoparticelle d’oro (AuNPs) hanno attratto la loro attenzione in 
questo campo grazie alle loro caratteristiche, alla loro biocompatibilità e facile produzione. Infatti, 
negli ultimi anni AuNPs sono state testate come carrier per oligosaccaridi in modelli animali. 
Delle nanoparticelle naturali sono le Generalized Modules for Membrane Antigen (GMMA). Le 
GMMA sono Outer Membrane Vescicles (OMV) che sono rilasciate naturalmente durante la 
crescita di batteri manipolati geneticamente per aumentare il grado di produzione delle vescicole e 
ridurre la loro tossicità. Come per altri nano-sistemi, le GMMA possono presentare in maniera 
multivalente gli antigeni, favorendo l’attivazione delle cellule B, ma hanno anche il vantaggio di 
presentare un effetto self-adiuvante. 
In questo lavoro di tesi, oligosaccaridi corti di Streptococco di Gruppo A vengono sintetizzati e 
coniugati alla proteina carrier CRM197 (Cross-Reacting Material 197) per valutare la loro 
antigenicità comparandola al coniugato del polisaccaride naturale. Gli stessi oligomeri verranno 
coniugati alle GMMA e alle AuNPs per confrontare le GMMA come carrier alternativo alla 
proteina carrier CRM197 e verificare se l’effetto multivalente delle AuNPs può aumentare l’affinità 
di legame tra gli antigeni oligosaccaridici e gli anticorpi 
 
Abstract 
Glycoconjugate vaccines are one of the most effective ways of preventing bacterial and fungal 
infections. They are generally composed of a saccharide antigen covalently linked to a carrier 
protein to convert the saccharide from a T-independent to a T-dependent antigen, resulting in 
increased immunogenicity from infancy and memory response. 
Currently, most of the conjugate vaccines are produced from polysaccharides extracted and purified 
from bacterial cultures. However, use of synthetic oligosaccharides constitutes a promising 
alternative approach. Synthetic saccharides have well-defined structure and can be equipped with a 
linker at their reducing end for selective conjugation allowing sugar epitopes preservation. 
Moreover, synthetic conjugates allow to avoid the handling of pathogens and presence of bacterial 
impurities and are characterized by minimal batch-to-batch variability and higher quality control 
standards compared to conjugates with native polysaccharides. New techniques such as solid phase 
automated synthesis and chemo-enzymatic approaches reduce reaction time and use of protective 
groups during synthetic steps and favor oligosaccharides production at large scale.  
In addition, nanoparticles have been recently proposed as potential multivalent delivery systems 
also for carbohydrate-based vaccines. Gold nanoparticles (AuNPs) have attracted great attention in 
this field due to their unique characteristics of biocompatibility and easy production. In the last 
years, AuNPs have been tested as carrier for short synthetic oligosaccharides in animal models.  
Natural nanoparticles can be obtained by the methodology called Generalized Modules for 
Membrane Antigens (GMMA). GMMA are Outer Membrane Vescicles (OMV) naturally released 
from Gram-negative bacteria genetically manipulated to increase blebbing and reduce toxicity. 
Similar to other nanoparticle systems, GMMA combine the multivalent display of carbohydrates, 
favoring B-cell activation and in a conformation that resembles on native bacteria, with optimal size 
for immune stimulation. GMMA also work as self-adjuvants, due to the presence of structures 
acting as agonist of Toll-like receptors 2 and 4, two receptors expressed on antigen presenting cells 
surface playing a crucial role in the innate immune response. 
Here the chemical synthesis to obtain oligosaccharide fragments of Group A Carbohydrate (GAC) 
and the preparation of the corresponding glycoconjugates with CRM197 (cross-reacting material 
197, a non-toxic mutant of diphtheria toxin) carrier protein have been reported. The main aim was 
to explore such synthetic structures for the development of a vaccine against Group A 
Streptococcus (GAS) disease for which no vaccine is currently available. The use of well-defined 
synthetic structures will help to better understand the impact of GAC structural features on the 
immune response induced. Synthetic oligomers have been conjugated to GMMA and AuNPs, with 
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the aim to i) compare GMMA and CRM197 as carrier systems, and ii) to explore multivalency on 
AuNPs to increase antibodies binding affinity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 
 
CONTENTS 
1 INTRODUCTION ............................................................................................................................ 1 
1.1 General principles of vaccination .................................................................................................. 1 
1.2 Carbohydrate-based vaccines ......................................................................................................... 3 
1.3 Glycoconjugate vaccines ................................................................................................................ 4 
1.4 Advantages to use synthetic oligosaccharides for vaccine development ....................................... 5 
1.5 Alternative carrier system to develop glycoconjugate vaccines .................................................... 6 
1.5.1 Glyco Gold-Nanoparticles (AuNPs): an inorganic core for oligosaccharide ............................. 6 
1.5.2 Generalized Modules for Membrane Antigens (GMMA) .......................................................... 7 
1.6 Group A Streptococcus: a disease in need of a vaccine ................................................................. 9 
1.7 The M protein and vaccine currently in use ................................................................................. 10 
1.8 Group A Carbohydrate (GAC) as universal GAS antigen ........................................................... 10 
1.9 Polyrhamnose: an alternative antigen to develop aGAS vaccine ................................................ 12 
 
2 AIM OF THE PROJECT ................................................................................................................ 14 
2.1 Synthetic approach to develop aGAS glycoconjugate vaccine .................................................... 14 
2.2 Investigation of multivalent nanosystem for vaccine development ............................................. 16 
 
3 RESULT AND DISCUSSION ....................................................................................................... 18 
3.1 Synthesis of oligorhamnoses: tetraRha and hexaRha .................................................................. 18 
3.2 Synthesis of GAC dimer .............................................................................................................. 20 
3.3 Synthesis and characterization of CRM197 conjugates ................................................................. 24 
3.3.1 Conjugation of oligosaccharides to CRM197 by SIDEA chemistry .......................................... 24 
3.3.2 Conjugation of tetraRha and hexaRha to CRM197 by maleimido chemistry ............................ 27 
3.3.3 Conjugation of tetraRha and hexaRha to CRM197-SH by using the SBAP linker .................... 31 
3.4 Immunogenicity study in mice: oligo-SIDEA-CRM197 conjugates compared to GAC-CRM197 33 
3.5 STD-NMR of GAC-dimer, tetraRha and GlcNAc: is the GlcNAc an immunodominant epitope 
of GAC? .................................................................................................................................... 36 
3.6 Investigating multivalent antigen presentation ............................................................................ 40 
3.6.1 Salmonella Typhimurium GMMA as carrier for GAC and synthetic oligosaccharides ........... 40 
3.6.2 Immunogenicity study in mice: GMMAox-GAC conjugate compared to CRM197-GAC 
conjugate ................................................................................................................................... 45 
3.6.3 Synthesis, characterization and evaluation in competitive ELISA of glyco-AuNPs ................ 47 
 
7 
 
4 MATERIALS AND METHODS .................................................................................................... 50 
4.1 General method for the synthesis of CRM197 conjugates with SIDEA linker.............................. 50 
4.10 Particles size distribution characterization ................................................................................. 59 
4.10.1 Dynamic Light Scattering (DLS) ............................................................................................ 59 
4.10.2 Nanoparticle Tracking Analysis (NTA) .................................................................................. 59 
4.11 Immunogenicity of conjugates in mice ...................................................................................... 61 
4.2 General method for the synthesis of CRM197 conjugates with malemido chemistry ................... 50 
4.2.1 Derivatization of oligomers with N-acetyl homocysteine linker .............................................. 50 
4.2.2 Derivatization of oligomers with EMCS linker ........................................................................ 51 
4.2.3 Derivatization of tetraRha with SATA linker ........................................................................... 51 
4.2.4 Derivatization of CRM197 with N-acetyl homocysteine linker ................................................. 51 
4.2.5 Derivatization of CRM197 with EMCS linker ........................................................................... 52 
4.2.6 Conjugation reactions with CRM197-SH and oligoRha-EMCS ................................................ 52 
4.2.7 Conjugation reactions with CRM197-EMCS and hexaRha-SH ................................................. 52 
4.2.8 Conjugation reactions with CRM197-EMCS and hexaRha-SH ................................................. 53 
4.3 General method for the synthesis of CRM197 conjugates with SBAP linker ............................... 53 
4.4 Synthesis of GAC-ADH ............................................................................................................... 53 
4.5 General method for the synthesis of GMMA conjugates with BS
3 linker ................................... 54 
4.6 General method for the synthesis of GMMA conjugates with reductive amination chemistry ... 55 
4.7 General method for the synthesis of glycol-gold nanoparticles ................................................... 55 
4.8 General methods for glycoconjugates characterization ............................................................... 57 
4.8.1 Glycan quantification ................................................................................................................ 57 
4.8.2 Protein quantification ................................................................................................................ 57 
4.8.3 SDS-PAGE analysis .................................................................................................................. 57 
4.8.3 Size Exclusion High Performance Liquid Chromatography (SEC-HPLC) .............................. 58 
4.9 STD NMR experiments ............................................................................................................... 58 
 
5 CONCLUSIONS ............................................................................................................................. 62 
 
6 EXPERIMENTAL SESSION ......................................................................................................... 64 
 
7 REFERENCES................................................................................................................................ 65 
 
 
1 
 
1 INTRODUCTION 
1.1 General principles of vaccination 
Immune system is responsible to identify and kill invading agents, known as pathogens, from 
viruses to microbes (bacteria, parasites, fungi), and distinguish them from the healthy tissue through 
specific interactions. The immune system can be classified into subsystems, the innate immune 
system and the adaptive immune system (including humoral immunity and cell-mediated 
immunity). The innate response is usually triggered when microbes are identified by pattern 
recognition receptors (PRRs), which recognize components that are conserved among broad groups 
of microorganisms, the pathogen-associated molecular patterns (PAMPs). Innate immune defense is 
non-specific, meaning these systems respond to pathogens in a generic way. This system does not 
confer long-lasting immunity against a pathogen. Innate response is able to activate adaptive 
immunity when it does not prevail on the intruder. The adaptive immune system allows for a 
stronger immune response as well as immunological memory, where each pathogen is 
"remembered" by a signature antigen. The adaptive immune response is antigen-specific and 
requires the recognition of specific "non-self" antigens during antigen presentation. Antigen 
specificity allows for the generation of responses that are tailored to specific pathogens which is 
maintained in the body by memory cells. Should a pathogen infect the body more than once, these 
specific memory cells are used to quickly eliminate it. 
Vaccination takes advantage of this potential of adaptive immunity. Vaccination basically mimics a 
natural infection without causing disease by inducing in the host an immune response that leads to 
the production of antibodies (Abs). Abs are produced by B lymphocytes and they are able to 
recognize and specifically bind pathogen (or portion representative of it)1 to facilitate uptake and 
elimination of the pathogen by other immune cells. Other important immune effectors are cytotoxic 
CD8+ T lymphocytes (CTL) that may limit the spread of infectious agents by recognizing and 
killing infected cells or by secreting specific antiviral cytokines. The generation and maintenance of 
both B and CD8+ T cell responses is supported by growth factors and signals provided by CD4+ T 
helper (Th) lymphocytes, which are historically subdivided into T helper 1 (Th1), T helper 2 (Th2) 
and T helper 17 (Th17) subtypes. These effector cells are controlled by regulatory T cells (Treg) 
that are involved in maintaining immune tolerance2. Most of the antigens and vaccines trigger both 
B and T cell responses, and the two responses are interconnected: CD4+ T cells are required for 
most Abs responses, while Abs confer significant influences on T cell responses to intracellular 
pathogens3.  
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The stimulation of antigen-specific T cell responses requires their activation by specific antigen 
presenting cells (APCs), basically dendritic cells (DCs) recruited by inflammatory signals to the site 
of infection. APCs present antigens on Major Histocompatibility Complex (MHC) class II 
molecules, which is recognized by Th CD4+. The activation of a resting helper T cell induce T cell 
to release cytokines and other stimulatory signals that stimulate the activity of macrophages, CTL 
and B cells, the latter producing Abs. The stimulation of B cells and macrophages succeeds a 
proliferation of T helper cells. 
The central role for mature DCs in the activation of vaccine responses reflects their unique ability to 
provide both antigen-specific and co-stimulation signals to T cells. In fact, T cells require at least 
two signals to become fully activated: i) a first antigen-specific signal provided through the T cell 
receptor which interacts with the antigen peptide-loaded MHC class II molecules on the surface of 
the APCs; ii) a second antigen-unspecific signal, a co-stimulatory incentive, provided by the 
interaction between co-stimulatory molecules expressed on the membrane of the APCs upon 
maturation with its counterparts on the T cell.  
 
 
Figure 1: T-cell independent and dependent responses. 
 
The very first requirement to elicit vaccine responses is thus to provide sufficient stimuli through 
vaccine antigens and eventually adjuvants, to trigger an inflammatory reaction that is mediated by 
cells of the innate immune system4. The protective efficacy of a vaccine is often conferred by 
microorganism-specific Abs, but just triggering a specific Abs response is not enough. The quality 
of Abs responses, such as Abs avidity has been identified as a determining factor of efficacy. 
Although B lymphocytes represent the main driver of Abs production once differentiated in plasma 
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cells, T cells can largely contribute to effective and long-lasting immune responses. Indeed, these 
cells are essential to immune memory, and novel vaccine targets have been identified against which 
T cells are likely to be the prime effectors. 
In general, the Abs response to bacterial polysaccharides is poorly affected by adjuvants, IgM 
represents the major class of antibodies induced and since their immune response does not induce 
memory, it is not boosted by subsequent immunizations (Figure 1). 
Polysaccharides are T-cell independent (TI) antigens as they do not require T-cell activation for the 
induction of specific B-cell (Abs) responses. Polysaccharides directly activate polysaccharide-
specific B cells which differentiate then into plasma cells to produce Abs, but memory B cells are 
not formed. Moreover a pre-existing memory B-cell pool can be depleted by immunization with 
unconjugated polysaccharide, with risk of hypo-responsiveness on subsequent immunizations5. 
Differently from polysaccharides, proteins are T-cell dependent (TD) antigens; following 
interaction with APC (like DCs) macrophages and B-cells, protein antigens are internalized and 
processed into small peptides which are then re-exposed and presented to T lymphocytes in 
association with the MHC class II molecules. Interaction with T cells induces B cells to 
differentiate into plasma cells and memory B cells, thus initiating downstream adaptive immune 
responses. TD antigens are immunogenic early in infancy and the immune response induced can be 
boosted, enhanced by adjuvants and it is characterized in the production of antigen-specific IgG. 
 
1.2 Carbohydrate-based vaccines 
Polysaccharides are important virulence factor that are present on bacteria surface. They are specific 
for each bacterium and can be either polymers formed by one monosaccharide unit (homopolymers) 
or more complex oligosaccharide repeats (heteropolymers), that can be charged or neutral. 
Surface polysaccharides have several functions: smooth surface and negative charge limits the 
ability to enhance phagocytosis. They protect microorganisms from desiccation when they are 
exposed to the external environment (an example is the hyaluronic capsule of Group A 
Streptococcus, whose adhesive properties help the pathogen to invade the host); mimic molecules 
produced by human cells so that the pathogen is not recognized as foreign by immune system 
(serogroup B meningococcal capsular polysaccharide, hyaluronic acid). 
In 1945 the first vaccine composed by purified polysaccharides from selected pneumococcal 
serotypes was tested in humans6. 
Polysaccharide vaccines against meningococcus serogroups ACWY, Streptococcus pneumoniae 
and Haemophilus influenzae type b were licensed between the seventies and the eighties,7,8 but they 
did not completely solve the problem of bacterial diseases caused by encapsulated microorganisms. 
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Being T-cell independent antigens, one of their main features which emerged from clinical trials, 
was their scarce immunogenicity in children under two years of age.9,10 Consequently, 
polysaccharide vaccines can be used in adults, but not in infancy and elderly which are the most 
sensitive target populations. 
 
1.3 Glycoconjugate vaccines  
The limitation of carbohydrate-based vaccines can be overcome by covalent linkage of the 
carbohydrate moiety to a carrier protein as source of T-cell epitopes to make a glycoconjugate. 
The first application of this concept to a vaccine for human use started in 1980 with the 
development of the first conjugate vaccine against Haemophilus influenzae type b (Hib) that was 
later on licensed between 1987 and 1990.11,12 Glycoconjugate vaccines are among the safest and 
most efficacious vaccines developed during the last 30 years. They are a potent tool for prevention 
of life-threatening bacterial infectious disease; in fact, many other glycoconjugate vaccines have 
been licensed against bacterial pathogens such as Neisseria meningitidis, Streptococcus 
pneumoniae. 
Many parameters of glycoconjugate vaccine can influence the immune response: the nature of the 
carrier protein, the site used for conjugation (random approach vs site specific approach), the 
glycan/protein ratio, the length of glycan, the chemistry used for conjugation13. 
 
 
Figure 2: different approach for glycoconjugate synthesis. 
 
Two main approaches are employed to prepare glycoconjugate vaccine (Figure 2). One is based on 
the random chemical activation of the glycan followed by covalent binding with the protein 
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obtaining a cross-linked structure between the polysaccharide and the protein. A second approach is 
based on the generation, by controlled fragmentation of the native polysaccharide, of appropriately 
sized oligosaccharides which are then activated at their terminal groups, usually with a linker 
molecule, and subsequently conjugated to the carrier protein obtaining a radial structure. Depending 
on the conjugation chemistry employed, a linker molecule can be used in order to facilitate the 
coupling between the protein and the saccharide chains and, in some cases, preliminary 
derivatization of the protein carriers is also required. 
Bioconjugation is the new approach to prepare glycoconjugates, based on glyco-engineering of the 
bacterial N-glycosylation pathway in bacteria such as Escherichia coli. The polysaccharide, 
encoded by the inserted genes, is produced on a polyisoprenoid carrier then transferred to an 
asparagine residue of the carrier protein which has to contain at least one (native or engineered) N-
glycosylation site.14,15 
Different clinical trials have been conducted to compare the immunogenicity of different conjugate 
vaccines with different carrier proteins.16–20 It is very difficult to make a direct comparison of the 
effect of different protein carriers, due to the coexistence of other variables as conjugation 
chemistry, saccharide chain length, adjuvant, formulation technology, and previous or concomitant 
vaccination with other antigens. 
In the last years, studies about the role of saccharide/protein conjugation site on influencing 
immunogenicity were reported.21 Two studies were conducted on CRM197 (cross-reacting material 
197, a non-toxic mutant of diphtheria toxin) to understand if there are predominant attachment sites 
when random conjugation at lysines occur.22,23 6 out of the 40 lysine residues came out as the most 
exposed ones, but a complete control of conjugations to lysines is not possible. To overcome this 
problem, a novel conjugations strategy allowed selective introduction of synthetic oligosaccharide 
or polysaccharide on other residues such as tyrosines or disulfide bond.24,25 
 
1.4 Advantages of synthetic oligosaccharides in vaccine development 
Currently, most of the conjugate vaccines are produced from poly- or oligosaccharides extracted 
and purified from microbial cultures5. However microbial contamination (such as endotoxins) and 
heterogenicity (capsular polysaccharide fragments of different size) are inevitable drawbacks. 
Synthetic approach provide well-defined, homogeneous and characterized oligosaccharides useful 
to support structural analyses to reveal protective epitopes, especially when carbohydrates are 
composed by complex structure.26 
The use of synthetic oligosaccharides for vaccine development has many advantages: i) in theory, a 
well-established and optimized synthetic route can provide a much higher amount of carbohydrate 
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antigens than the natural source; ii) the fermentation of pathogenic bacteria is avoided; iii) 
possibility to evaluate the influence of antigen chain length, density and structure on 
immunogenicity; iv) introduction of a single reactive group per molecule for covalent conjugation, 
consistency and easiness of characterization; v) reproduciblity of biological process and high safety 
profile; vi) the use of automated system for the synthesis of oligosaccharides can facilitate the 
implementation of a synthetic vaccine approach at industrial scale. 
There are a lot of examples of glycoconjugate vaccines exploiting synthetic glycan antigens27 to 
combat bacterial and fungal infections at preclinical and clinical level. The feasibility of this 
approach has been shown by the licensing of QuimiHib®,28 a glycoconjugate vaccine against 
Haemophilus influenzae type b, which is a second generation vaccine of synthetic glycan 
conjugated to TT carrier protein.27,28 
In the last years, also the enzymatic synthesis of oligosaccharides was developed and generally it 
gives high yields, with complete regio- and stereospecificity without the need of installation and 
removal of a large number of protecting and activating groups. When combined, chemical and 
enzymatic approaches can lead to the production of well-defined synthetic oligosaccharides, 
avoiding huge synthesis timelines above all when challenging structures motifs and/or 
oligosaccharides with several repeating units are needed.29 
 
1.5 Alternative carrier system to develop glycoconjugate vaccines 
1.5.1 Glyco Gold-Nanoparticles (AuNPs): an inorganic core for oligosaccharide 
The growing interest in nanoscience, the discipline aimed at the preparation and manipulation of 
materials at a nanometric scale, has led to in-depth study of the properties of organic-inorganic 
hybrid materials.30 These materials present new collective chemical-physical properties due to the 
interaction between organic and inorganic units and they find numerous applications in different 
fields such as electronics, catalysis,  and biomedical. 
Among the large number of nanomaterials, gold nanoparticles (AuNPs) offer great potential for 
many applications due to their biocompatibility, low toxicity, chemical stability, and plasmonic 
features. Thanks to the high surface/volume ratio and to the easy surface functionalization which 
exploits the strong Au-S bond (~50 Kcal/mol), AuNPs are suitable polyfunctional scaffolds to 
explore the multivalent presentation of antigens (Figure 3).31 Moreover, some examples of 
carbohydrate antigens conjugated to AuNPs showing high in vivo immunogenicity have been 
already reported.32 
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Figure 3: AuNPs coated with carbohydrates. 
 
The AuNP-based multivalent systems have been explored in the field of carbohydrate-based 
vaccine and AuNPs coated with synthetic glycan can be used as nanocarriers to improve the 
enhancement of immune response. The introduction of a T-cell helper on AuNP surface can trigger 
a T-dependent response and glyco-AuNPs can be considered as novel platform for vaccine 
development.31–33 The examples in the use of AuNPs as nanocarriers for vaccine development has 
been reported for Streptococcus Pneumoniae type 14 and type 19F and by Neisseria Meningitidis 
serogroup A.31 In each case, AuNPs were coated with the glycan antigens and the ovalbumin (OVA 
323-339) T-cell helper peptide. The nanosystems were able to induce high Abs titers and the size of 
AuNPs has an impact on the immune response. Indeed, it is known that multivalency depends on 
the size and morphology of AuNPs and, as consequence, can influence the immune response 
induced. 
 
1.5.2 Generalized Modules for Membrane Antigens (GMMA) 
Gram-negative bacteria naturally release outer membrane vesicles (OMV) during the growth.34,35 
The genetic modification of bacteria induce over blebbing of OMV, known as Generalized Modules 
for Membrane Antigen, GMMA (Figure 4).36 
 
 
Figure 4: Generalized Modules for Membrane Antigens (GMMA) blebbing. 
 
GMMA contain the membrane antigens, like proteins, lipids, and the lipopolysaccharide (LPS), the 
main virulence factor of Gram-negative bacteria. Different genetic modification of bacteria can be 
introduced in order to detoxify LPS of resulting GMMA, modulating the degree of acyl chains of 
Lipid A.37 GMMA can be obtained in high yield and with low production and manufacturing costs 
compared to classical vaccines. OMV-based vaccines have been successfully developed and used, 
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i.e. BexSero®, MenBvac®, MeNZB, and other promising vaccine against Bordetella pertussis,38 
Burkholderia pseudomallei39,40 and Vibrio cholerae41,42 were tested. The main problem of OMV 
vaccines is the manipulations of large volume of bacteria for the manufacturing and the safety due 
to LPS for administration in humans. GMMA based vaccine can overcome these limits. 
The advantages in the use of GMMA for vaccine development are many: they present optimal size 
for immune-stimulation (~100 nm), adjuvant effect, ability to be uptaken from mammalian cells and 
can result in a multivalent vaccine. Indeed, it is possible to delete the undesired antigens or 
overexpress the desired antigens using a combination of different and subsequent genetic 
modification.43,44 Because of their composition which combines proteins and components activating 
the immune system (TLR2 and TLR agonists), GMMA hold the potential to be used as carrier 
alternative to more traditional proteins (TT, CRM197).
45 
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1.6 Group A Streptococcus: a pathogen in need of a vaccine 
Streptococcus pyogenes (Group A streptococcus, GAS) is a Gram-positive bacterium with a 
diameter of 0.5-1.0 μm that grows in long chain, 1-2 mm colonies, with β-hemolytic activities after 
24 hours. GAS is an optional anaerobic bacterium, capsulated, asporigen, with homolactic 
metabolism and catalase negative. GAS cell wall consists of several proteins: R and T proteins are 
epidemiologic markers; the M protein (encoded by emm gene) is the most virulence factor and 
responsible of more than 200 emm serotypes. GAS is surrounded by a peptidoglycan layer 
consisting in N-acetylglucosamine and N-acetylmuramic acid repeating units, while the capsule is 
composed of hyaluronic acid46 (Figure 5). The cell surface exposes also a carbohydrate, the 
Lancefield Group A Carbohydrate (GAC), consisting of -L-Rhap(1→3)--L-Rhap(1→2)-[-D-
GlcpNAc-(1→3)] repeating units.47,48 
 
 
Figure 5: Group A Streptococcus. 
 
Distribution of GAS emm types varies according to geographic and socio-economic factors. In 
industrialized countries (Europe, United States, New Zealand) a significant percentage of GAS isolates 
belongs to emm types 1, 3, 12 and 28 and are responsible for 40% of disease in these countries, while in 
developing countries (Africa, Asia) they are less common.49,50,51 
GAS cause a large range of superficial infections, like pharyngitis, scarlet fever and impetigo, and post- 
infection sequelae, like acute rheumatic fever, rheumatic hearth disease and acute poststreptococcal 
glomerulonephritis which are predominant in impoverished communities. Acute rheumatic fever and 
rheumatic hearth disease are the major cause of heart disease in children, adolescents and young adults 
responsible of more than 350,000 deaths per year among children aged 5-14 years. The cases of 
pharyngitis and scarlet fever are greater than those of more severe disease; although, these diseases seem 
relatively unimportant they cause significant healthcare-related social costs, in particular because of the 
use of antibiotics50. 
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GAS is resistant to immune defense system of the host thanks to the presence of surface-bound and 
secreted virulence factors. Moreover, it is resistant to opsonophagocytosis due to the presence of 
complement inhibitors, like M protein, leukocidal toxins and immunoglobulin (Ig) binding proteins.51 
 
1.7 The M protein and vaccine currently in use 
There are no safe and efficacious licensed vaccine against GAS due to the diversity of GAS emm strains, 
antigenic variation and differences in the geographical distribution of serotypes. Moreover, the 
autoimmune reaction raised by GAS antigen represent an additional critical issue.50,52 
The main driver of autoimmunity is the M protein which is formed by 3 domains: the N-terminal 
domain, highly variable and responsible of emm types differentiation; the B-repeat domain, 
inducing not-opsonic Abs; the C-repeat domain, that is highly conserved.53 Several studies involved 
M protein formulation administered to human volunteers followed by challenge with GAS bacteria, 
resulting in decreased GAS colonization but increased incidence of acute rheumatic fever in 
immunized subjects.50,53 Several M protein-based vaccines have been investigated using the N-
terminal region of the protein that maybe is not involved in autoimmunity.54 There are three 
formulations of M protein-based vaccine: a hexavalent preparation54, a 26-valent preparation55 and 
a 30-valent formulation, currently, the only one in clinical Phase I56 which is well tolerated by adult 
volunteers. The main problem of these vaccines is that they are protective only against the serotypes 
included in the formulation. To overcome this problem, other M protein-based vaccines have been 
designed using the highly conserved C-region of the M protein, since this can eliminate concerns 
about autoimmunity57. These vaccines, J8 and J14, contain shorter B cell epitopes from C-region of 
M protein and induced protective and bactericidal Abs.58–60 
 
1.8 Group A Carbohydrate (GAC) as universal GAS antigen 
The group A carbohydrate (GAC), composed of -L-Rhap(1→3)--L-Rhap(1→2)-[-D-GlcpNAc-
(1→3)] repeats3 (Figure 6), is a polysaccharide exposed on the cell wall of GAS. Since this polysaccharide 
is preserved and expressed by all GAS serotypes and, therefore, it has been considered a common antigen 
to develop a GAS vaccine. Indeed, GAC conjugated to tetanus toxoid (TT) induces high Abs titers in 
rabbits.61  
In 2005, Sabharwal et al. reported that GAC-TT conjugate is able to induce Abs titers in animal model and 
humans and the titers of these Abs increase with increasing age. The raised Abs were opsonic and induced 
protection after active and passive challenge in mice.61,62 
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Figure 6: Group A Carbohydrate (GAC) repeating unit. 
 
Several studies have been published about the use of GAC oligosaccharides in order to identify the 
minimal epitope recognized from Abs. The synthetic strategy used to prepare GAC trisaccharide 
and GAC hexasaccharide (GAC dimer) was reported by M. Pinto and coworkers. An efficient and 
convergent synthesis of GAC oligosaccharides was achieved in 1996 by the same group, following 
a strategy that limit the number of protections and deprotections to prepare an allyl glycoside for 
conjugation to a carrier protein. The oligomers were conjugated to BSA (bovine serum albumin) 
and Ovalbumin carrier proteins using N-acryloylated or diethyl squarate linkers.63–65 
Epitope mapping studies were conducted to understand the minimal epitope recognized by 
monoclonal Abs (mAbs) using STD-NMR and other bidimensional NMR experiments. STD-NMR 
spectra of the trisaccharide were acquired in the presence of mAbs resulting in a strong 
enhancement of GlcNAc signal, especially the acetyl group. The STD-NMR spectra of GAC dimer 
showed an extended pattern of signals: the strongest binding is with GlcNAc, while the weak 
interaction was observed between the mAbs and the methyl group of Rha units, suggesting that the 
GlcNAc is the immunodominant epitope recognized, while the Rha residues are an extended surface 
of binding.66,67 In 2011, Kabanova et al reported the conjugation to CRM197 of GAC dimers and 
tetramers bearing an amino linker at the reducing end and presenting the GlcNAc residue at the 
upstream end or within the backbone protein68 (Figure 7). These conjugates were fully characterized 
and used for mice immunization with the GAC-CRM197 conjugate as positive control. 
 
 
Figure 7: GAC oligosaccharides used for study in mice in reference [67] 
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The conjugated oligosaccharides showed Abs titers comparable to the native GAC. Furthermore, 
they induced protection against two GAS isolates of M1 and M23 serotypes after challenge. Of 
note, the GAC dimer and tetramer conjugated to CRM197 induced similar Abs titers, regardless of 
the GlcNAc position, however the loading on protein was higher for the shorter oligomers. 
Therefore, higher levels of glycan incorporation onto the protein could compensate the shorter 
length. Recently, M. Pinto et al. reported the mice immunization with conjugates of synthetic GAC 
dimer to TT carrier protein.69 They confirmed the immunogenicity of the GAC dimer-TT conjugate 
by primary and secondary Abs response (IgM and IgG response). The Abs titers were similar to 
GAC-TT conjugate, according to the data reported by Kabanova. Collectively these data indicate 
that the GAC dimer has a sufficient chain length to be used as a potential synthetic structure to 
develop an anti-GAS glycoconjugate vaccine. 
 
1.9 Polyrhamnose: an alternative antigen to develop a GAS vaccine 
GAS causes an autoimmune response that leads to rheumatic disease and the main driver of 
autoimmunity is the M protein. During the last years, it was hypothesized that GlcNAc side chain of 
GAC can induce cross-reactive Abs relevant to immunopathogenesis of rheumatic diseases.70 
Monoclonal Abs against the GlcNAc epitope of GAC were proved able to recognize myosin, a 
protein associated with myocarditis and rheumatic disease.  
Glycoproteins from human heart valves, when used to immunize rabbits, produce antibodies that 
bind GAC in a manner inhibited by GlcNAc (but not by rhamnose and other sugars), and 
persistence of anti-GlcNAc/GAC antibodies (from 1 to 20 years) are a marker of poor prognosis of 
heart valve problems in rheumatic heart disease, whereas antibodies against streptolysin O and the 
polyrhamnose core of GAC decline independently of valve complications. The specificity and 
persistence of elevated anti-GAC (GlcNAc) antibody titers for rheumatic mitral valve heart disease 
was also suggested in a study of 30 patients versus equal-sized control groups of individuals, 
patients with congenital heart disease, and patients with nonrheumatic mitral valve prolapse. 
Finally, anti-GlcNAc monoclonal antibodies (mAbs), cross-reactive for heart or brain tissue, have 
been derived from patients with rheumatic fever and related cardiac or neurological 
complications.71 
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Figure 8: GAC repeating unit and polyRha repeating unit. 
 
Moreover, it has been reported that Abs to GAC lacking the GlcNAc side chain and containing only 
the polyrhamnose (polyRha) backbone (Figure 8) promoted opsonophagocytic killing of multiple 
GAS strains and protected against systemic GAS challenge after passive immunization.71 
Henningham et al proposed that GlcNAc side chain is a virulence factor in the context of other 
antigens.72 The GlcNAc side chain contributes to innate immune resistance of serotype M1 of GAS 
but the relative contribution is different among individual strains and, consequently, the GlcNAc 
could not be a universal prerequisite for GAS virulence in animal model that depends on the relative 
contribution of other virulence factors that each strain possesses. 
Based on these findings, polyRha has been proposed as alternative antigen to develop an anti-GAS 
glycoconjugate vaccine. 
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2 AIM OF THE PROJECT 
2.1 Synthetic approach to develop an anti-GAS glycoconjugate vaccine 
GAS causes a range of diseases, from simple superficial skin infections and pharyngitis to severe 
invasive infections.49 As reported in the introduction, GAC, a conserved surface polysaccharide 
comprising -L-Rhap(1→3)--L-Rhap(1→2)-[-D-GlcpNAc-(1→3)] repeats, has been proposed for 
the design of an efficacious anti-GAS glycoconjugate vaccine.62 
Although the main driver of GAS autoimmune responses is the so-called M protein,50 some studies 
have linked GlcNAc side chain of GAC with cross-reactive epitopes that might also be responsible 
for rheumatic diseases.71 On the other hand, it has been shown that Abs induced by the polyRha 
backbone alone promote opsonophagocytic killing of multiple GAS strains and, therefore, polyRha 
could be an alternative to GAC for a broadly conserved vaccine candidate against GAS infections. 
Synthetic GAC oligosaccharides (hexasaccharides and dodecasaccharides, Figure 7), conjugated to 
CRM197 carrier protein, have been tested as vaccine antigens in a mouse challenge model showing 
similar immunoprotection to conjugates of native GAC.68 Two repeating units (GAC-dimer) have 
been reported as the minimal GAC epitope that could secure efficient opsonophagocytosis and 
protection.73 
 
 
Figure 9: Synthetic target: tetraRha 1, hexaRha 2, GAC-dimer 3. 
 
In this context the major aim of my PhD project was the synthesis of oligorhamnose (oligoRha) 
structures with two different chain length, tetraRha 1 and hexaRha 2, and the dimer structure of two 
repeating units of GAC (GAC-dimer 3) (Figure 9). Such oligomers have been conjugated to 
CRM197 carrier protein. Immunological evaluation in mice of these well-defined constructs, in 
comparison to native GAC, helps to clarify the role of GlcNAc residues and polyrhamnose 
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backbone in the immune response induced by GAC glycoconjugate. In particular, the first objective 
was to clarify if oligoRha can be an antigen to develop a GAS vaccine. It is reported that 
polyrhamnose extracted from modified GAS bacteria was recognized by an autoreactive human 
mAb derived from a patient with rheumatic carditis.71 However the use of synthetic well-defined 
and purified structures conjugated to a carrier protein helps clarify the role of polyRha core of GAC 
during the immune response. Two different length of oligorhamnoses were chosen: tetraRha 1 has 
the same number of rhamnose units of GAC-dimer 3, which is known to raise high Abs titers 
comparable to the native GAC polysaccharide.68 HexaRha 2 is one unit longer than tetraRha 1 to 
understand if the chain length can have an impact during the immune response induced. 
Different conjugation chemistries have been explored to find the best conditions for preparing 
glycoconjugates with synthetic oligomers. The use of well-defined and purified oligosaccharides to 
make a conjugate can allow to use a site-selective conjugation approach instead of the random 
approach resulting in higher synthetic reproducibility compared to the conjugate of the native GAC. 
Moreover, shorter oligosaccharide can allow to evaluate the influence of antigen chain length and 
density on the immunogenicity. 
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2.2 Investigation of multivalent nanosystem for vaccine development 
Recently, different kinds of nanosized systems have been used as alternative carriers to more 
traditional proteins.74 In this context, the GSK Vaccines for Global Health (GVGH) Institute is 
using GMMA as carriers for protein and polysaccharide antigens. GMMA are OMV naturally 
released from Gram-negative bacteria that are genetically modified to enhance the level of particles 
produced and reduce reactogenicity.37,43 Here, Salmonella Typhimurium GMMA will be used as 
carrier for native GAC and GAC oligomers (tetraRha 1, hexaRha 2 and GAC-dimer 3 showed in 
Figure 9), with the potential to result in a vaccine covering both nontyphoidal Salmonella44 and 
GAS diseases. Different conjugation chemistries will be explored – targeting LPS or proteins on 
GMMA surface (Figure 10) to evaluate possible impact on glycan loading and immune response 
induced. 
 
 
Figure 10: Strategy of GMMA conjugates synthesis: targeting the GMMA protein with a linker and targeting the LPS 
of GMMA with reductive amination reaction after oxidation of LPS sugar units. 
 
Alternatively, AuNPs are suitable polyfunctional scaffolds to explore the multivalent presentation 
of antigens.  
To explore the multivalency of AuNPs, two different types of AuNPs will be prepared, sphere and 
star, and will be coated with oligoRha 1 and 2. AuNPs will be tested as nanoscaffolds to increase 
antibodies (Abs) binding affinity. 
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3 RESULT AND DISCUSSION 
3.1 Synthesis of oligorhamnoses: tetraRha and hexaRha 
The synthesis of tetraRha and hexaRha has been performed starting from building blocks 4 and 5, 
already available in GSK Vaccines Lab (Adamo R.’s group). The synthetic approach followed had 
been already reported22 and it is summarized in Figure 11. 
 
 
Figure 11: Synthesis of tetraRha 1 and hexaRha 2. Reagents and conditions: i) a) Ir cat, THF, H2; I2, H2O; b) CCl3CN, 
DBU, DCM, 95% yield; ii) TMSOTf, DCM, 0°C, 75%-86% yield; iii) HO(CH2)3NHCbz, TMSOTf, DCM, 0°C, 60% 
yield; iv) NaOMe/MeOH, quantitative yield; v) H2O/EtOH 1:1 + 5% HCl, H2(20 bar), Pd/C, 90% yield. 
 
The allyl glycoside 7 was prepared from monosaccharides 4 and 5. Compound 5 was deallylated 
and activated as trichloroacetimidate, which is a good leaving group in the glycosylation step. The 
deallylation involves the use of Iridium catalyst and hydrogen to isomerize the allyl group; addition 
of iodine and water gives the hydrolysis. Then donor 6, needed to install the -L-Rhap(1→3)-α-L-
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Rhap(1→OAllyl) moiety, was prepared from the hemiacetal by reaction with trichloracetonitrile and 
DBU in 95% yield. Donor 6 reacted with acceptor 4 (0°C and trimethylsilyl triflate as promoter) to 
give disaccharide 7 in 75% yield, which is a key intermediate for both the donor and the acceptor 
leading to longer structures. Compound 7 was deallylated and activated as trichloroacetimidate. 
Benzyl N-(3-hydroxypropyl)-carbamate was reacted with donor 8 under the a before mentioned 
conditions leading to 9 in 60% yield. Deacetylation of 9 with sodium methoxide in methanol 
provided the disaccharide acceptor 10. This was reacted with the disaccharide donor 8 to obtain 
tetrarhamnose 11, in 86% yield. Next, 11 was deacetylated and compound 12 was glycosylated with 
donor 8 to obtain hexasaccharide 13, in 86% yield. 
Finally, target compounds 1 and 2 were obtained with two deprotection steps: deacetylation of the 
downstream rhamnose residue, followed by hydrogenolysis. The latter reaction was conducted at high 
pressure of hydrogen (20 bar) in the presence of Pd/C catalyst in EtOH/H2O 1:1 + 5% aq. HCl. Final 
products were obtained both in 90% yield. 
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3.2 Synthesis of GAC dimer 
The synthesis of oligoRha described in Figure 11 cannot be used to prepare the GAC-dimer because 
the introduction of the GlcNAc residues requires an orthogonal protective group at 3-OH of the two 
rhamnose units to be glycosylated. The naphtyl group was chosen as additional and orthogonal 
protecting group and three new monosaccharide building blocks were prepared: the acceptor 22 
(bearing the linker moiety), the donor precursor 28 and the allyl glycoside acceptor 30 (Figure 12).  
 
 
Figure 12: Synthesis of building blocks 22, 28 and 30. Reagents and conditions: i) I2, Ac2O, quantitative yield; ii) 
HO(CH2)3NHCbz, BF3Et2O, DCM, 0°C→rt, 62% yield; iii) a) MeONa/MeOH; b) (CH3O)2C(CH3)2/DCM 4:1, p-TsOH, 
85% yield; iv) NaH, BnBr, DMF, 72%-95% yield; v) TFA 50%, DCM, quantitative yield; vi) Bu2SnO, toluene; NapBr, 
TBAI, 45°C, 54%-58% yield; vii) DDQ, DCM/MeOH 4:1, 82% yield; viii) CH2CHCH2OH, BF3Et2O, DCM, 0°C→rt, 
60% yield; ix) Py, Ac2O, 98% yield. 
 
The treatment of Rha peracetate 15 with benzyl N-(3-hydroxypropyl)-carbamate or allyl alcohol in the 
presence of BF3Et2O in dichlorometane gave α-glycosides 16 and 23 in 62% and 60% yield, respectively. 
Compound 16 was deacetylated with MeONa/MeOH and the isopropylidene acetal was introduced at 2- 
and 3-positions to give 17 in 87% yield, which was benzylated at 4-OH using benzyl bromide and sodium 
hydride and converted into compound 19 by removal of the isopropylidene acetal. 
The naphtylmethyl group was regioselectively installed in the equatorial 3-OH of diol 19 by reaction with 
dibutyltin oxide and subsequent treatment with 2-(bromomethyl) naphtalene and tetrabutylammonium 
iodide for in situ formation of the more reactive NapI intermediate in 54% yield. Compound 20 was 
benzylated at 2-OH; using a large excess of NaH and BnBr, N-benzylation also occurred, providing 
rhamnoside 21 in 78% yield. Compound 21 was treated with dichloro dicyano benzoquinone in 
DCM/MeOH 4:1 to remove the Nap group obtaining the monosaccharide acceptor 22 in 82% yield. 
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Likewise, the same manipulations of protective groups were applied to monosaccharide 23 to synthesize 
the alcohol intermediate 27 (yield 58%). Subsequent 2-O-acetylation of 27 provided allyl glycoside 28, 
whereas 2-O-benzylation followed by removal of the Nap group with DDQ led to the formation of 
acceptor 30 in 82% yield (Figure 12). 
 
Figura 13: Synthesis of tetrasaccharide 38. Reagents and conditions: i) Ir cat, THF, H2; I2, H2O; CCl3CN, DBU, DCM, 
85% yield; ii) TMSOTf, DCM, 0°C, 72%-87% yield; iii) NaOMe/MeOH, quantitative yield; iv) DDQ, DCM/MeOH 
4:1, 78% yield. 
 
As illustrated in Figure 13, compound 28 was deallylated and activated as trichloroacetimidate 32 
(85% yield), which reacted with acceptor 22 in the presence of TMSOTf to give disaccharide 33 
containing the linker for future conjugation in 85% yield. Disaccharide 33 was treated with MeONa 
in MeOH to remove the acetate leading to the formation of disaccharide acceptor 34. In parallel, 
donor 32 and acceptor 30 were coupled to obtain disaccharide 35 in 72% yield. This intermediate is 
a key building block in our synthesis because it is the common precursor of both the acceptor and 
the donor required for chain elongation Disaccharide 35 was deallylated and activated as 
trichloroacetimidate 36 to react with disaccharide 34 and obtain tetrasaccharide 37 in 87% yield. 
The simultaneous cleavage of the two Nap groups provided compound 38 in 78% yield (Figure 13). 
A number of glucosamine donors to perform a double glycosylation were tested by using different 
conditions, as reported in Table 1. Donors 39, 40 and 41 (Figure 14) were already available in L. 
Lay’s group (University of Milan) and R. Adamo’s group (GSK Vaccines). With thioglycosides 39 
and 40 the product of double glycosylation was never isolated due to the formation of many 
byproducts that made the reaction mixture difficult to purify. On the contrary, using 
trichloroacetimidate 41 as the donor the product of double glycosylation was successfully obtained 
(Figure 14). 
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Figure 14: Synthesis of GAC-dimer 3. Reagents and conditions: i) NaOMe/MeOH, phthalic anhydride, TEA; Ac2O, 
Py, 47% yield; ii) p-methoxyphenol, BF3 Et2O, DCM, 0°C, 89% yield; iii) NaOMe/MeOH; benzaldehyde dimethyl 
acetal, PTSA, CH3CN, 84% yield; iv) BnBr, NaH, DMF, 82% yield; v) CAN, CH3CN; CCl3CN, DBU, DCM, 70% 
yield; vi) TMSOTf, DCM, 0°C, 47% yield; vii) ethylenediamine, EtOH; Py, Ac2O; NaOMe/MeOH; H2O/EtOH 1:1, 
Pd/C, H2(3 bar), 40% yield. 
 
Table 1: reaction conditions of double glycosilation reactions 
Reagents Conditions 
Donor 39 
Acceptor 38 
Triflic acid 0.2 eq, N-iodosuccinimide 2.5 eq, DCM, -40°C→0°C 
[acceptor 38] = 50 mM, mol/mol donor/acceptor = 5 
Donor 39 
Acceptor 38 
Ag Triflate 0.2 eq, N-iodosuccinimide 5 eq, DCM, -40°C→0°C 
[acceptor 38] = 50 mM, mol/mol donor/acceptor = 5 
Donor 40 
Acceptor 38 
Ag Triflate 0.2 eq, N-iodosuccinimide 5 eq, DCM, -40°C→0°C 
[acceptor 38] = 50 mM, mol/mol donor/acceptor = 5 
Donor 41 
Acceptor 38 
Trimethylsilyl triflate 0.2 eq DCM, 0°C 
[acceptor 38] = 100 mM, mol/mol donor/acceptor = 5 
 
A double glycosylation of tetrasaccharide acceptor 38 was performed with the donor 41 and 
TMSOTf as a promoter to give the fully protected GAC-dimer 42 in 47% yield. Donor 41 was 
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prepared starting from the commercially available D-glucosamine chloroidrate. Compound 43 was 
synthesized introducing the phthalimido group at 2-posistion followed by O-acetylation. The p-
methoxyphenyl (PMP) group was introduced at the anomeric position by the treatment of 43 with p-
methoxyphenol using BF3Et2O as a promoter to give compound 44 in 89% yield. After 
deacetylation, the benzylidene acetal was introduced at 4- and 6-OH to achieve compound 45 in 
84% yield. Final 3-O-benzylation, deprotection of the anomeric position and conversion of the 
hemiacetal into trichloroacetimidate provided 41 (70% yield). 
Hexasaccharide 42 was fully characterized and subjected to global deprotection. The cleavege of 
the two phtalimido groups followed by N-acetylation, treatment with NaOMe in MeOH, and 
hydrogenolysis of the remaining protecting groups allowed to obtain the target compound GAC-
dimer 3 in 40% yield (Figure 14). 
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3.3 Synthesis and characterization of CRM197 conjugates 
The synthesized oligomers were conjugated to CRM197 carrier protein. Different chemistries were 
tested in order to obtain good conjugation efficiency. In the following paragraphs the synthesis of 
glycoconjugates by using SIDEA [adipic acid bis-(N-hydroxysuccinimide) ester], EMCS (N-
malemidocaproyl-oxysuccinimide ester) and SBAP [succinimidyl 3-(bromoacetamido)propionate] 
linkers will be illustrated. 
 
3.3.1 Conjugation of oligosaccharides to CRM197 by SIDEA chemistry 
OligoRha 1 and 2 were conjugated to CRM197 carrier protein, through adipic acid bis-(N-
hydroxysuccinimide) ester (SIDEA) chemistry (Figure 15a). 
 
 
Figure 15: a) synthesis of tetraRha-SIDEA-CRM197 1b and hexaRha-SIDEA-CRM197 2b conjugates. Reagents and 
conditions: i) SIDEA, TEA, DMSO/H2O 9:1; ii) NaPi 100mM pH 7.5, [CRM197] = 5mg/mL, w/w glycan/CRM197 1:1; 
b) SDS-PAGE of oligoRha conjugates 1b and 2b in comparison to unreacted CRM197. 
 
The derivatization reactions of 1 and 2 with SIDEA linker were performed using a large excess of 
SIDEA to favor the formation of monofunctionalized derivatives OS-SIDEA 1a and 2a. Use of 
triethylamine (TEA) facilitates the reaction, and the use of DMSO/H2O = 9:1 prevents the 
hydrolysis of the active ester. The classical purification procedure of the activated OS through 
precipitation with ethyl acetate68 (AcOEt) did not work, probably due to the short chain length of 
the oligomers. For this reason, a different purification procedure was tested: excess of unreacted 
SIDEA was precipitated by addition of HCl (55 ppm) and OS-SIDEA collected in the supernatant 
was lyophilized. The derivatized oligoRha, 1a and 2a, were characterized by High Performance 
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Anion Exchange Chromatography with Pulsed Amperometric Detection (HPAEC-PAD) to quantify 
the glycan recovered and by trinitrobenzenesulphonic acid (TNBS) colorimetric assay to detect the 
unreacted amino groups and calculate the percentage of –NH2 groups derivatized with SIDEA. We 
obtained a good recovery of oligoRha, 73% for tetraRha-SIDEA 1a and 71% for hexaRha-SIDEA 
2a, with a derivatization of -NH2 groups of 95% and 91%, respectively. Conjugation to CRM197 
was performed in sodium phosphate buffer (NaPi 100mM pH 7.5) working with a weight ratio of 
oligoRha-SIDEA to CRM197 of 1:1 (Figure 15a) and protein concentration of 5 mg/mL. The 
conjugates, 1b and 2b, were purified by size exclusion chromatography (SEC) and the fractions 
corresponding to the purified conjugates, separated from the unconjugated OS, were pooled and 
concentrated by Vivaspin 10k. Resulting products were characterized by HPAEC-PAD, 
Bicinchonic Acid Assay (microBCA) and Sodium Dodecyl Sulfate–Polyacrylamide Gel 
Electrophoresis (SDS-PAGE). The protein recovery was about 60% for both the conjugates and the 
average molar ratio of tetraRha to CRM197 and hexaRha to CRM197 resulted 4 and 5, respectively. 
The SDS-PAGE analysis confirmed conjugate formation, with typical smears for the conjugates at 
higher molecular weight compared to the protein alone (Figure 15b). The SDS-PAGE analysis also 
showed weak bands at higher molecular weight, suggesting that CRM197 crosslinking took also 
place. The chemistry used is in fact a selective approach that can induce the formation of a 
conjugate with “sun” structure, where different glycan chains are terminally linked to the protein. 
However, the step of purification of OS-SIDEA derivatives is critical and if not all the excess of 
SIDEA linker is removed, this can lead to crosslinking among CRM197 molecules. To overcome this 
problem, we tried to optimize the purification step using the hexaRha 2 as model. 
HexaRha 2 was derivatized with SIDEA linker as previously described to give 2a. Purification of 
the activated intermediate was performed this time by desalting on a prepacked G10 SEC column. 
Sample was loaded in DMSO/H2O 1:1 and eluted with H2O. The foregoing HexaRha-SIDEA 2a 
was concentrated and immediately added to CRM197 to limit active ester groups deactivation. 
Conjugation with CRM197 was performed using a weight ratio of hexaRha to CRM197 2 to 1 in NaPi 
100 mM pH 7.2 (assuming a 65% OS recovery post G10 column) and with CRM197 concentration 
of 5 mg/mL. Conjugation occurred overnight at room temperature. SDS-PAGE of the purified 
conjugate CRM197-SIDEA-hexaRha 2b1 (Figure 16b) showed absence of crosslink among CRM197 
molecules, indicating more efficient removal of SIDEA in excess by G10 desalting compared to 
precipitation procedure. 
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Figura 16: a) synthesis of hexaRha-SIDEA-CRM197 2b1 and GAC-dimer-SIDEA-CRM197 3b conjugates; Reactions 
and conditions: i) SIDEA, TEA, DMSO; ii) NaPi 100mM pH 7.2, [CRM197] = 5 mg/mL, w/w glycan/CRM197 2:1; b) 
SDS-PAGE of conjugates 2b1 and 3b. 
 
Resulting conjugate had a molar ratio hexaRha/CRM197 of 3.7, as also confirmed by MALDI-MS 
analysis. Same derivatization and conjugation conditions were applied to produce GAC-dimer-
SIDEA-CRM197 conjugate 3b (Figure 16a). Purified conjugate showed a GAC-dimer to CRM197 
molar ratio of 5, as determined by microBCA and HPAEC-PAD analysis. Also in this case no 
crosslinking among CRM197 molecules was observed in SDS-PAGE (Figure 16b).  
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3.3.2 Conjugation of tetraRha and hexaRha to CRM197 by maleimido chemistry  
TetraRha 1 and hexaRha 2 were used to explore the efficiency of maleimido chemistry for 
conjugation. 
The idea was to derivatize oligoRha with N-ε-maleimidocaproyl-oxysuccinimidoyl ester (EMCS) 
and CRM197 with N-acetyl homocysteine as a thiol linker or, other way around, to insert EMCS on 
the protein and N-acetyl homocysteine on oligoRha before performing conjugation (Figure 17).  
 
 
 
Figure 17: Synthesis of derivatized oligoRha with thiol or EMCS linkers before conjugation to CRM197-EMCS or 
CRM197-SH respectively. Reagents and conditions: i) EMCS (or N-Acetyl homocysteine), TEA, DMSO/H2O 9:1; ii) N-
Acetyl homocysteine, Borate 100mM pH 11 + 45 mM EDTA + 16mM DTT; iii) EMCS in DMSO, NaPi 100mM pH 8 
+ 1 mM EDTA. Conjugation conditions are reported in Table 2. 
 
TetraRha 1 and hexaRha 2 were derivatized with N-acetyl homocysteine in the presence of TEA 
and in DMSO/H2O 9:1 to give oligoRha-SH 1c and 2c, respectively (Figure 17). After purification 
by desalting on a G10 prepacked column, products formation was confirmed by ESI-MS, but also 
the presence of residual unreacted tetraRha 1 and hexaRha 2. 
Similar reaction conditions were used to prepare oligoRha derivatized with EMCS leading to 
tetraRha-EMCS 1d and hexaRha-EMCS 2d. ESI-MS spectra of derivatized tetraRha-EMCS 1d and 
hexaRha-EMCS 2d showed product formation. CRM197 was derivatized with both linkers, EMCS 
and N-Acetyl homocysteine (Figure 17). EMCS linker is not soluble in water and was dissolved in 
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DMSO before addition to CRM197 in NaPi 100 mM pH 8 + 1mM EDTA, while the thiol linker was 
introduced using N-Acetyl homocysteine in buffer at pH 11 containing ethylendiamine tetraacetic 
acid (EDTA) and dithiotreitol (DTT). The presence of EDTA and DTT is necessary to preserve the 
–SH groups from oxidation to S-S. The average number of linker molecules introduced per CRM197 
was calculated by MALDI-MS and resulted to be of 10 for EMCS and of 7 for N-Acetyl 
homocysteine. Analysis by HPLC-SEC showed in both cases only one peak maintaining elution 
time of underivatized CRM197. 
The derivatized CRM197-EMCS reacted with tetraRha-SH 1c and hexaRha-SH 2c to give the 
corresponding conjugates 1e and 2e, while CRM197-SH reacted with tetraRha-EMCS 1d and 
hexaRha-EMCS 2d to obtain the corresponding conjugates 1f and 2f (Figure 17). Conjugations 
were performed using the conditions summarized in Table 2. Conjugation performed between 
CRM197-EMCS and hexaRha-SH 2c with high concentration of CRM197-EMCS, 45 mg/mL, 
resulted in high % of unconjugated protein, with conjugate recovery of only 10% by microBCA. 
Purified conjugate was characterized by a molar ratio of hexaRha to CRM197 of 0.7. Conjugation 
was repeated with lower concentration of CRM197-EMCS, 10 mg/mL, but also in this case there was 
free CRM197-EMCS and the recovery of conjugate was 11% in terms of protein. No conjugate 
formation was observed using tetraRha-SH 1c.  
 
Table 2: conjugation reactions conditions 
Reagents Conjugation conditions Note 
CRM197-EMCS + 2c 
[CRM197]= 45 mg/mL, 
NaPi 100 mM pH 7.2  + 1 mM EDTA 
w/w glycan/CRM197 1:1, 4h, rt 
Presence of unconjugated 
CRM197 in reaction mixture* 
CRM197-EMCS + 2c 
[CRM197]= 10 mg/mL, 
NaPi 100 mM pH 7.2 + 1 mM EDTA 
w/w glycan/CRM197 1:1, overnight, rt 
Presence of unconjugated 
CRM197 in reaction mixture* 
CRM197-EMCS + 1c 
[CRM197]= 10 mg/mL, 
NaPi 100 mM pH 7.2 + 1 mM EDTA 
w/w glycan/CRM197 1:1, overnight, rt 
No conjugate formation was 
observed* 
CRM197-SH + 2d 
[CRM197]= 4.6 mg/mL, 
MES 100mM pH 6.2 + 1 mM EDTA 
w/w glycan/CRM197 1:1, overnight, rt 
Precipitation of CRM197 
CRM197-SH + 1d 
[CRM197]= 10 mg/mL, 
NaPi 50 mM pH 7.2  + 1 mM EDTA 
w/w glycan/CRM197 1:1, overnight, rt 
Precipitation of CRM197 
*as shown by HPLC-SEC analysis of the reaction mixture 
 
HexaRha-EMCS 2d was conjugated to CRM197-SH in MES (4-morpholine ethane sulfonic acid) 
100 mM pH 6.2 + 1mM EDTA, but protein precipitation occurred due to the low pH of reaction. 
When the tetraRha-EMCS 1d was conjugated to CRM197-SH in NaPi buffer at pH 7.2 protein 
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precipitation was observed again. We concluded that in the absence of fast conjugation to OS, 
CRM197-SH tends to aggregate and precipitate. 
As by using N-acetyl homocysteine not all the OS molecules resulted derivatized, we decided to 
introduce the -SH function through the linker N-succinimidoyl S-acetylthioacetate (SATA) and to 
test again the conjugation with CRM197-EMCS (Figure 18). The tetraRha 1 was derivatized with 
SATA in the conditions previously described for the other linkers. The acetate group was then 
cleaved with hydroxylamine 500 mM in the presence of EDTA to preserve –SH groups from 
oxidation (S-S formation). Conjugation was performed between tetraRha-(SATA)SH 1h and 
CRM197-EMCS in NaPi 100 mM pH 7.2 + 20 mM EDTA, but also in this case no conjugate 
formation was verified by HPLC-SEC. 
 
 
Figura 18: Synthesis of tetraRha-SATA and deprotection. Reactions and conditions: i) SATA, TEA, DMSO/H2O 9:1; 
ii) hydroxylamine 500mM + EDTA 25mM; iii) EMCS in DMSO, NaPi 100mM pH 8 + 1mM EDTA; iv) NaPi 100mM 
pH 7.2 + 20mM EDTA. 
 
To understand the reason why the CRM-EMCS did not react with OS-SH, we decided to 
characterize one freshly prepared CRM197-EMCS by Ellman colorimetric method.
75 The synthesis 
of CRM197-EMCS resulted reproducible, indeed 9 chains of EMCS per CRM197 were introduced 
according to MALDI-MS, but just 20% of the introduced linkers were able to react with cysteamine 
in the Ellman assay. This means that even if EMCS linkers are introduced on CRM197, they are 
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subjected to rapid degradation at some extent that prevents their reaction with -SH functionalized 
molecules. 
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3.3.3 Conjugation of tetraRha and hexaRha to CRM197-SH by using the SBAP 
linker 
CRM197-SH was also reacted with oligoRha derivatized with SBAP linker (Figure 19).  
 
 
Figura 19: Synthesis of CRM197-SH-oligoRha by means of oligoRha derivatized with SBAP linker. Reactions and 
conditions: i) SBAP, TEA, DMSO/H2O 9:1; ii) N-Acetyl homocysteine, Borato 100 mM pH 11 + 45mM EDTA + 
16mM DTT iii) NaPi 100mM pH 7.2 + 1 mM EDTA, [CRM197] = mg/mL, w/w glycan/CRM197 1:1. 
 
The oligoRha 1 and 2 were derivatized with SBAP in the presence of TEA in DMSO/H2O 9:1, to 
obtain tetraRha 1l and hexaRha 2g. CRM197 was derivatized with N-acetyl homocysteine 
introducing an average of 7 chains of linkers per CRM197, as verified by MALDI-MS (paragraph 
3.3.2, Figure 17). Conjugation reactions were performed in a buffer at pH 7.2 in the presence of 
EDTA (Figure 19). Differently from reaction with oligoRha-EMCS 1d and 2d (Figure 17) this time 
no precipitation of CRM197 was observed. Recovery in terms of CRM197 was around 50% for both 
conjugates, 1m and 2h. Molar ratio oligoRha to CRM197 was of 1.5 for 1m conjugate and 1 for 2h 
conjugate. 
Using a more reactive linker (SBAP instead of EMCS) the precipitation of CRM197-SH is avoided, 
but the loading of oligoRha on protein was very low compared to the loading obtained with SIDEA 
chemistry (paragraph 3.3.1). Among all the chemistries tested, SIDEA chemistry provided the best 
result, with an average of 5 oligosaccharide chains introduced per CRM197 molecule. 
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3.4 Immunogenicity study in mice: oligo-SIDEA-CRM197 conjugates compared 
to GAC-CRM197 
A first study in mice was performed by testing hexaRha-SIDEA-CRM197 conjugate 2b (paragraph 
3.3.1, Figure 15) and native the GAC-CRM197 conjugate, already available in GVGH laboratory. 
CD1 female mice, 5 weeks old (8 per group) were immunized intraperitoneally (IP) with 200 µL of 
formulated vaccines at day 0 and day 28. Sera were collected at days -1, 14, 27 and 42, when mice 
were sacrificed. The immunization scheme is summarized in Table 3. Conjugates were formulated 
with Alhydrogel (2 mg/mL as Al3+ content in the final formulation) and the glycan dose was 
normalized at 2 µg of Rha per dose. Consequently, the CRM197 dose resulted different for the two 
groups, depending on the glycan loading in the two conjugates: 2 chains of GAC per CRM197 and 5 
chains of hexaRha per CRM197. 
 
Table 3: immunization scheme  
Antigen 
Rha (saccharide) dose 
per mouse per 
injection 
CRM197 (protein) dose 
per mouse per injection 
mol/mol 
Glycan/CRM197 
GAC-CRM197  
+ Alhydrogel (2 mg/mL) 
2 µg 12.1 µg 2 
hexaRha-SIDEA-CRM197 2b 
+ Alhydrogel (2 mg/mL) 
2 µg 24.0 µg 5 
 
 
 
Figure 20: a) Anti-GAC and anti-Rha IgG titers (bars) induced in mice (dots) by hexaRha-SIDEA-CRM197 2b 
compared to GAC-CRM197; b) Fluorescent Activated Cell Sorting (FACS) of anti-Rha Abs induced by hexaRha-
SIDEA-CRM197 2b with two GAS strains (strain 1 = GAS 443; strain2 = GAS 51 emm1) 
 
b) a) 
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The sera were analysed to estimate the anti-GAC IgG and anti-Rha IgG titer by ELISA assay 
(Figure 20). HexaRha conjugated to CRM197 was able to induce anti-Rha IgG titer comparable to 
the conjugate of native GAC, but anti-GAC IgG titers induced were significantly lower compared to 
GAC conjugate (Figure 20a). Based on these results, the ability of anti-Rha Abs to bind the GAS 
bacterial surface was explored by FACS analysis and using. two GAS strains, GAS 443, which is a 
wild type strain, and GAS 51 emm1 that does not produce M protein. Anti-Rha sera were not able to 
recognize either of GAS strains (in green, Figure 20b), while anti-GAC sera did (in blue, Figure 
20b) 
A second study in mice is currently ongoing comparing tetraRha-SIDEA-CRM197 1b, hexaRha-
SIDEA-CRM197 2b1 and GAC-dimer-SIDEA-CRM197 3b (paragraph 3.3.1) to verify the ability of 
GAC-dimer to induce an anti-GAC IgG response comparable to native GAC conjugate and to 
further elucidate the role of GlcNAc on the immune response induced. 
 
 
Figura 21: a) Competitive ELISA of GAC-CRM197 conjugate and oligoRha (tetraRha 1, hexaRha 2, octaRha, decaRha, 
tetradecaRha, hexadecaRha) using triRha-BSA conjugate as coating antigen and mouse anti-triRha Abs; b) Competitive 
ELISA of GAC-CRM197 conjugate, GAC-dimer 3 and oligoRha (tetraRha 1, hexaRha 2, octaRha, decaRha, 
tetradecaRha, hexadecaRha) using GAC-HSA conjugate as coating antigen and mouse anti-GAC Abs. 
 
To confirm the previous data and verify if oligoRha length can have an impact on the immune 
response induced by oligoRha, a competitive ELISA experiment was performed with tetraRha 1, 
hexaRha 2 and longer oligoRha (octaRha, decaRha, tetradecaRha, hexadecaRha) prepared in Leiden 
by automated synthesis.76 A first experiment was performed by using triRha-BSA conjugate as 
coating antigen and sera generated by mice immunized with a triRha-CRM197 conjugate (Figure 
21a). Data show that Abs generated against oligoRha recognise oligoRha of different chain length: 
longer chains induce stronger binding affinity. Abs generated against triRha, however, poorly 
recognize the GAC-CRM197 conjugate, suggesting that GlcNAc can mask the polyRha structure to 
Rha-specific Abs. A second experiment was performed by using GAC-HSA conjugate as coating 
b) a) 
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antigen and anti-GAC sera (Figure 21b): Abs generated against GAC do not recognize oligoRha 
structures, independently of their size, while they recognize GAC-CRM197 and GAC dimer 3, 
suggesting that GlcNAc could be a dominant epitope. These results are in agreement with those 
reported in literature by Michon F. and coworkers.73 
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3.5 STD-NMR of GAC-dimer, tetraRha and GlcNAc: is the GlcNAc an 
immunodominant epitope of GAC? 
The Saturation Transfer Difference (STD)-NMR methodology was used to clarify the role of 
GlcNAc side chain in GAC polysaccharide. A commercial anti-GAC polysaccharide mAb from 
AbNova was used to perform the experiments. The assignment of NMR proton signals of 
oligosaccharides was obtained by combining mono- and bi-dimensional homo- and hetero-nuclear 
experiments. GAC-dimer was tested (Figure 22) using a molar ratio mAb/GAC-dimer 100:1 in Tris 
d-11 50 mM in D2O at pH 7.2 +/- 0.1. Qualitative analysis showed that GAC-dimer binds the mAb, 
and the two acetamides of GlcNAc side chains are the groups primarily involved in the interaction, 
with 100% (defined as reference at 100% because the highest intense peak) and 80% binding. Of 
note, Rha backbone is involved in the binding through positions H-2 and H-4 of the second and 
third Rha with a percentage between 40-60% and weakly with proton H-6 (~12%). These data are 
in agreement with those reported by Pinto M. and coworkers66,67, confirming that the minimal motif 
recognized is the motif α-L-Rhap-(1-2)-[β-D-GlcpNAc-(1-3)]-α-L-Rhap: both GlcNAc residues of 
the GAC-dimer 3 are involved in the interaction with the mAb with a major interaction for the inner 
trisaccharide. 
 
 
Figure 22: STD-NMR of GAC-dimer with anti-GAC mAb. Top spectra: 1H NMR of GAC-dimer. Bottom spectra: 1H 
STD-NMR. 
 
To elucidate the role of the tetraRha in the binding with mAb, STD-NMR of its complex was 
compared with GAC-dimer. The tetraRha amount in the tube was normalized to the same amount of 
Rha contained in GAC-dimer sample tube. Figure 23 shows that, despite the absence of the GlcNAc 
residues, the anti GAC mAb binds to tetraRha. The protons H-2 of α-L-Rhap-(1-2)-α-L-Rhap motif 
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are preferentially involved in a binding between 60-100% while the binding with protons H-4 and 
H-6 is weaker (~ 27%). 
 
 
Figure 23: STD-NMR of tetraRha. Top spectra: 1H NMR of tetraRha. Bottom spectra: 1H STD-NMR. 
 
To understand which of the two structures, the GAC-dimer and the tetraRha, preferentially binds 
mAb, an additional STD-NMR experiment was performed using the two glycans in a sort of 
competition experiment with mAb (Figure 24).  
 
 
Figure 24: 1H STD-NMR of competition between GAC-dimer and tetraRha. Top spectra: 1HNMR of tetraRha. Middle 
spectra: 1H NMR of GAC-dimer. Bottom spectra: 1H STD-NMR. 
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The mAb showed preferential binding for GAC-dimer and compared to the tetraRha, as 
demonstrated by the high intensity of the two acetamides peaks and the depletion of 100% proton 
H-2 signal of tetraRha (Figure 23) to 47% (Figure 24). These results, together with the 
immunogenicity study in mice FACS analysis of anti-Rha sera and the competitive ELISA reported 
in the previous paragraphs, suggest that the GlcNAc side chain is an immunodominant epitope of 
GAC polysaccharide and that GlcNAc masks the rhamnose backbone. Our results are in agreement 
with published data showing that GAC polysaccharide adopts a helical conformation, where the 
polyRha backbone is the core of the helix and GlcNAc residues are exposed on the periphery.73 
Finally, 1H STD-NMR of GlcNAc alone with mAb was performed in order to verify the hypothesis 
that GlcNAc binds the mAb only in the context of polyRha backbone. A GlcNAc structure blocked 
in the anomeric position in β-configuration with an amino linker was prepared in Milan in Lay L.’s 
laboratory. The NMR tube was prepared as previously described, using the same molar amount of 
GlcNAc that was contained in the GAC-dimer sample. The STD-NMR of GlcNAc did not show 
any relevant interaction (Figure 25), indicating that the mAb doesn’t bind to GlcNAc alone, while it 
strongly binds GlcNAc side chain of GAC-dimer.  
 
 
Figura 25: 1H STD-NMR of GlcNAc, tetraRha and GlcNAc-linker. 
 
To conclude, all these experiments support the hypothesis that the GlcNAc side chain is a dominant 
epitope in the GAC polysaccharide and it is recognized by GAC specific Abs in the context of the 
polyRha backbone. To further support this finding, a competitive ELISA has been performed to 
compare the GAC-dimer, tetraRha, GlcNAc alone and one synthetic fragment of GBSIII 
polysaccharide (Group B Streptococcus type III), which contains the GlcNAc residue, in order to 
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understand if anti-GAC sera can recognize the GlcNAc alone or in a context different from GAC 
structure (as it is the case of GBSIII). Anti-GAC Abs were not able to recognize either GlcNAc, 
GlcNAc-HSA or GBSIII oligomer, confirming that antibodies generated by GAC polysaccharide 
are able to recognize GlcNAc in the context of the polyRha backbone only. 
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3.6 Investigating multivalent antigen presentation 
3.6.1 GMMA as carrier for GAC and synthetic oligosaccharides 
In order to evaluate GMMA as alternative carrier to the more traditional protein CRM197, GAC and 
the synthetic oligomers were conjugated to GMMA (a strain modified for overblebbing and to 
reduce LPS toxicity, modulating the degree of lipid A acyl chains37). 
GAC, tetraRha 1 and hexaRha 2 were conjugated to GMMA by using two different chemistries, i.e. 
targeting proteins on GMMA surface through a bifunctional linker and targeting LPS molecules on 
GMMA by performing oxidation of cis diols followed by reductive amination reaction (paragraph 
2.2).  
To prepare the GMMA-GAC conjugate, the adipic acid dihydrazide (ADH) linker was introduced at 
the reducing end of GAC by reductive amination reaction in a buffer at pH 4.5 (Figure 26).  
 
 
Figura 26: synthesis of GAC-ADH. Reaction and contidions: i) NaCNBH3, NaOAc 20mM pH 4.5, 30°C, 5 days, 
[GAC] = 30 mg/mL, w/w/w GAC/ADH/NaCNBH3 1:1:1 
 
GAC-ADH was recovered in 90% yield as estimated by HPAEC-PAD. TNBS colorimetric assay 
indicated 56% saccharide chains were activated (assuming an average size of 7.5 kDa for GAC), 
and analysis by Ultra High Performance Liquid Chromatography (UHPLC) was performed to 
quantify free ADH %, that resulted to be 5% (reported as free /total NH2 groups).  
To prepare the conjugates by targeting proteins on GMMA, the bifunctional linker 
bis(sulfosuccinimidyl)suberate (BS3) was used (Figure 27). GMMA were derivatized with BS3 
linker at pH 6 with GMMA concentration of 4 mg/mL and using large excess of BS3 ([BS3] = 50 
mg/mL) to avoid crosslinking among GMMA. Resulting GMMA-BS3 were purified by 
ultracentrifuge (UC), and the solutions of GAC-ADH, tetraRha 1 or hexaRha 2 in PBS were added 
to GMMA pellet ([GMMA] = 10 mg/mL, w/w glycan/GMMA 3:1). Reaction mixtures were stirred 
overnight at room temperature. The resulting conjugates, GMMA-GAC, GMMA-tetraRha and 
GMMA-hexaRha, were purified by two UC steps and re-suspended in PBS.  
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Figura 27: Synthesis of GMMA conjugates, GMMA-GAC, GMMA-tetraRha and GMMA-hexaRha, with BS3 
chemistry. Reactions and conditions: i) MES 100mM pH 6, 25°C, 30 min [GMMA] = 4 mg/mL, [BS3] = 50 mg/mL; ii) 
GAC-ADH or tetraRha 1 or hexaRha 2, PBS, rt, overnight, [GMMA] = 10 mg/mL, w/w glycan/GMMA 3:1. 
 
Table 4: Characterization of GMMA-BS3 and GMMA conjugates 
 Protein recovery Activated NH2  Activated esters  
GMMA-BS3 100% 61% 32% 
 Protein recovery Z-average d (nm) 
Glycan chain numbers/ GMMA 
particle 
GMMA-GAC 66% 90.26 159 
GMMA-tetraRha 67% 91.86 1392 
GMMA-hexaRha 65% 62.74 959 
 
The full characterization of GMMA-BS3and GMMA conjugates is summarized in Table 4. 
61% of Lys residues on GMMA were derivatized with BS3 linker (by TNBS) and 32% of BS3 
linkers was as active esters at the time of conjugation. Conjugates recovery in terms of GMMA 
proteins was about 65% for all the conjugates and glycan loading decreased with the length of the 
saccharide chain: GMMA-GAC loading < GMMA-hexaRha loading < GMMA-tetraRha loading, 
probably due to the steric hindrance. For the conjugate GMMA-GAC, a higher weight ratio 
GAC/GMMA during the conjugation was used (GAC/GMMA 10:1 instead of 3:1) in order to 
increase the number of saccharide chains per GMMA particles, but this only resulted in 259 instead 
of 159 chains of GAC per GMMA particle. 
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A second conjugation strategy was also tested: LPS molecules of GMMA were oxidized to generate 
aldehyde groups which then reacted under reductive amination conditions with GAC-ADH, 
tetraRha 1 and hexaRha 2 (Figure 28). The oxidation mainly occurs on Rha residues of O-antigen 
repeats, probably because the O-antigen is the most exposed portion of LPS of GMMA.  
 
 
Figura 28: Synthesis of GMMA conjugates by reductive amination chemistry. Reactions and conditions: i) NaIO4 10 
mM, NaOAc 100mM pH 5, 2h, rt [GMMA] = 2.38 mg/mL; ii) GAC-ADH, NaCNBH3 NaOAc 100 mM pH 4.5rt, 
overnight [GMMA] = 5 mg/mL, w/w/w GAC-ADH/GMMA/NACNBH3 1:1:1; iii) tetraRha 1 or hexaRha 2, NaCNBH3, 
NaPi 100 mM pH 7.2, rt, overnight, [GMMA] = 5 mg/mL, w/w/w GAC-ADH/GMMA/NACNBH3 1:1:1. 
 
Table 5: Characterization of GMMAox and GMMAox conjugates 
 Protein recovery % oxidation*  
GMMAox 100% 73%  
 
Protein recovery Z-average d (nm) 
glycan chain numbers/ GMMA 
particle 
GMMAox-GAC 59% 94.39 1198 
GMMAox-tetraRha 51% 81.01 2186 
GMMAox-hexaRha 53% 82.74 1079 
*Rhamnose units oxidized 
GMMA were oxidized with NaIO4 (10 mM in the final reaction mixture) in a buffer at pH 5 for 2 
hours with GMMA concentration of 2.38 mg/mL, then purified by UC. The reductive amination 
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reaction was then carried out with NaCNBH3 as reducing agent. Reaction was performed at pH 4.5 
for GAC-ADH (having a hydrazide linker) and at pH 7.2 for oligoRha (having an amino linker) 
working with a weight ratio glycan/GMMA/NaCNBH3 1:1:1 ([GMMA] = 5 mg/mL). The resulting 
conjugates, GMMAox-GAC, GMMAox-tetraRha and GMMAox-hexaRha, were purified by two 
UC steps. Characterisation of GMMAox conjugates is reported in Table 5. 
73% of Rha units of LPS on GMMA were oxidized (% oxidation was calculated by comparing 
starting GMMA with GMMAox) and the number of glycan chains per GMMA particle was higher 
compared to the corresponding GMMA-BS3 conjugates (Table 4). Conjugation chemistry has an 
impact on glycan loading on GMMA. The high difference in the number of saccharide chains per 
GMMA linked with the two methodologies could be due to the different exposition of proteins 
compared to LPS molecules on GMMA surface. LPS and in particular their OAg portion are more 
exposed than proteins, therefore more accessible to glycans. It is also important to consider the high 
percentage of LPS oxidation (about 70%, Table 5) that allows to have many reactive groups. 
 
 
Figure 29: Synthesis of GMMAox-GAC and GMMAox-GAC-dimer conjugates. Reactions and conditions: i) NaIO4 
5mM, NaPi 100 mM pH 6.5, 25°C, 30min, [GMMA] = 2 mg/mL; ii) GAC-ADH, NaOAc 100 mM pH 4.5, rt, 
overnight, [GMMA] = 5 mg/mL, w/w/w GAC.ADH/GMMA/NaCNBH3 3:1:3; iii) GAC-dimer 3, NaPi 100 mM pH 
7.2, rt, overnight, [GMMA] = 5 mg/mL, w/w/w GAC.ADH/GMMA/NaCNBH3 3:1:3. 
 
GMMAox conjugate with GAC was prepared in different oxidation conditions (Figure 29, Table 6) 
to preserve the LPS structural integrity. Same procedure was used to prepare a GMMAox-GAC-
dimer conjugate (Figure 29). GMMA were oxidized with NaIO4 (5 mM in the final reaction 
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mixture) in a buffer at pH 6.5 for 30 min, working with a GMMA concentration of 2 mg/mL, then 
purified by UC. The reductive amination reactions were performed with NaCNBH3 as reducing 
agent at pH 4.5 for GAC-ADH and 7.2 for GAC-dimer 3 using a weight ratio 
GMMA/glycan/NaCNBH3 1:3:3 and with GMMA concentration of 5 mg/mL. 
 
Table 6: Characterization of GMMAox and GMMAox conjugates 
 Protein recovery % oxidation  
GMMAox 68% 9%  
 Protein recovery Z-average d (nm) glycan chain/ GMMA particle 
GMMAox-GAC 50% 127.4 1813 
GMMAox-GAC-dimer 31% 107.50 2124 
 
The resulting conjugates, GMMAox-GAC and GMMAox-GAC-dimer, were purified three times by 
UC to ensure the removal of all unreacted glycan. This time, the percentage of oxidation of GMMA 
was of 9%. This always resulted in high number of sugar chains linked: 1813 chains of GAC-ADH 
were introduced per GMMA particle, and 2124 of GAC-dimer 3 (Table 6). 
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3.6.2 Immunogenicity study in mice: GMMAox-GAC conjugate compared to 
CRM197-GAC conjugate 
In order to evaluate GMMA as alternative carrier to more traditional CRM197 carrier protein for 
GAS carbohydrate antigens, a preliminary study in mice was conducted to test GMMAox-GAC 
conjugate (paragraph 3.6.1, Figure 28) in comparison to GAC-CRM197 conjugate, already available 
in GVGH laboratory. Because of its higher glycan loading compared to the corresponding conjugate 
prepared by BS3 chemistry (paragraph 3.6.1, Figure 27), the GMMA conjugate prepared by 
reductive amination chemistry was tested only. 
 
Table 7: immunization scheme 
Antigen 
Rha dose per 
mouse per 
injection 
Protein dose per 
mouse per injection 
mol/mol 
glycan/CRM197 
n° GAC chains 
per GMMA 
particle 
GMMAox-GAC 
+ Alhydrogel (2 mg/mL) 
2 µg 15.4 µg nd 1198 
GAC-CRM197 
+ Alhydrogel (2 mg/mL) 
2 µg 12.1 µg 2 nd 
 
Conjugates were formulated with Alhydrogel (2 mg/mL Al3+ in the final formulation) and 
compared at 2 μg Rha per dose (Table 7). CD1 female mice 5 weeks old were injected IP at days 0 
and 28 and sera were collected at days -1, 14, 27 and 42. Sera were analyzed by ELISA assay for 
determining anti-GAC IgG and anti-OAg IgG titers (Figure 30). 
 
 
Figure 30: Anti-GAC and anti-OAg IgG titers (bars) induced in mice (dots) by GMMAox-GAC conjugate in 
comparison to GAC-CRM197 conjugate. 
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GMMAox-GAC was able to induce anti-GAC IgG titers comparable to GAC-CRM197 (p value = 
0.07) confirming possibility to test GMMA as carrier for GAC antigen. Also, GMMAox-GAC 
induced high anti-OAg IgG titers meaning that this conjugate has the potential to result in a 
multivalent vaccine covering both GAS and bacterial diseases. 
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3.6.3 Synthesis, characterization and evaluation in competitive ELISA of glyco-
AuNPs 
AuNPs are suitable nanosystems to explore the effect of multivalent antigens presentation.31 
TetraRha 1 and hexaRha 2 were conjugated to two different types of AuNPs, spheres and stars, by 
using poly(ethylene glycol) 2-mercaptoethyl ether acetic acid PEG average Mn 5000, n=113, 
(HOOC-PEG5000-SH) as a linker (Figure31). The AuNPs and the corresponding nanosystems with 
tetraRha 1 and hexaRha 2 were prepared by L. Polito (CNR–ISTM, Nanotechnology Lab.). The 
carboxyl group of HOOC-PEG5000-SH was activated as pentafluoro phenyl ester and coupled with 
oligoRha 1 and 2 to give 1-PEG and 2-PEG. Sphere and star AuNPs were coated with 1-PEG and 
2-PEG to give sphere-tetraRha, sphere-hexaRha, star-tetraRha and star-hexaRha. 
 
 
Figura 31: a) Synthesis of AuNPs coated with tetraRha 1 and hexaRha 2. Reactions and conditions: i) 
pentafluorophenol, EDAC, DCM; ii) DIPEA, DCM; b) TEM imagines of sphere-hexaRha and star-hexaRha. 
 
The resulting derivatized nanosystems were characterized by HPAEC-PAD, dynamic light 
scattering (DLS), transmission electron microscopy (TEM) and nanoparticle tracking analysis 
(NTA). Figure 31 show the TEM imagines (sphere-hexaRha and star-tetraRha as samples) where is 
clear the shape of the core, sphere and star, and the diameter of the Au core was 12 nm for sphere 
and 14 nm for star. The combination of HPAEC-PAD to quantify the total amount of sugar linked 
and NTA to count particles number allowed to calculate the number of oligoRha chains per 
b) a) 
46 
 
nanoparticle. Results obtained are summarized in Table 8. Data show that the number of oligoRha 
chains per nanoparticle increased with shorter oligomer. The morphology of the nanoparticles also 
influenced glycan loading. Indeed, star NPs were characterized by a lower loading than sphere NPs, 
probably meaning that anisotropic NPs have a decreased surface area available to bind oligoRha 
chains. 
 
Table 8: Characterization of oligoRha-AuNPs 
Sample 
Diameter (Mode 
nm) 
Z-potential number of NPs/mL 
n° oligoRha chains/ 
NP 
Sphere-tetraRha 44.1±0.5 -23.74±0.72 3.12E+12 4890 
Star-tetraRha 53.9±0.2 -25.66±0.81 3.06E+12 2120 
Sphere-hexaRha 45.9±0.3 -22.47±1.67 2.45E+12 3325 
Star-hexaRha 55.4±0.3 -24.31±0.97 1.85E+12 1640 
 
 
Figura 32: Competitive ELISA of AuNPs coated with tetraRha 1 and hexaRha 2. Coating antigen: triRha-BSA. Sera: 
anti-triRha. 
 
Obtained nanosystems were evaluated by competitive ELISA in comparison with unconjugated 
tetraRha 1 and hexaRha 2 chains for their ability to bind anti-Rha Abs (Figure 32). IC50 values 
(concentration of antigens needed to reduce to half serum standard ELISA titer), were almost in the 
same range for all nanosystems and lower compared to unconjugated tetraRha 1 and hexaRha 2, 
even if characterized by different antigen length and loading. We can conclude that there is a 
correlation between antigen chain length and density for these nanosystems. The same antibody 
binding affinity was obtained with the nanosystem that present high density loading and the shorter 
antigen (sphere-tetraRha) and with the nanosystem that present low density loading and the longer 
antigen (star-hexaRha). 
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4 MATERIALS AND METHODS  
4.1 General method for the synthesis of CRM197 conjugates with SIDEA linker 
TetraRha and hexaRha (10 mg/mL) were dissolved in 300 μL of DMSO/H2O 9:1. TEA (5 eq) and 
SIDEA (12 eq) were added. Reactions occurred for 1 h, then an aqueous solution of HCl 82.5 ppm 
was added (50 ppm in the final solutions) to precipitate the SIDEA in excess. The mixtures were 
centrifugated for three times and the supernatants were lyophilized. The derivatized oligomers were 
characterized by HPAEC-PAD for sugar quantification and TNBS assay for amino groups 
quantification,77 allowing to calculate the % of derivatization of oligomers with SIDEA. Derivatized 
oligomers were conjugated to CRM197 in NaPi 100mM pH 7.5 working with a CRM197 
concentration of 5 mg/mL and a weight ratio oligoRha-SIDEA to CRM197 of 1:1. Conjugations 
occurred at room temperature in 3 h. Reaction mixtures were purified by HiPrepTM 16/60 
Sephacryl® S-100 HR column. Samples were diluted to 1 mL of PBS, loaded and eluted in PBS 
with a flow rate of 0.5 mL/min. Pooled fractions corresponding to pure conjugates were 
concentrated by Vivaspin 10k. Conjugates were characterized by micro BCA, SDS-PAGE and 
HPAEC-PAD. 
A different purification procedure was then followed to prepare SIDEA intermediates for hexaRha 
and GAC-dimer. Oligomers were derivatized with SIDEA linker as previous described and purified 
by prepacked single-use PD MidiTrap G-10. Reaction mixtures were loaded in DMSO/H2O 1:1 and 
eluted with water, according to manufacturer instructions. Eluted hexaRha-SIDEA and GAC-dimer-
SIDEA were dried in SpeedVac Concentrator®, then conjugated to CRM197 in NaPi 100mM pH 7.2 
working with CRM197 concentration of 5 mg/mL and a ratio glycan/CRM197 of 2:1 in weight. 
Conjugation occurred overnight at room temperature. Reaction mixtures were purified and 
characterized as previously described. 
 
4.2 General method for the synthesis of CRM197 conjugates with malemido 
chemistry 
4.2.1 Derivatization of oligomers with N-acetyl homocysteine linker 
TetraRha and hexaRha were derivatized with N-acetyl homocysteine. Oligomers (80 mM) were 
dissolved in DMSO/H2O 9:1. TEA (5 eq) and N-acetyl homocysteine (20 eq) were added. Reaction 
occurred in 4 h at room temperature. Derivatized oligomers were purified by prepacked single-use 
PD MidiTrap G-10. Reaction mixtures were loaded in water and eluted with water according to 
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manufacturer instructions. Eluted oligomers were dried in SpeedVac Concentrator® then 
characterized by Dische assay and ESI-MS. 
 
4.2.2 Derivatization of oligomers with EMCS linker 
TetraRha and hexaRha were derivatized with EMCS linker. Oligomers (80 mM) were dissolved in 
DMSO/H2O 9:1. TEA (5 eq) and EMCS (20 eq) were added. Reaction occurred in 4 h at room 
temperature. Derivatied oligomers were purified by prepacked single-use PD MidiTrap G-10. 
Reaction mixtures were loaded in water and eluted with water according to manufacturer 
instructions. Eluted oligomers were dried in SpeedVac Concentrator® then characterized by Dische 
assay and ESI-MS. 
 
4.2.3 Derivatization of tetraRha with SATA linker 
TetraRha was derivatized with SATA linker. TetraRha (50 mM) was dissolved in DMSO/H2O 9:1. 
TEA (5 eq) and SATA (20 eq) were added. Reaction occurred in 4 h at room temperature. 
Derivatized oligomers were purified by prepacked single-use PD MidiTrap G-10. Reaction mixtures 
were loaded in water and eluted with water according to manufactures instructions. Eluted 
oligomers were concentrated in SpeedVac Concentrator® then characterized by Dische assay and 
ESI-MS. 
TetraRha-SATA (10 mg/mL) was deprotected from acetate groups in 500 mM hydroxylamine + 25 
mM EDTA in PBS for 3 h at room temperature. Resulting tetraRha-SH was purified by prepacked 
single-use PD MidiTrap G-10. Reaction mixture was loaded in NaPi 50 mM pH 7.2 + 20 mM 
EDTA and eluted with the same buffer according to manufacturer instructions. Eluted oligomer was 
concentrated in SpeedVac Concentrator® then characterized by Dische assay and ESI-MS. 
 
4.2.4 Derivatization of CRM197 with N-acetyl homocysteine linker 
N-acetyl homocysteine was added to a solution of CRM197 protein (5 mg/mL) in borate 100 mM pH 
11 + 45 mM EDTA + 16 mM DTT, with a molar ratio linker/Lys of 6.6. Reaction occurred in 4 h at 
room temperature. CRM197-SH was purified by Amikon 10k with conjugation buffer and 
characterized by micro-BCA, MALDI-MS, SEC-HPLC and SDS-PAGE. 
 
4.2.5 Derivatization of CRM197 with EMCS linker 
EMCS dissolved in DMSO (4 mg/mL) was added to a solution of CRM197 protein (4.7 mg/mL) in 
NaPi 100 mM pH 8 + 1 mM EDTA, with a molar ratio linker/Lys of 0.3. Reaction occurred in 4 h 
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at room temperature. CRM197-EMCS was purified by Amikon 10k with conjugation buffer and 
characterized by micro-BCA, MALDI-MS, SEC-HPLC and SDS-PAGE. 
 
4.2.6 Conjugation reactions with CRM197-SH and oligoRha-EMCS 
CRM197-SH (4.6 mg/mL) in MES 100 mM pH 6.2 + 1 mM EDTA was added to dried hexaRha-
EMCS in weight ratio hexaRha/CRM197 1:1. Conjugation occurred overnight at room temperature. 
Protein precipitation was observed. 
CRM197-SH (10 mg/mL) in NaPi 100 mM pH 7.2 + 1 mM EDTA was added to dried tetraRha-
EMCS in weight ratio tetraRha/CRM197 1:1. Conjugation occurred overnight at room temperature. 
Protein precipitation was observed. 
 
4.2.7 Conjugation reactions with CRM197-EMCS and hexaRha-SH 
CRM197-EMCS (45 mg/mL or 10 mg/mL) in NaPi 100 mM pH 7.2 + 1 mM EDTA was added to 
dried hexaRha-SH in weight ratio hexaRha/CRM197 1:1. Conjugation reactions occurred overnight 
at room temperature. Reaction mixtures were purified by HiPrepTM 16/60 Sephacryl® S-100 HR 
column. Sample was diluted to 1 mL of PBS, loaded and eluted in PBS with a flow rate of 0.5 
mL/min. Pooled fractions corresponding to pure conjugates were concentrated by Amikon 10k. 
Conjugates were characterized by micro BCA, SDS-PAGE and Dische assay, SEC-HPLC. No 
conjugate formation was observed with tetraRha-SH. 
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4.2.8 Conjugation reactions with CRM197-EMCS and hexaRha-SH 
CRM197-EMCS (10 mg/mL) in NaPi 50 mM pH 7.2 + 20mM EDTA was added to dried tetraRha-
SH in weight ratio tetraRha/CRM197 1:1. Conjugation reaction occurred overnight at room No 
conjugate formation was observed by SEC-HPLC. 
 
4.3 General method for the synthesis of CRM197 conjugates with SBAP linker 
TetraRha and hexaRha were derivatized with SBAP linker. Oligomers (100 mM) were dissolved in 
DMSO/H2O 9:1. TEA (5 eq) and SBAP (20 eq) were added. Reaction occurred in 4 h at room 
temperature. Derivatized oligomers were purified by prepacked single-use PD MidiTrap G-10. 
Reaction mixtures were eluted with water according to manufacturer instructions. Eluted oligomers 
were dried in SpeedVac Concentrator® then characterized by Dische assay and ESI-MS. 
CRM-SH (10 mg/mL) in NaPi 100 mM pH 7.2 + 1 mM EDTA was added to dried oligomers 
working in a weight ratio oligomers/CRM197 1:1. Conjugation reactions occurred overnight at room 
temperature. Reaction mixtures were purified by HiPrepTM 16/60 Sephacryl® S-100 HR column. 
Sample was diluted to 1 mL of PBS, loaded and eluted in PBS with a flow rate of 0.5 mL/min. 
Pooled fractions corresponding to pure conjugates were concentrated by Amikon 10k. Conjugates 
were characterized by micro BCA, SDS-PAGE and Dische assay, SEC-HPLC. 
 
4.4 Synthesis of GAC-ADH 
GAC polysaccharide (30 mg/mL) was dissolved in NaOAc 20 mM pH 4.5, then ADH linker and 
NaCNBH3 were added working in a weight ratio GAC/ADH/NaCNBH3 1:1:1. Reaction occurred in 
5 days at 30 °C. GAC-ADH was purified by prepacked single-use PD10 desalting column twice: 
GAC-ADH was diluted to 2.5 mL total volume to have final NaCl concentration of 3 M and eluted 
in NaCl 3M, collecting 3.5 mL of foregoing product. GAC-ADH was then dried in SpeedVac 
Concentrator®. Dried GAC-ADH was then dissolved in 2.5 mL of water and loaded in prepacked 
single-use PD10 desalting column. Elution was performed in water according to manufacturer 
instructions. 
GAC-ADH was characterized by HPAEC-PAD, and TNBS assay77. Free ADH was detected by 
reversed Phase-Ultra High-Performance Liquid Chromatography (RP-UHPLC). A 600 nmol/mL 
solution of ADH was used to create a calibration curve in the 0.8-20 nmol/mL of amino groups 
range in a final volume of 250 μL. Samples were diluted with MilliQ water in order to obtain amino 
groups concentration in the range of calibration curve. A volume of 250 μL of 70 mM Sodium 
Phosphate pH 7.5 solution and a volume of 250 μL of 0.1% solution of TNBS were added to 
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standards and samples, then incubated for 2 h at 40 °C. Samples (10 μL injected) were eluted on a 
Kinetex reversed-phase column (2.6 μm, 50x4.6 mm, Phenomenex) on a Waters Alliance UPLC 
system with in-line UV, fluorescence emission, dRI detectors. Samples were eluted with a flow rate 
of 1.0 mL/min and eluent mixture was generated by the pump system. The eluent program (total run 
time 50 minutes) was: 90% water, 10% ACN in isocratic condition for 10 min; linear gradient 10% 
water, 90% ACN in 10 min; 10% water, 90% ACN in isocratic condition for 10 min; 90% water, 
10% ACN in isocratic condition for 20 min (column re-equilibration). Detection was done at 425 
nm. The amount of free ADH in the samples was calculated using the calibration curve built with 
the peak areas of derivatized ADH standards at 425 nm. The percentage of activated GAC was 
calculate as % of linked ADH moles/GAC moles. 
 
4.5 General method for the synthesis of GMMA conjugates with BS
3 linker 
GMMA were derivatized with BS3 linker. GMMA were suspended in MES 100 mM pH 6 at 
concentration of 4 mg/mL and BS3 (50 mg/mL) was added. Reaction occurred for 30 min at 25°C 
controlled temperature. Derivatized GMMA-BS3 were purified by ultracentrifuge (UC) at 110K 
rpm for 16 minutes. A small portion of GMMA-BS3 was resuspended in PBS for characterization 
by micro BCA for total protein content, and TNBS assay77 to estimate % of NH2 groups on GMMA 
derivatised with BS3 linker. Total active esters groups introduced were quantified by RP-HPLC as 
sulfo N-hydroxysuccinimide (sulfo NHS) groups. A 1000 nmol/mL solution of sulfo NHS was used 
to create a calibration curve in the 5-300 nmol/mL range. GMMA-BS3 were diluted with MilliQ 
water in order to obtain sample sulfo NHS concentration in the range of the calibration curve. 
Samples and calibration curve were prepared in 200 μL total volume and hydrolyzed with 400 μL 
of ammonia (NH4OH) 0.17% for 1 h at room temperature. Samples were concentrated in SpeedVac 
Concentrator® and re-suspended in 200 μL of MilliQ water. 
A volume of 200 μL for samples and calibration curve was injected and analyzed on TSK 3000. 
GAC-ADH, tetraRha and hexaRha in PBS were respectively added to GMMA-BS3 pellets to have 
GMMA concentration of 10 mg/mL and weight ratio of GMMA to glycan of 1:3. Reactions were 
mixed overnight at room temperature. The resulting conjugates GMMA-GAC, GMMA-tetraRha 
and GMMA-hexaRha were purified by two UC steps (110K rpm for 30 min) and re-suspended in 
PBS. Full characterization was done by micro BCA, HPAEC-PAD and DLS. 
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4.6 General method for the synthesis of GMMA conjugates with reductive 
amination chemistry 
GMMA suspended in NaOAc 100 mM pH 5 (GMMA concentration 2.38 mg/mL) were oxidized 
with NaIO4 10 mM for 2 h at room temperature in the dark. Oxidized GMMA were purified by UC 
at 110K rpm for 30 min. A small portion of GMMAox was re-suspended in PBS for 
characterization by micro BCA (total protein recovery) and HPAEC-PAD (for estimating % OAg 
oxidation). The % OAg oxidation was calculated on Rha, considering that the un-oxidized GMMA 
has a molar ratio Rha:Man of 1:1.  
The oxidation step was also performed by using different reaction conditions. GMMA 2192 ΔtolR 
ΔPagP ΔmsbB suspended in NaPi 100 mM pH 6.5 (GMMA concentration 2 mg/mL) were oxidized 
with NaIO4 5 mM for 30 min at 25°C in the dark. 
GAC-ADH in NaOAc 100 mM pH 4.5 and tetraRha and hexaRha or GAC-dimer in NaPi 100 mM 
pH 7.2 were respectively added to GMMAox pellets to have GMMAox concentration of 5 mg/mL. 
The reducent agent NaCNBH3 was added (weight ratio GMMA/glycan/NaCNBH3 1:1:1 or 1:3:3) 
and reaction mixtures were stirred overnight at room temperature. Resulting conjugates GMMAox-
GAC, GMMAox-tetraRha, GMMAox-hexaRha were purified twice by UC (110K rpm for 30 min) 
and characterized by micro BCA (total protein content), HPAEC-PAD (total sugar content) and 
DLS (average particle size determination). 
 
4.7 General method for the synthesis of glycol-gold nanoparticles 
Two different shape of gold nanoparticles (AuNPs), sphere (12 nm from Transmissio Electron 
Microscopy, TEM) and star (14 nm from TEM), were prepared by Laura Polito (CNR-ISTM, 
Nanotechnology Lab, Milan). That AuNPs were coated with TetraRha and hexaRha by meand 
PEG5000 linker. 
The carboxylic acid group of HOOC-PEG5000-SH was activated as pentafluoro phenyl ester. 
HOOC-PEG5000-SH (80 mg, 0.016 mmol) was dissolved in 800 μL of DCM dry. Pentafluorophenol 
(6.1 mg, 0.033 mmol) and ethyl-3-(3-dimethylaminopropyl)carbodiimide (6.3 mg, 0.33 mmol) were 
added. Reaction mixture was stirred for 24 h, when TLC (DCM/MeOH 80:20) showed the 
disappearance of starting material. The solvent was concentrated under reduced pressure and 
product was precipitated from cooled Et2O and filtered.  
The filtered PFP-PEG5000-SH (30 mg, 0.006 mmol) was dissolved in 400 μL of dried DCM and 
solution was degassed for 1 h. DIPEA (3.10 mg, 0.024 mmol) was added. A solution of oligoRha 
(tetraRha or hexaRha) in dried DMF (400 μL, 0.012 mmol) was added to the reaction mixture drop 
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by drop. The reaction occurred for 36 h, when TLC (DCM/MeOH 80:20) showed the disappearance 
of starting material. Solvent was removed under vacuum. The crude was dissolved in water and 
purified by G25 Sephadex. The yield was 30 % after two steps for both tetraRha-PEG (30.7 mg) 
and hexaRha-PEG (30.2 mg). 
OligoRha-PEG were characterized by HPAEC-PAD to quantify tetraRha (313 μg) and hexaRha 
(246 μg).  
Under argon atmosphere, 30 mg of the suitable oligoRha-PEG5000-SH were dissolved in 5 mL of 
water containing 9 mg of NaOH. Au NPs were prepared by L. Polito (CNR-ISTM, Nanotechnology 
Lab, Milan) with a reported procedure78. Then, the oligoRha-PEG5000-SH solution was added to the 
colloidal solution containing citrate-capped AuNPs (sphere or star) while Argon was bubbling 
inside the solution (for 5 minutes) and the reaction mixture stirred for further 48 h at room 
temperature. Functionalized sphere-oligoRha and star-oligoRha were then purified by means of 
Amikon centrifugal Filter units to a volume of 5 mL.  
Nanosystems were characterized by DLS (Z-average), TEM (determination of diameter of core 
shape), NTA (nanoparticle quantification in NP/mL) and HPAEC-PAD (tetraRha or hexaRha 
quantification). The combination of NTA analysis with HPAEC-PAD analysis allowed to calculate 
the number of oligoRha chains per NP. 
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4.8 General methods for glycoconjugates characterization 
4.8.1 Glycan quantification 
Total saccharide concentration was determined by HPAEC-PAD analysis (ICS-3000 dionex 
system). Conjugates (450 μL) were hydrolyzed in 4M trifluoroacetic acid in a final volume of 600 
μL for 4h at 100 °C, dried and dissolved in water. Samples of 25 μL were injected in CarboPac 
PA10 analytical column (4 x 250 mm) with CarboPac PA10 guard column (4 x 250 mm). Isocratic 
separations were performed using 50 mM NaOH followed by 500 mM NaOH regeneration step and 
re-equilibration, set to a flow rate of 1.0 mL/min. Monosaccharide peaks were detected directly 
using quadruple-potential waveform pulsed amperometry on a gold electrode and an Ag/AgCl 
reference electrode. Raw data were elaborated with Chromeleon software (Dionex) with 0.5-10 
μg/mL calibration curves of Rha, GlcNAc for CRM197 conjugates and with 0.5-10 μg/mL 
calibration curve of Rha, GlcNAc, Gal, Glc, Man for GMMA conjugates.  
Fast quantification of glycans on CRM197 conjugates or derivatized oligosaccharides was achieved 
by Dische assay. Samples were hydrolyzed in sulfuric acid 100% at 100 °C: methyl furfural (from 
rhamnose) was formed and made reacted with cysteine. Absorbance was measured at 396 nm and 
427 nm before and after cysteine addition. Rhamnose concentration was calculated by subtracting 
the 427 nm contribute to 396 nm methyl pentose contribute in the range 2-32 μg/mL calibration 
curve of fucose.  
 
4.8.2 Protein quantification 
Total protein quantification was performed by micro BCA (Thermo Scientifics). A 2 mg/mL 
solution of serum bovine albumin (BSA) was used to create a calibration curve in the range 5-20 
μg/mL. Samples were diluted with MilliQ water in order to obtain sample protein concentration in 
the range of the calibration curve with a final volume of 500 μL. The micro BCA reagent was 
prepared according to manufacturer instructions and 500 μL were added to each sample, then 
incubated for 1 h at 60°C. Absorbance at 562 nm was measured by spectrophotometer per each 
samples and protein concentration was calculated. 
 
4.8.3 SDS-PAGE analysis 
SDS-PAGE was performed on pre-casted polyacrylamide gels (NuPAGE®Invitrogen). 3-8% 
gradient or 7%. Gel were used. Electrophoretic runs were performed in Tris-Acetate SDS running 
buffer (NuPAGE®Invitrogen) loading 2.5- 5µg of protein per sample, using the electrophoretic 
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chamber with a voltage of 150V for 45 minutes. After electrophoretic running, the gel was washed 
in water for 3 times and then stained with dye comassie (TermoFisher). 
 
4.8.3 Size Exclusion High Performance Liquid Chromatography (SEC-HPLC) 
SEC-HPLC was performed on Waters Alliance (system, eluting the samples on a TSK 3000. with 
0.1M NaCl 0.1M NaPi 5% CH3CN pH 7.2 on SWXL (Tosoh Bioscience) at flow rate of 0.5 
mL/min, with 80 µL of injection volume loading 50 µg of sample in protein content. The resulting 
chromatographic data were processed using Empower 3 software.  
This analysis was performed to analyze glycoconjugate reaction mixtures in comparison to free 
CRM197 to verify glycoconjugate formation and, eventually, the presence of unreacted CRM197.  
 
4.9 STD NMR experiments 
NMR experiments were carried out on a Bruker 600 MHz NMR instrument equipped with a TBI 
cooled probe at controlled temperature (± 0.1 K). Data acquisition and processing were performed 
using TOPSPIN 3.1 software. Proton-Carbon Saccharides resonances were assigned collecting both 
1D (1H and 13C) and 2D (COSY, HSQC, HMBC, NOESY) experiments, using standard pulse 
sequences. STD-NMR experiments were acquired with 96 scans over 96 accumulations and spectral 
width of 8000 Hz (12 ppm) at 298 K; a saturation transfer of 2/4 sec. was applied to enhance the 
saturation transfer effect, irradiating at a frequency of 8.0 and -2.0 ppm (4000 and -1000 Hz 
respectively). Spectra acquired irradiating at a frequency of 8.0 ppm provide better signal/noise 
ration. To avoid pitfalls in the interpretation of STD-NMR spectra, a negative control spectrum was 
always recorded in absence of mAb (ligand and buffer only at the same molar concentration and pH 
of the protein-saccharide sample). The STD negative controls were always subtracted to the relative 
protein-saccharide STD spectrum, obtaining the STDD experiments.  
Monoclonal antibody (anti-GAC from Abnova) was exchanged in the working buffer (Tris d-11 50 
mM in D2O at pH 7.2 +/- 0.1) through 2mL Zeba Spin desalting column pre-equilibrated with 3 
cycles of working buffer. Oligomers were dissolved in the working buffer too. 200 μg of mAb were 
prepared in a final volume of 510 μL of buffer with 100 equivalents of GAC-dimer. Tetrarhamnose 
and N-acetyl glucosamine samples were prepared using the same Rha and the same GlcNAc molar 
concentration contained in GAC-dimer, respectively, and mixed with 200 μg of mAb in 510 μL of 
buffer. 
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4.10 Particles size distribution characterization 
4.10.1 Dynamic Light Scattering (DLS) 
DLS measurements of GMMA conjugates were performed with a Malvern Zetasizer Nano ZS 
(Malvern, Herremberg, Germany) equipped with a 663 nm He-Ne laser and operating at an angle of 
173°. Scattering light detected at 173° was automatically adjusted by laser attenuation filters.  
DLS measurements of gold glyco-nanoparticles were performed by L. Polito (CNR-STM, 
Nanotechnology Lab, Milan) with a Brookhaven instrument equipped with a 632.8 nm He-Ne laser 
and operating at an angle of 173°. Scattering light detected at 173° was automatically adjusted by 
laser attenuation filters.  
For data analysis the viscosity and refractive index (RI) of PBS buffer solution (at 25°C) were used 
for GMMA conjugates, while water was used for glyco-gold nanoparticles.  
The software used to collect and analyze the data was the Zetasizer software version 7.11. 
Temperature was set at 25 °C. 60 μL of each sample at 50 μg/mL protein content were measured in 
single-use polystyrene micro cuvette (ZEN0040, Alfatest) with a path length of 10 mm. The 
hydrodynamic diameter of GMMA conjugates and glycol-gold nanoparticles was expressed by a Z-
average value of three measurements for each replicate.  
 
4.10.2 Nanoparticle Tracking Analysis (NTA) 
NS300 Nanosight instrument (Nanosight Ltd, Salisbury, UK) equipped with CMOS camera and 
488 nm monochromatic laser beam was used. Data acquisition and processing were performed 
using NTA software 3.2. Automatic settings for the minimum track length, the minimal expected 
particle size and blur setting were applied. Viscosity settings for water were applied and 
automatically corrected for the temperature used (25 °C). Particle movement was analyzed by NTA 
software with camera level at 16, slider shutter at 1300 and slider gain at 512. Different detection 
threshold values were tested, adjusted for the sample appearance after dilution. Five movies of 30s 
at 25 frames per second were recorded, generating five replicate histograms that were averaged. 
Several dilutions of the samples were analysed and duplicates were recorded for every diluted 
sample.  
Samples were slowly injected in the sample chamber using a 1 mL syringe in 5 to 10 seconds under 
controlled flow, using NanoSight syringe pump (speed 20). Each video was then analyzed to 
determine the respective mean and mode particle size. Concentrations of the sample are reported in 
nanoparticle per mL and particle frame. 
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4.11 Immunogenicity of conjugates in mice 
Animal studies were performed at Toscana Life Science Animal Care Facility and were approved 
by the Italian Ministry of Health (Approval number 479/2017-PR of 09/06/2017). The groups of 
eight five weeks old female CD1 mice were immunized by intraperitoneal injection. All conjugates 
were compared at same rhamnose dose (2 μg Rha) formulated on Alhydrogel as adjuvant at 2 
mg/mL Al3+ concentration. Mice received the vaccines at days 0 and 28. Sera were bled at days -1 
(and pooled for each gorup), 14, 27 and 42. Sera were analyzed by ELISA from GVGH 
Immunoassay unit. 
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5 CONCLUSIONS 
GAS causes autoimmune responses that can lead to RHD and, consequently, to the death of about 
350,000 people worldwide annually and no vaccine is available against this pathogen. GAS clinical 
isolates express the GAC, a conserved surface polysaccharide comprising of -L -Rhap(1→3)--L-
Rhap(1→2)--D-GlcpNAc-(1→3) repeats. Although the main driver of GAS autoimmune responses is 
the so-called M protein; some studies have linked GlcNAc side chain of GAC with cross-reactive 
epitopes that might also be responsible for rheumatic diseases. On the other hand, the polyrhamnose 
backbone could be an alternative to GAC for a broadly conserved vaccine candidate against GAS 
infections. 
Here, the chemical synthesis for producing fragments of GAC polysaccharide was developed with 
the final aim to investigate the role of structural features of GAC on the immune response induced 
by the corresponding glycoconjugate vaccine. TetraRha, hexaRha and GAC dimer were synthesized 
and fully characterized. For the first time well-defined synthetic structures were available to 
immunize mice and look at the role of GlcNAc on the immune response induced by GAC 
polysaccharide.  
Different conjugation chemistries were tested for linking oligosaccharides produced to CRM197. 
Among the chemistries tested, the use of SIDEA homo-bifunctional linker resulted in higher 
glycosylation degree and the process of intermediate SIDEA derivative was optimized to avoid 
protein crosslinking and to obtain well defined sun-like structure conjugates. 
By immunizing mice with hexaRha-CRM197 and GAC-CRM197 conjugates we clarified that 
hexaRha is able to induce anti-Rha specific Abs, similar to those induced by GAC-CRM conjugate, 
but is not able to induce anti-GAC Abs. Anti-Rha Abs produced do not recognize GAC on GAS 
bacterial surface, as shown by FACS analysis. Such results were also confirmed by competitive 
ELISA experiments: anti-GAC Abs were not able to bind oligoRha independently of 
oligosaccharides chain length, while anti-Rha Abs showed dose-dependent binding, and affinity for 
the antibodies increased with oligosaccharides chain length. Finally, STD-NMR of tetraRha, GAC-
dimer and GlcNAc suggested that the rhamnose backbone plays an important role in the 
presentation of GlcNAc side chain which is involved in a strong binding with mAbs, while GlcNAc 
alone is not recognized.  
An immunogenicity study is ongoing to test also GAC dimer-CRM197 conjugate in mice, with the 
aim to verify possibility to use the synthetic oligosaccharide as alternative to native GAC in the 
development of a conjugate vaccine against GAS and to corroborate the concept that GlcNAc plays 
a dominant role on the immune response induced by GAC. STD-NMR results seem to indicate that 
GlcNAc residue is recognized in the context of GAC polysaccharide structure removing concerns 
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related to autoimmunity. To further support this finding, a competitive ELISA is ongoing by testing 
different structures that contain GlcNAc residues (GAC-dimer, GlcNAc alone and GBS III 
fragment). 
In this study GMMA were also tested as carrier for GAC, showing ability to induce similar anti-
GAC Abs response compared to the traditional CRM197 carrier protein. Presence of GAC on 
GMMA did not interfere with the immune response induced by GMMA itself, supporting the use of 
GMMA for the development of multivalent vaccines.  
The opportunity to decorate spherical and anisotropic AuNPs with oligoRha has been also verified. 
Sphere and star AuNPs were used and for analytical methods were put in place to quantify number 
of oligosaccharide chains per nanoparticle. Different loading of oligoRha per AuNP was obtained 
according to oligosaccharides chain length and NP shape. As expected, these nanosystems 
confirmed much higher Abs binding affinity compared to free oligosaccharides (multivalency 
effect).  
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6 EXPERIMENTAL SESSION 
General Methods for chemical synthesis of oligosaccharides 
All chemicals were of reagent grade and were used without further purification. Reactions were 
monitored by thin-layer chromatography (TLC) on Silica Gel 60 F254 (Sigma Aldrich) or with high 
performance thin-layer chromatography (HPTLC); after examination under UV light, compounds 
were visualized by heating with 10% (v/v) ethanolic H2SO4. In the work up procedures, organic 
solutions were washed with the amounts of the indicated aqueous solutions, then dried with 
anhydrous Na2SO4, and concentrated under reduced pressure at 30-50ºC on a water bath. Column 
chromatography was performed using Silica Gel 200-400 mesh or Biotage SNAP Ultra. 
1H NMR spectra were measured at 400 MHz (except where otherwise specified) and 298 K with a 
Bruker AvanceIII spectrometer; H values were reported in ppm, relative to the internal standard 
Me4Si (H = 0.00, CDCl3) or the water signal (H = 4.79 ppm, D2O). 13C NMR spectra were 
measured at 100 MHz (except where otherwise specified) and 298 K with a Bruker AvanceIII 
spectrometer; C values are reported in ppm relative to the signal of CDCl3 (C = 77.0, CDCl3). 
NMR signals were assigned by homonuclear and heteronuclear 2-dimensional correlation 
spectroscopy (COSY, HSQC).  
Mass was measured by Electron Spray Ionization (ESI) or Matrix-Assisted Laser Ionization 
(MALDI) spectroscopy. Optical rotation was measured with a P-2000 Jasco polarimeter at 25°C. 
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Synthesis of oligorhamnoses: tetrarhamnose and hexarhamnose 
2-O-acetyl-3,4-di-O-benzyl-α-rhamnopyranosyl trichloroacetimidate [6]. 
A solution of allyl monosaccharide 5 (3 g, 7.04 mmol) in THF (150 mL) containing 1,5-
cyclooctadienebis(methyldiphenylphosphine)-Iridium(I)-hexafluorophosphate (297 mg, 0.352 
mmol) was degassed for 1 h, then hydrogen was flown for 10 min. The mixture was stirred for 30 
min, when 1HNMR showed isomerization of the double bond. Water (51 mL) and I2 (3.57 g, 14.08 
mmol) were added. The mixture was stirred for 15 min, then partitioned with 10% NaS2O3 (30 mL) 
and DCM (100 mL for 3 times). Organic layers were unified, washed with 5% NaHCO3 (150 mL), 
H2O (150 mL) and brine (150 mL), then dried with Na2SO4 and concentrated under vacuum. The 
deallylated intermediate was purified by flash chromatography (hexane/AcOEt 80:20→60:40) to 
afford 2.63g of foregoing product, which was dissolved in DCM (50 mL), then CCl3CN (4 mL, 
41.16 mmol) and DBU (0.3 mL, 2.06 mmol) were added. The mixture was stirred for 1.5 h, 
concentrated under vacuum and purified on silica gel (hexane/AcOEt + 1% TEA 80:20→60:40). 
Compound 6 was recovered in 95% yield after two steps and checked by 1HNMR and used in the 
next step to preserve the trichloroacetimidate from hydrolysis.  
1HNMR: (CDCl3, 400 MHz): δ = 8.68 (s, 1H, NH), 7.41-7.30 (m, 10 H, Ph), 6.22 (d, 1H, J1,2= 1.6 
Hz, H-1), 5.52 (dd, 1H, J1,2= 2.0 Hz, J2,3= 2.8 Hz, H-2), 4.96 (d, 1H, J = 10.4 Hz, PhCHH), 4.76 (d, 
1H, J = 10.8 Hz, PhCHH), 4.66 (d, 1H, J = 10.8 Hz, PhCHH), 4.61 (d, 1H, J = 11.2 Hz, PhCHH), 
4.03 (dd, 1H, J2,3= 3.2 Hz, J3,4= 9.2 Hz, H-3), 4.00-3.93 (m, 1H, H-5), 3.56 (t, 1H, J3,4= 9.6 Hz, H-
4), 2.22 (s, 3H, CH3CO), 1.38 (d, 3H, J5,6= 6.4 Hz, H-6). 
 
Allyl (2-O-acetyl-3,4-di-O-benzyl-α-rhamnopyranosyl)-(1-3)-2,4-di-O-benzyl-α-
rhamnopyranoside [7]. 
To a stirred solution of acceptor allyl 2,4-di-O-benzyl-α-L-rhamnopyranoside 4 (2.03 g, 5.28 mmol) 
and donor 6 (3.35 g, 6.34 mmol) in DCM (50 mL) containing activated 4 Å molecular sieves (2.03 
g), TMSOTf (1.19 mL, 0.528 mmol) was added at 0°C. The mixture was stirred at 0°C for 30 min. 
After neutralization with TEA, the mixture was concentrated and purified by flash chromatography 
(hexane/AcOEt 85:15) to afford product 7 in 75% yield. 
1HNMR: (CDCl3, 400 MHz): δ = 7.42-7.23 (m, 20H, Ph), 5.92-5.82 (m, 1H, CH2-CH=CH2), 5.55 
(dd, 1H, J1,2= 1.6 Hz, J2,3= 3.2 Hz, H-2
II), 5.25 (ddd, 1H, J1= 1.6 Hz, J2 = 3.2 Hz, CH2-CH=CHH), 
5.17 (ddd, 1H, J1= 1.2 Hz, J2 = 2.8 Hz, CH2-CH=CHH), 5.13 (d, 1H, J1,2= 1.2 Hz, H-1
II), 4.96 (d, 
1H, J = 10.8 Hz, PhCHH), 4.84 (d, 1H, J = 10.8 Hz, PhCHH), 4.80 (d, 1H, J1,2= 1.6 Hz, H-1
I), 4.70 
(s, 2H, PhCHH), 4.67-4.62 (3 d, 3H, PhCHH), 4,48 (d, 1H, J = 10.4 Hz, PhCHH), 4.18-4.12 (m, 
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2H, CHH-CH=CH2, H-3
II), 4.00-3.84 (m, 3H, CHH-CH=CH2, H-3
I, H-5II), 3.77-3.69 (m, 2H, H-2I, 
H-5I), 3.65 (t, 1H, J3,4 = 9.6 Hz, H-4
I), 3.45 (t, 1H, J3,4 = 9.6 Hz, H-4
II), 2.11 (s, 3H, CH3CO), 1.33 
(d, 3H, J5,6 = 6.0 Hz, H-6
I), 1.30 (d, 3H, J5,6 = 6.4 Hz, H-6
II). 
 
Characterization in agreement to J.Zhang, J. Mao, H. Chen, M. Cain, Tetrahedron Asymmetry, 
1994, 5, 2283. 
 
2-O-acetyl-3,4-di-O-benzyl-α-rhamnopyranosyl-(1-3)-2,4-di-O-benzyl-α-rhamnopyranosyl 
trichloroacetimidate [8]. 
A solution of disaccharide 7 (2.95 g, 3.92 mmol) in THF (150 mL) containing 1,5-
cyclooctadienebis(methyldiphenylphosphine)-Iridium(I)-hexafluorophosphate (330 mg, 0.390 
mmol) was degassed for 1 h, then hydrogen was flown for 10 min. The mixture was stirred for 30 
min, when 1HNMR showed isomerization of the double bond. Water (50 mL) and I2 (2.0 g, 7.84 
mmol) were added. The mixture was stirred for 15 min, then partitioned with 10% NaS2O3 (30 mL) 
and DCM (100 mL for 3 times). Organic layers were unified, washed with 5% NaHCO3 (150 mL), 
H2O (150 mL) and brine (150 mL), then dried with Na2SO4 and concentrated. The deallylated 
intermediate was purified on silica gel (hexane/AcOEt 80:20→60:40) to afford 2.8 g of foregoing 
product, which was dissolved in DCM (40 mL), then CCl3CN (2.4 mL, 23.58 mmol) and DBU 
(0.176 mL, 1.18 mmol) were added. The mixture was stirred for 2 h, concentrated and purified by 
flash chromatography (hexane/AcOEt + 1% TEA 70:30). Compound 8 was recovered in 95% yield 
after two steps. The presence of trichloroacetimidate was confirmed by 1HNMR with typical NH 
signal at 8.46 ppm. Compound 8 has been used immediately in the next step to preserve the 
trichloroacetimidate from hydrolysis.  
1HNMR: (CDCl3, 400 MHz): δ = 8.46 (s, 1H, NH), 7.33-7.21 (m, 20H, Ph), 6.19 (d, 1H, J1,2 = 1.3 
Hz, H-1I), 5.46 (dd, 1H, J1,2 = 1.5 Hz, J2,3 = 2.7 Hz, H-2
II), 5.04 (s, 1H, H-1II), 4.85 (d, 1H, J = 11.0 
Hz, PhCHH), 4.74 (d, 1H, J = 10.9 Hz, PhCHH), 4.69-4.49 (m, 5H, PhCHH), 4.42 (d, 1H, J = 10.9 
Hz, PhCHH), 4.05 (dd, 1H, J2,3= 3.2 Hz, J3,4= 9.8 Hz, H-3
II), 3.86-3.81 (m, 3H, H-3I, H-5I, H-5II), 
3.70-3.61 (m, 2H, H-2I, H-4I), 3.34 (t, 1H, J3,4 = 8.8 Hz, H-4
II), 2.07 (s, 3H, CH3CO), 1.27 (d, 3H, 
J5,6 = 6.2 Hz, H-6
I), 1.13 (d, 3H, J5,6 = 6.4 Hz, H-6
II).  
 
Characterization in agreement to S. Crotti, H. Zhai, J. Zhou, M. Allan, D. Proietti, W. Pansegrau, 
Q.Y. Hu, F. Berti, R. Adamo, ChemBioChem, 2014, 15, 836. 
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3-(benzyloxycarbonyl)aminopropyl (2-O-acetyl-3,4-di-O-benzyl-α-rhamnopyranosyl)-(1-3)-
2,4-di-O-benzyl- α-rhamnopyranoside [9]. 
To a stirred solution of 3-(benzyloxycarbonyl)aminopropanol (732 mg, 3.5 mmol) and disaccharide 
8 (1.5 g, 1.75 mmol) in DCM (17 mL) containing activated 4 Å molecular sieves (732 mg), 
TMSOTf (0.397 mL, 0.175 mmol) was added at 0°C. The mixture was stirred at 0°C for 2 h. After 
neutralization with TEA, the mixture was concentrated and purified by flash chromatography 
(hexane/AcOEt 90:10→70:30). Compound 9 was recovered in 60% yield.  
1HNMR: (CDCl3, 400 MHz): δ = 7.41-7.21 (m, 25H, Ph), 5.53 (dd, 1H, J1,2 = 1.6 Hz, J2,3 = 3.2 Hz, 
H-2II), 5.10 (s, 2H, CH2Cbz), 4.95 (d, 1H, J = 10.4 Hz, PhCHH), 4.82 (d, 1H, J = 10.5 Hz, PhCHH), 
4-75-4.60 (m, 7H, PhCHH, H-1I, H-1II), 4.47 (d, 1H, J = 11.6 Hz, PhCHH), 4.07 (dd, 1H, J2,3 = 3.6 
Hz, J3,4 = 9.2, H-3
I), 3.97 (dd, 1H, J2,3 = 3.2 Hz, J3,4 = 9.2, H-3
II), 3.92-3.83 (m, 1H, H-5II), 3.75-
3.59 (m, 4H, H-2I, H-4I, H-5I, O-CHH-CH2-CH2-NH), 3.47-3.37 (m, 2H, H-4
II, O-CHH-CH2-CH2-
NH), 3.32-3.22 (m, 2H, O-CH2-CH2-CH2-NH), 2.10 (s, 3H, CH3CO), 1.80-1.74 (m, 2H O-CH2-
CH2-CH2-NH), 1.31 (d, 3H, , J5,6 = 6.0 Hz, H-6
I), 1.28 (d, 3H, J5,6 = 6.0 Hz, H-6
II). 
 
Characterization in agreement to S. Crotti, H. Zhai, J. Zhou, M. Allan, D. Proietti, W. Pansegrau, 
Q.Y. Hu, F. Berti, R. Adamo, ChemBioChem, 2014, 15, 836. 
 
3-(benzyloxycarbonyl)aminopropyl (3,4-di-O-benzyl-α-rhamnopyranosyl)-(1-3)-2,4-di-O-
benzyl- α-rhamnopyranoside [10]. 
Compound 9 (950 mg, 1.05 mmol) was dissolved in MeOH (10 mL) and a solution 0.1M of 
NaOMe/MeOH was added until pH 9. The mixture was stirred for 1h, then neutralized with 
Amberlite resin (H+ form). After filtration, compound 10 was concentrated and recovered in 
quantitative yield. 
1HNMR: (CDCl3, 400 MHz): δ = 7.40-7.24 (m, 25H, Ph), 5.14 (d, 1H, , J1,2 = 1.2 Hz, H-1II), 5.10 
(s, 2H, CH2Cbz), 4.91 (d, 1H, J = 10.8, PhCHH), 4.76-4.59 (m, 7H, PhCHH, H-1
I), 4.05 (dd, 1H, 
J2,3 = 3.2 Hz, J3,4 = 9.2, H-3
I), 4.01 (dd, 1H, J1,2 = 1.6 Hz, J2,3 = 2.8, H-2
II), 3.89-3.83 (m, 2H, H-3II, 
H-5II), 3.74-3.63 (m, 3H, H-2I, H-5I, O-CHH-CH2-CH2-NH), 3.58 (t, 1H, J3,4 = 9.2 Hz, H-4
I), 3.51-
3.38 (m, 2H, H-4II, O-CHH-CH2-CH2-NH), 3.32-3.22 (m, 2H, O-CH2-CH2-CH2-NH), 1.81-1.75 (m, 
2H, O-CH2-CH2-CH2-NH), 1.31 (d, 3H, J5,6 = 6.0 Hz, H-6
I), 1.26 (d, 3H, J5,6 = 6.0 Hz, H-6
II). 
 
Characterization in agreement to S. Crotti, H. Zhai, J. Zhou, M. Allan, D. Proietti, W. Pansegrau, 
Q.Y. Hu, F. Berti, R. Adamo, ChemBioChem, 2014, 15, 836. 
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3-(benzyloxycarbonyl)aminopropyl (2-O-acetyl-3,4-di-O-benzyl-α-rhamnopyranosyl)-(1-3)-
(2,4-di-O-benzyl-α-rhamnopyranosyl)-(1-2)-(3,4-di-O-benzyl-α-rhamnopyranosyl)-(1-3)-2,4-
di-O-benzyl- α-rhamnopyranoside [11]. 
To a stirred solution of acceptor 10 (904 mg, 1.05 mmol) and donor 8 (1.0 g, 1.26 mmol) in DCM 
(11 mL) containing activated 4 Å molecular sieves (904 mg), TMSOTf (0.238 mL, 0.105 mmol) 
was added at 0°C. The mixture was stirred at 0°C for 30 min. After neutralization with TEA, the 
mixture was concentrated and purified by flash chromatography (hexane/AcOEt 80:20→60:40) to 
afford the product 11 in 86% yield. 
1HNMR: (CDCl3, 400 MHz): δ = 4.42-7.15 (m, 45H, Ph), 5.55 (dd, 1H, J1,2 = 1.6 Hz, J2,3 = 2.7 Hz, 
H-2IV), 5.14-5.03 (m, 4H, H-1II, H-1III, CH2Cbz), 4.97-4.77 (m, 4H, H-1
IV, PhCHH, H-1I), 4.74-
4.43 (m, 14H, PhCHH), 4.18-4.11 (m, 2H, H-2III, H-3IV), 4.05 (s, 1H, H-2II), 4.00 (dd, 1H, J2,3 = 3.2 
Hz, J3,4 = 9.2, H-3
I), 3.94 (dd, 1H, J2,3 = 3.6 Hz, J3,4 = 9.6, H-3
II), 3.91-3.83 (m, 2H, H-3III, H-5I), 
3.82-3.51 (m, 8H, H-2I, H-4I, H-4II, H-5II, H-5III, H-5IV, O-CHH-CH2-CH2-NH), 3.46-3.36 (m, 3H, 
H-4III, H-4IV, O-CHH-CH2-CH2-NH), 3.31-3.21 (m, 2H, O-CH2-CH2-CH2-NH), 2.10 (s, 3H, 
CH3CO), 1.82-1.74 (m, 2H, O-CH2-CH2-CH2-NH), 1.31-1.16 (m, 12H, H-6
I, H-6II, H-6III, H-6IV).  
 
Characterization in agreement to S. Crotti, H. Zhai, J. Zhou, M. Allan, D. Proietti, W. Pansegrau, 
Q.Y. Hu, F. Berti, R. Adamo, ChemBioChem, 2014, 15, 836. 
 
3-(benzyloxycarbonyl)aminopropyl (3,4-di-O-benzyl-α-rhamnopyranosyl)-(1-3)-(2,4-di-O-
benzyl-α-rhamnopyranosyl)-(1-2)-(3,4-di-O-benzyl-α-rhamnopyranosyl-(1-3)-2,4-di-O-benzyl-
α-rhamnopyranoside [12]. 
Compound 11 (1.4 g, 0.903 mmol) was dissolved in MeOH (8 mL) and a solution 0.1M of 
NaOMe/MeOH was added until pH 9. The mixture was stirred for 1h, when 1HNMR showed the 
disappearance of the acetate signal at 2.10 ppm. the reaction was neutralized with Amberlite (H+ 
form). After filtration, compound 12 was concentrated and used in the next step without other 
purification. 
 
3-aminopropyl α-rhamnopyranosyl-(1-3)-α-rhamnopyranosyl-(1-2)-α-rhamnopyranosyl-(1-3)-
α-rhamnopyranoside [1]. 
Compound 12 (630 mg, 0.416 mmol) was dissolved in a mixture EtOH/H2O 1:1 + HCl 5% (8mL) 
and 10% Pd/C (100 mg) was added. The hydrogenation was performed with appropriate reactor 
using high H2 pressure (20 bar). The mixture was stirred overnight, then filtered through a celite pad 
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and the filtered was concentrated under vacuum. The residue was lyophilized to afford tetraRha 1 in 
90% yield.  
1HNMR: (D2O, 400 MHz): δ = 5.18 (s, 1H, H-1II), 5.04 (s, 1H, H-1III), 4.94 (s, 1H, H-1IV), 4.80 (s, 
1H, H-1I), 4.15 (s, 1H,), 4.06 (s, 2H,), 4.00 (s, 1H,), 3.90 (dd, J2,3 = 2.8 Hz, J3,4 = 9.6, H-3
III), 3.8-
3.6 (m, 9H), 3.57-3.39 (m, 6H), 3.09-3.01 (m, 2H, O-CH2-CH2-CH2-NH), 1.97-1.89 (m, 2H, O-
CH2-CH2-CH2-NH), 1.28-1.19 (m, 12H, H-6
I, H-6II, H-6III, H-6IV).  
 
Characterization in agreement to S. Crotti, H. Zhai, J. Zhou, M. Allan, D. Proietti, W. Pansegrau, 
Q.Y. Hu, F. Berti, R. Adamo, ChemBioChem, 2014, 15, 836. 
 
3-(benzyloxycarbonyl)aminopropyl (2-O-acetyl-3,4-di-O-benzyl-α-rhamnopyranosyl)-(1-3)-
(2,4-di-O-benzyl-α-rhamnopyranosyl)-(1-2)-(3,4-di-O-benzyl-α-rhamnopyranosil)-(1-3)-(2,4-
di-O-benzyl-α-rhamnopyranosyl)-(1-2)-(2,4-di-O-benzyl-α-rhamnopyranosyl)-(1-3)-3,4-di-O-
benzyl-α-rhamnopyranoside [13]. 
To a stirred solution of acceptor 12 (1.0 g, 0.66 mmol) and donor 8 (677 mg, 0.792 mmol) in DCM 
(7 mL) containing activated 4 Å molecular sieves (1.0 g), TMSOTf (0.149 mL, 0.066 mmol) was 
added at 0°C. The mixture was stirred at 0°C for 1h. After neutralization with TEA, the mixture was 
concentrated and purified with Biotage SNAP 50g column (hexane/AcOEt 0→100%) to afford 
product 11 in 86% yield. 
1HNMR: (CDCl3, 400 MHz): δ = 7.41-7.20 (m, 65H, Ph), 5.57 (dd, 1H, J1,2 = 1.6 Hz, J2,3 = 3.2 Hz, 
H-2VI), 5.16-5.02 (m, 7H, H-1VI, H-1V, H-1IV, H-1III, H-1II, CH2Cbz), 4.97-4.77 (m, 7H, H-1
I, 
PhCHH), 4.75-4.43 (m, 20H, PhCHH), 4.19 (dd, 1H, J2,3 = 2.8 Hz, J3,4 = 9.2, H-3
VI), 4.12 (dd, 1H, 
J2,3 = 3.2 Hz, J3,4 = 9.6, H-3
V), 4.07 (dd, 1H, J1,2 = 2.0 Hz, H-2
V), 4.02 (dd, 1H, J2,3 = 3.2 Hz, J3,4 = 
9.2, H-3IV), 3.95 (dd, 1H, J2,3 = 3.6 Hz, J3,4 = 9.6, H-3
III), 3.93-3.51 (m, 17H), 3.50-3.39 (m, 4.51), 
3.33-3.25 (m, 2H, O-CH2-CH2-CH2-NH), 2.11 (s, 3H, CH3CO), 1.82-1.70 (m, 2H, O-CH2-CH2-
CH2-NH), 1.31-1.22 (m, 12H, H-6
VI, H-6V, H-6IV, H-6III), 1.19 (d, 3H, J5,6 = 6.4 Hz, H-6
II), 1.11 (d, 
3H, J5,6 = 6.0 Hz, H-6
I). 13CNMR (CDCl3, 100MHz): δ = 169.88 (CO), 156.37 (CONH), 138.79, 
138.29, 138.03, 128.39, 128.30, 128.15, 127.74, 127.56 (Ph), 100.96, 100.64, 99.71, 99.46, 99.103, 
97.53 (C-1), 81.16, 80.69, 80.65, 80.34, 79.99, 79.82, 78.17, 78.05, 77.85, 76.53, 75.51, 75.20, 
74.72, 72.72, 72.41, 72.27, 71.75, 69.00, 68.76, 68.53, 68.30, 66.63, 65.17, 38.50, 29.65, 21.02 
(CH3CO), 18.04. MALDI: [M+Na]
+= 2232.13. 
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3-aminopropyl α-rhamnopyranosyl-(1-3)-α-rhamnopyranosyl-(1-2)-α-rhamnopyranosyl-(1-3)- 
α-rhamnopyranosyl-(1-2)-α-rhamnopyranosyl-(1-3)-α-rhamnopyranoside [2]. 
Compound 13 (1.2 g, 0.543 mmol) was dissolved in MeOH (5mL) and a solution 0.1M 
NaOMe/MeOH was added until pH 9. The mixture was stirred for 2h, when the 1HNMR showed 
the disappearance of the acetate signal at 2.11 ppm. The reaction was neutralized with Amberlite 
(H+ form), filtered and concentrated. The resulting intermediate 14 was dissolved in EtOH/H2O 1:1 
+ HCl 5% in presence of 10% Pd/C (100 mg) to perform hydrogenation at high pressure of H2 (20 
bar). The reaction was stirred overnight, then filtered through a celite pad. The filtrated was 
concentrated under vacuum and lyophilized to afford hexaRha 2 in 90% yield.  
1HNMR: (D2O, 400 MHz): δ = 5.16 (bs, 2H, H-1VI, H-1V), 5.02 (s, 1H, H-1IV), 4.93 (bs, 2H, H-1III, 
H-1II), 4.81-4.66 (H-1I), 4.17-3.88 (m, 8H, H-3VI, H-3V, H-3IV, H-3III, H-4VI, H-4V, H-4IV, H-4III), 
3.87-3.64(m, 25H, O-CHH-CH2-CH2-NH, H-2
VI, H-2V, H-2IV, H-2III, H-2II, H-2I, H-3II, H-3I, H-4II, 
H-5VI, H-5V, OH), 3.62-3.42 (m, 6H, O-CHH-CH2-CH2-NH, H-4
II, H-5IV, H-5III, H-5II, H-5I), 3.10 
(bs, 2H, O-CH2-CH2-CH2-NH), 1.97 (bs, 2H, O-CH2-CH2-CH2-NH), 1.34-1.20 (m, 18H, H-6
VI, H-
6V, H-6IV, H-6III, H-6II, H-6I). 13CNMR (D2O, 100MHz): δ = 102.23, 101.92, 101.86, 100.71, 
100.70, 99.50, 77.97, 77.86, 77.75, 72.05, 71.87, 71.59, 71.50, 71.19, 70.00, 69.77, 69.76, 69.18, 
69.17, 69.16, 69.15, 69.10, 69.00, 64.68, 37.38, 26.47, 16.58, 16.57, 16.55, 16.53, 15.51, 16.49. 
ESI: [M+Na]+= 974.48. [α]D25 = -32.40˚ (c 0.5, D2O).  
 
67 
 
Synthesis of GAC-dimer 
1,2,3,4-tetra-O-acetyl-α-rhamnopyranose [15].  
In a solution of Ac2O (250 mL) and I2 (2.4 g, 9.60 mmol) at 0 °C, L-rhamnose (50 g, 274 mmol) 
was added. The mixture was stirred for 15min, then a solution of 10% NaS2O3 (100 mL) was added 
and product was extracted with DCM (120 mL) for three times. Organic layers were unified and 
washed with a solution of 5% NaHCO3 (200 mL), H2O (200 mL) and brine (200 mL), dried and 
concentrated under vacuum. The product 15 was recovered in α/β mixture (40% β from NMR) in 
quantitative yield.  
1HNMR: (CDCl3, 400 MHz): δ = 6.02 (s, 1H, H-1α), 5.84 (s, 1H, H-1β), 5.48 (bs,1H, H-3 β), 5.31 
(dd, 1H, J2,3 = 3.6 Hz, J3,4 = 10.4 Hz, H-3α), 5.26-5.24 (m, 1H, H-2α), 5.16-5.07 (m, 3H, J3,4 = 10.0 
Hz, H-4α, H-2β, H- 4β), 3.98-3.91 (m, 1H, H-5α), 3.71-3.64 (m, 1H, H-5β), 2.23 (s, 3H, CH3CO), 
2.21 (s, 3H, CH3CO), 2.17 (s, 3H, CH3CO), 2.16 (s, 3H, CH3CO), 2.10 (s, 3H, CH3CO), 2.07 (s, 
3H, CH3CO), 2.01 (s, 3H, CH3CO), 1.3 (d, 1H, J5,6 = 6.4 Hz, H-6β), 1.24 (d, 1H, J5,6 = 6.0 Hz, H-
6α). 13CNMR (CDCl3, 100 MHz): δ = 170.06, 169.83, 168.36, 90.58 (C-1α), 90.27 (C-1β), 71.40 
(C-5β), 70.67, 70.42, 70.20, 68.72 (C-5α),68.65, 68.60, 68.47, 22.12, 20.81, 20.73, 20.60, 17.40(C-
6α), 17.32 (C-6β). ESI: [M+Na]+= 355.12. [α]D25 = -57.87˚ (c 1.1, CHCl3).  
 
3-(benzyloxycarbonyl) aminopropyl 2,3,4-tri-O-acetyl-α-rhamnopyranoside [16]. 
3-(benzyloxycarbonil)aminopropanol (37.80 g, 180.66 mmol) and compound 15 (20 g, 60.22 
mmol) were dissolved in DCM (250 mL). The reaction mixture was cooled at 0°C and BF3·Et2O 
(22.3 mL, 180.66 mmol) was added slowly. After 30 min, the reaction was left to warm at room 
temperature, then stirred overnight at 40°C. The reaction was neutralized with TEA at 0°C, 
concentrated under reduced pressure and purified by flash chromatography (hexane/AcOEt 1:1). 
The α-product 16 was recovered in 62% yield. 
1HNMR: (CDCl3, 400 MHz): δ = 7.39-7.32 (m, 5H, Ph), 5.29 (dd, 1H, J2,3 = 3.2 Hz, J3,4 = 9.6 Hz, 
H-3), 5.25 (dd, 1H, J1,2 = 1.6 Hz, J2,3 = 3.6 Hz, H-2), 5.13 (s, 2H, CH2Cbz), 5.08 (t, 1H, J3,4 = 10.0 
Hz, H-4), 4.9 (bs, 1H, NH), 4.73 (d, J1,2 = 1.6 Hz, H-1), 3.91-3.83 (m, 1H, H-5), 3.80-3.75 (m, 1H, 
O-CHH-CH2-CH2-NH), 3.54-3.48 (m, 1H, O-CHH-CH2-CH2-NH), 3.36-3.31 (m, 2H, O-CH2-CH2-
CH2-NH), 2.17 (s, 3H, CH3CO), 2.06 (s, 3H, CH3CO), 2.01 (s, 3H, CH3CO), 1.90-1.80 (m, 2H O-
CH2-CH2-CH2-NH), 1.24 (d, 3H, J5,6 = 6.0 Hz, H-6). 
13CNMR (CDCl3, 100 MHz): δ = 170.16, 
169.84, 156.46, 128.51, 128.08, 97.54 (C-1), 71.05 (C-4), 69.89 (C-2), 69.12 (C-3), 66.70 
(CH2Cbz), 66.51 (C-5), 65.79 (O-CH2-CH2-CH2-NH), 38.47 (O-CH2-CH2-CH2-NH), 29.68 (O-
CH2-CH2-CH2-NH), 20.91, 20.81, 20.72, 17.44 (C-6). ESI: [M+Na]
+= 504.41. [α]D25 = - 25.20˚ (c 
0.5, CHCl3). 
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3-(benzyloxycarbonyl) aminopropyl 2,3-O-isopropylidene-α-rhamnopyranoside [17]. 
Compound 16 (15 g, 31.17 mmol) was dissolved in MeOH (200 mL) and a solution 0.1M of 
NaOMe/MeOH was added until pH 9. The mixture was stirred overnight, then neutralized with 
Amberlite (H+ form), filtered and concentrated. The crude was dissolved in 2,2-
dimethoxypropane/DCM 4:1 (200 mL) and p-TsOH (1.48 g, 7.79 mmol) was added. The mixture 
was stirred overnight at room temperature, then neutralized with TEA at 0 °C and concentrated. 
Product 17 was recovered in 87% yield after purification by flash chromatography (hexane/AcOEt 
50:50). 
1HNMR: (CDCl3, 400 MHz): δ = 7.39-7.32 (m, 5H, Ph), 5.13 (CH2Cbz), 4.95 (s, 1H, H-1), 4.92 
(bs, 1H, NH), 4.14 (d, 1H, J2,3 = 2.8 Hz, H-2), 4.08 (t, 1H, J3,4 = 7.2 Hz, H-3), 3.83-3.77 (m, 1H, O-
CHH-CH2-CH2-NH), 3.68-3.61 (m, 1H, H-5), 3.54-3.48 (m, 1H, O-CHH-CH2-CH2-NH), 3.41 (dd, 
1H, J3,4 = 7.2 Hz, J4,5 = 9.2 Hz, H-4), 3.36-3.18 (m, 2H, O-CH2-CH2-CH2-NH), 1.88-1.79 (m, 3H, 
OH, O-CH2-CH2-CH2-NH), 1.54 (s, 3H, OCH3), 1.37 (s, 3H, OCH3), 1.30 (d, 3H, J5,6 = 6.0 Hz, H-
6). 13CNMR (CDCl3, 100 MHz): δ = 128.56, 128.55, 128.18, 128.14, 97.33 (C-1), 78.31 (C-2), 
75.85 (C-3), 74.51 (C-4), 66.77 (CH2Cbz), 66.01 (C-5), 65.36, 38.62, 29.55, 27.96 (OCH3), 26.25 
(OCH3), 17.48. ESI: [M+Na]
+= 418.39. [α]D25 = -25.20˚ (c 0.5, CHCl3).  
 
3-(benzyloxycarbonyl)-3-N-benzyl aminopropyl 4-O-benzyl-2,3-O-isopropylidene- -α-
rhamnopyranoside [18]. 
To a solution of compound 17 (5 g, 8.68 mmol) in DMF (80 mL) at 0°C, NaH (1.25 g, 52.08 mmol) 
was added. Benzyl bromide (4 mL, 34.72 mmol) was introduced dropwise. The mixture was stirred 
overnight at room temperature, then concentrated to the minimum amount of solvent (~20 mL) and 
cooled at 0°C. H2O (20 mL) was added slowly and the product was extracted with DCM (20 mL for 
five times). Organic layers were unified and washed with brine (40 mL), dried and concentrated 
under vacuum. The product 18 was recovered in 72% yield after purification by flash 
chromatography (hexane/AcOEt 90:10→60:40).  
1HNMR: (CDCl3, 400 MHz): δ = 7.40-7.22 (m, 15H, Ph), 5.21 (bs, 2H, CH2Cbz), 4.90 (d, bs, 2H, J 
= 11.2 Hz, PhCHH, H-1), 4.65 (d, 1H, J = 11.2 Hz, PhCHH), 4.53 (s, 2H, PhCH2), 4.25 (bs, 1H, H-
2), 4.10 (bs, 1H, H-3), 3.67 (bs, 2H, H-5, O-CHH-CH2-CH2-NH), 3.38 (bs, 3H, O-CHH-CH2-CH2-
NH, O-CH2-CH2-CH2-NH), 3.22 (dd, 1H, J3,4 = 6.8 Hz, J4,5 = 9.2 Hz, H-4), 1.82 (bs, 2H, O-CH2-
CH2-CH2-NH), 1.53 (s, 3H, OCH3), 1.39 (s, 3H, OCH3), 1.27 (d, 3H, J5,6 = 6.2 Hz, H-6). 
13CNMR 
(CDCl3, 100 MHz): δ = 138.31, 137.77, 136.68, 128.56, 128.49, 128.25, 127.87, 127.67, 127,66, 
127.40, 127.23, 109.29, 96.99 (C-1), 80.96 (C-4), 78.56, 76.67, 72.84, 67.32, 64.51, 50.76, 50.75, 
27.94, 26.42, 17.77. ESI: [M+Na]+= 598.60. [α]D25 = -25.70˚ (c 1.2, CHCl3).  
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3-(benzyloxycarbonyl)-3-N-benzyl aminopropyl 4-O-benzyl-α-rhamnopyranoside [19]. 
Compound 18 (5 g, 8.68 mmol) was dissolved in DCM (50 mL) and cooled at 0°C. A solution of 
TFA 50% in DCM was added (13 mL) and the mixture was stirred for 2h, when NMR showed the 
disappearance of methoxy signals (1.53 ppm and 1.39 ppm). The reaction was treated with a 
saturated solution of K2CO3 (20 mL). The organic layer was washed with H2O (20 mL) and brine 
(20 mL), dried and concentrated. The product was used in the next step without other purification. 
 
3-(benzyloxycarbonyl)-3-N-benzyl-aminopropyl 4-O-benzyl-3-O-naphthylmethyl- -α-
rhamnopyranoside [20]. 
To a solution of compound 19 (4.6 g, 8.68 mmol) in toluene (50 mL) 4Å activated molecular sieves 
(2.3 g) and Bu2SnO (2.58 g, 10.42 mmol) were added. The reaction was stirred for 4h at reflux, then 
it was cooled at 45°C and NapBr (2.16 g, 10.42 mmol) and TBAI (3.8 g, 10.42 mmol) were 
introduced. The mixture was stirred overnight, then filtered on a celite pad, concentrated and 
purified by flash chromatography (hexane/AcOEt 90:10→50:50) to afford product 20 in 54% yield. 
1HNMR: (CDCl3, 400 MHz): δ = 7.87-7.76 (m, 4H, Ph-Nap), 7.52-7.46 (m, 3H, Ph-Nap), 7.39-7.19 
(m, 15H, Ph), 5.21 (s, 2H, CH2Cbz), 4.95 (d, 1H, J = 11.2, PhCHH), 4.87-7.19 (bs, 3H, PhCH2, H-
1), 4.69 (d, 1H, J = 11.2, PhCHH), 4.51 (bs, 2H, PhCH2), 4.02 (bs, 1H, H-2), 3.88 (bs, 1H, H-3), 
3.70 (bs, 2H, O-CHH-CH2-CH2-NH, H-5), 3.49 (t, 1H, J3,4 = 9.6 Hz), 3.35 (bs, 3H, O-CHH-CH2-
CH2-NH, O-CH2-CH2-CH2-NH), 2.19 (bs, 1H, OH), 1.80 (bs, 2H, O-CH2-CH2-CH2-NH), 1.33 (d, 
3H, J5,6 = 6.4 Hz, H-6). 
13CNMR (CDCl3, 100 MHz): δ = 156.68, 138.40, 137.78, 136.71, 135.33, 
133.25, 133.05, 128.59, 128.42, 127.95, 127.70, 127.40, 127.24, 126.61, 126.20, 126.04, 125.76, 
98.95, 75.41, 72.09, 68.64, 67.42, 67.26, 65.15, 50.59, 27.81, 17.85. ESI: [M+Na]+= 698.74. [α]D25 
= -16.76˚ (c 0.6, CHCl3).  
 
3-(benzyloxycarbonyl)-3-N-benzyl-aminopropyl 2,4-di-O-benzyl-3-O-naphthylmethyl-α-
rhamnopyranoside [21]. 
To a solution of compound 20 (3.16 g, 4.67 mmol) in DMF (46 mL) at 0°C, NaH (224 mg, 9.34 
mmol) was added. Benzyl bromide (1.11 mL, 9.34 mmol) was introduced dropwise. The mixture 
was stirred overnight at room temperature, then concentrated to the minimum amount of solvent 
(~15 mL) and cooled at 0°C. H2O (10 mL) was added slowly and the product was extracted with 
DCM (15 mL for five times). Organic layers were unified and washed with brine (30 mL), dried, 
concentrated under vacuum and purified by flash chromatography (hexane/AcOEt 70:30) to afford 
product 21 in 78% yield.  
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1HNMR: (CDCl3, 400 MHz): δ = 7.84-7.69 (m, 4H, Ph-Nap), 7.48-7.43 (m, 3H, Ph-Nap), 7.39-7.17 
(m, 20H, Ph), 5.12 (s, 2H, CH2Cbz), 4.91 (d, 1H, J = 10.8, PhCHH), 4.79-4.62 (m, 6H, PhCHH, 
PhCH2, H-1), 4.44 (bs, 2H, PhCH2), 3.81 (bs, 2H, H-2, H-3), 3.59 (bs, 2H, O-CHH-CH2-CH2-NH, 
H-5), 3.50 (t, 1H, J3,4 = 8.8 Hz, H-4), 3.37-3.24 (m, 3H, O-CHH-CH2-CH2-NH, O-CH2-CH2-CH2-
NH), 1.75-1.69 (m, 2H, O-CH2-CH2-CH2-NH), 1.24 (d, 3H, J5,6 = 6.4 Hz, H-6). 
13CNMR (CDCl3, 
100 MHz): δ = 128.57, 128.38, 127.97, 127.86, 127.66, 127.33, 126.21, 126.05, 125.76, 97.93, 
80.54, 80.17, 75.46, 74.99, 72.74, 72.22, 68.08, 67.29, 64.98, 50.66, 29.91, 18.16. ESI: [M+Na]+= 
788.70. [α]D25 = -20.66˚ (c 2.3, CHCl3).  
 
3-(benzyloxycarbonyl)-3-N-benzyl-aminopropyl 2,4-di-O-benzyl-α-rhamnopyranoside [22]. 
To a solution of compound 21 (2.78 g, 3.63 mmol) in MeOH/DCM 4:1 (35 mL) DDQ (1.64 g, 7.26 
mmol) freshly crystallized from CHCl3 was added. The mixture was stirred for 2h, then quenched 
with a solution of 15% NaHCO3 (25 mL). Product 22 was extracted three times with DCM (20 mL). 
Organic layers were unified and washed with H2O (25 mL) and brine (25 mL), dried with Na2SO4 
and concentrated under reduced pressure. The mixture was purified by flash chromatography 
(hexane/AcOEt 90:10→60:40) to afford compound 22 in 82% yield. 
1HNMR: (CDCl3, 400 MHz): δ = 7.30-7.13 (m, 20H, Ph), 5.10 (s, 2H, CH2Cbz), 4.82 (d, 1H, J = 
10.8 Hz, PhCHH), 4.70-4.53 (m, 3H, PhCHH, H-1), 4.51-4.37 (m, 3H, PhCHH, PhCH2), 3.8 (bs, 
1H, H-2), 3.62-3.48 (m, 3H, O-CHH-CH2-CH2-NH, H-3, H-5), 3.33-3.13 (m, 4H, J3,4 = 8.8 Hz, O-
CHH-CH2-CH2-NH, O-CH2-CH2-CH2-NH, H-4), 2.19 (d, 1H, J = 8.4, OH), 1.67 (bs, 2H, O-CH2-
CH2-CH2-NH), 1.22 (d, 3H, J5,6 = 6.0 Hz, H-6). 
13CNMR (CDCl3, 100 MHz): δ = 128.64, 128.37, 
127.94, 127.75, 127.36, 97.00, 82.39, 78.68, 75.14, 72.94, 71.70, 67.21, 67.11, 65.02, 28.21, 17.92. 
ESI: [M+Na]+= 648.72. [α]D25 = -29.81˚ (c 1.2, CHCl3).  
 
Allyl 2,3,4- tri-O-acetyl-α-rhamnopyranoside [23]. 
Allyl alcohol (6.16 mL, 90.33 mmol) and compound 15 (20 g, 60.22 mmol) were dissolved in DCM 
(200 mL). The reaction mixture was cooled at 0°C and BF3·Et2O (11.14 mL, 90.33 mmol) was 
added slowly. After 30 min, the reaction was left to warm at room temperature, then stirred for 5h at 
40°C. The reaction was neutralized with TEA at 0°C, concentrated under reduced pressure and 
purified by flash chromatography(hexane/AcOEt 1:1). The α-product 23 was recovered in 60% 
yield. 
1HNMR: (CDCl3, 400 MHz): δ = 5.95-5.85 (m, 1H, CH2-CH=CH2), 5.35-5.29 (m, 2H, CH2-
CH=CHH, H-3), 5.26 (dd, 1H, J1,2= 1.2 Hz, J2,3= 3.2 Hz, H-2), 5.23 (dt, 1H, J1= 1.6 Hz, J2 = 2.8 
Hz, CH2-CH=CHH), 5.07 (t, 1H, J3,4 = 10.0 Hz, H-4), 4.78 (d, 1H, J1,2= 1.2 Hz, H-1), 4.18 (ddt, 1H, 
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J1= 1.6 Hz, J2= 5.2 Hz, J3= 7.2 Hz, CHH-CH=CH2), 4.01 (ddt, 1H, J1= 1.6 Hz, J2= 5.2 Hz, J3= 7.2 
Hz, CHH-CH=CH2), 3.93-3.86 (m, 1H, H-5), 2.15 (s, 3H, CH3CO), 2.05 (s, 3H, CH3CO), 1.99 (s, 
3H, CH3CO), 1.23 (d, 3H, J5,6 = 6.4 Hz, H-6). 
13CNMR (CDCl3, 100 MHz): δ = 170.11(CO), 
169.99(CO), 169.93 (CO), 133.25 (CH2-CH=CH2), 118.00 (CH2-CH=CH2), 96.46 (C-1), 71.17 (C-
4), 69.94 (C-2), 69.13 (C-3), 68.36 (CH2-CH=CH2), 66.41 (C-5), 20.91 (CH3CO), 20.77 (CH3CO), 
20.70 (CH3CO), 17.38 (C-6). ESI: [M+Na]
+= 353.73. [α]D25 = -58.94˚ (c 1.2, CHCl3).  
 
Allyl 2,3-O-isopropylidene-α-rhamnopyranoside [24]. 
Compound 23 (15 g, 45.4 mmol) was dissolved in MeOH (200 mL) and a solution 0.1M of 
NaOMe/MeOH was added until pH 9. The mixture was stirred overnight, then neutralized with 
Amberlite (H+ form), filtered and concentrated. The crude was dissolved in 2,2-
dimethoxypropane/DCM 4:1 (200 mL) and p-TsOH (2.15 g, 11.35 mmol) was added. The mixture 
was stirred overnight at room temperature, then neutralized with TEA at 0°C and concentrated. 
Product 24 was recovered in 85% yield after purification by flash chromatography (hexane/AcOEt 
60:40). 
1HNMR: (CDCl3, 400 MHz): δ = 5.98-5.87 (m, 1H, CH2-CH=CH2), 5.35-5.21 (dt, 2H, J1= 1.6 Hz, 
J2 = 2.8 Hz, CH2-CH=CH2), 5.02 (s, 1H, H-1), 4.23-4.17 (m, 2H, CHH-CH=CH2, H-2), 4.12 (t, 1H, 
J3,4 = 8.4 Hz, H-3), 4.05-3.97 (m, 1H, CHH-CH=CH), 3.74-3.67 (m, 1H, H-5), 3.42 (t, 1H, J3,4 = 
8.0 Hz, H-4), 2.47 (bs, 1H, OH), 1.55 (s, 3H, OCH3), 138 (s, 3H, OCH3), 1.31 (d, 3H, J5,6 = 6.4 Hz, 
H-6). 13CNMR (CDCl3, 100 MHz): δ = 133.29 (CH2-CH=CH2), 117.69 (CH2-CH=CH2), 95.61 (C-
1), 78-17 (C-3), 75.88 (C-2), 73.96 (C-4), 67.56 (CH2-CH=CH2), 66.13 (C-5), 27.65 (OCH3), 25.52 
(OCH3), 16.46 (C-6). ESI [M+Na]
+= 267.35. [α]D25 = -55.34˚ (c 1.1, CHCl3).  
 
Allyl 4-O-benzyl-2,3-O-isopropylidene-α-rhamnopyranoside [25]. 
To a solution of compound 24 (4 g, 16.37 mmol) in DMF (150 mL) at 0°C, NaH (785 mg, 32.74 
mmol) was added. Benzyl bromide (3.89 mL, 32.74 mmol) was introduced dropwise. The mixture 
was stirred for 6h at room temperature, then concentrated to the minimum amount of solvent (~20 
mL) and cooled at 0°C. H2O (40 mL) was added slowly and the product was extracted with DCM 
(30 mL for five times). Organic layers were unified and washed with brine (70 mL), dried with 
Na2SO4, concentrated under vacuum and purified by flash chromatography(hexane/AcOEt 70:30) to 
afford compound 25 in 95% yield.  
1HNMR: (CDCl3, 400 MHz): δ = 7.42-7.28 (m, 5H, Ph), 5.98-5.88 (m, 1H, CH2-CH=CH2), 5.32 
(dt, 1H, J1= 1.6 Hz, J2= 2.8 Hz, CH2-CH=CHH), 5.23 (dt, 1H, J1= 1.6 Hz, J2= 2.8 Hz, CH2-
CH=CHH), 5.04 (s, 1H, H-1), 4.93 (d, 1H, J = 12.4, PhCHH), 4.65 (d, 1H, J = 12.4 Hz, PhCHH), 
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4.31 (t, 1H, J3,4 =7.2 Hz, H-3), 4.22-4.16 (m, 2H, CHH-CH=CH2, H-2), 4.02 (ddt, 1H, J1= 1.6 Hz, 
J2= 5.2 Hz, J3= 7.2 Hz, CHH-CH=CH2), 3.78-3.71 (m, 1H, H-5), 3.25 (dd, 1H, J3,4 = 7.2 Hz, J4,5 = 
10.0 Hz, H-4), 1.54 (s, 3H, OCH3), 1.40 (s, 3H, OCH3), 1.31 (d, 3H, J5,6 = 6.4 Hz, H-6). 
13CNMR 
(CDCl3, 100 MHz): δ = 127.91, 133.95, 117.45, 95.64 (C-1), 80.70 (C-4), 78.09 (C-3), 76.35 (C-2), 
72.17, 67.35, 64.86 (C-5), 28.45, 26.36, 17.18.  
 
Allyl 4-O-benzyl-α-rhamnopyranoside [26]. 
Compound 25 (5.2 g, 15.54 mmol) was dissolved in DCM (70 mL) and cooled at 0°C. A solution of 
TFA 50% in DCM was added (16 mL) and the mixture was stirred for 2h, when NMR showed the 
disappearance of methoxy signals (1.54 ppm and 1.40 ppm). The reaction was treated with a 
saturated solution of K2CO3 (35 mL). The organic layer was washed with H2O (30 mL) and brine 
(30 mL), dried with Na2SO4 and concentrated. The product 26 was used in the next step without 
other purification. 
 
Allyl 4-O-benzyl-3-O-naphthylmethyl-α-rhamnopyranoside [27]. 
To a solution of compound 26 (4.5 g, 15.54 mmol) in toluene (70 mL) 4Å activated molecular 
sieves (2.2 g) and Bu2SnO (4.6 g, 18.65 mmol) were added. The reaction was stirred for 4h at 
reflux, then it was cooled at 45°C and NapBr (3.8 g, 18.65 mmol) and TBAI (6.8 g, 18.65 mmol) 
were introduced. The mixture was stirred overnight, then filtered on a celite pad, concentrated and 
purified by flash chromatography (hexane/AcOEt 90:10→50:50) to afford product 27 in 58% yield. 
1HNMR: (CDCl3, 400 MHz): δ = 7.89-7.78 (m, 4H, Ph-Nap), 7.53-7.49 (m, 3H, Ph-Nap), 7.40-7.30 
(m, 5H, Ph), 5.96-5.87 (m, 1H, CH2-CH=CH2), 5.30 (dt, 1H, J1= 1.6 Hz, J2= 2.8 Hz, CH2-
CH=CHH), 5.22 (dt, 1H, J1= 1.6 Hz, J2= 2.8 Hz, CH2-CH=CHH), 4.96 (d, 1H, J = 11.2 Hz, 
PhCHH), 4.91-4.85 (m, 3H, PhCH2, H-1), 4.70 (d, 1H, J = 11.2 Hz, PhCHH), 4.22-4.13 (m, 2H, 
CH2-CH=CHH, H-2), 4.03-3.96 (m, 2H, CH2-CH=CHH, H-3), 3.85-3.78 (m, 1H, H-5), 3.54 (t, 1H, 
J3,4 = 9.2 Hz, H-4), 1,37 (d, 3H, J5,6 = 6.0 Hz, H-6). 
13CNMR (CDCl3, 100 MHz): δ = 138.45, 
135.42, 133.76, 133.32, 133.11, 128.43, 128.37, 128.32, 127.96, 127.76, 127.72, 126.66, 126.24, 
126.20, 126.08, 125.90, 125.80, 125.42, 125.19, 117.48, 98,21 (C-1), 80.14 (C-3), 80.10 (C-4), 
75.49, 72.20, 68.66 (C-2), 67.91, 67.49 (C-5), 17.91 (C-6). [α]D25 = -50.09˚ (c 1.1, CHCl3).  
 
Allyl 2-O-acetyl-4-O-benzyl-3-O-naphthylmethyl-α-rhamnopyranoside [28]. 
Compound 27 (5 g, 11.50 mmol) was dissolved in pyridine (25 mL) and cooled at 0°C. Ac2O (25 
mL) was added dropwise and the mixture was stirred overnight at room temperature in presence of 
DMAP (14 mg, 0,115 mmol). The reaction was concentrated at minimum amount of solvent, 
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diluted with DCM (100 mL) and washed with a solution of 5% HCl (40 mL), H2O (40 mL) and 
brine (40 mL). Organic layer was dried with Na2SO4, concentrated under reduced pressure and 
purified by flash chromatography (hexane/AcOEt 70:30). Yield 98%.  
1HNMR: (CDCl3, 400 MHz): δ = 7.88-7.74 (m, 4H, Ph-Nap), 7.53-7.46 (m, 3H, Ph-Nap), 7.38-7.31 
(m, 5H, Ph), 5.95-5.86 (m, 1H, CH2-CH=CH2), 5.49 (dd, 1H, J1,2 = 2.0 Hz, J2,3 = 3.2 Hz, H-2), 5.29 
(dt, 1H, J1= 1.6 Hz, J2= 2.8 Hz, CH2-CH=CHH), 5.21 (dt, 1H, J1= 1.6 Hz, J2= 2.8 Hz, CH2-
CH=CHH), 4.99 (d, 1H, J = 10.8 Hz, PhCHH), 4.90 (d, 1H, J = 11.2 Hz, PhCHH), 4.83 (d, 1H, J1,2 
= 2.0 Hz, H-1), 4.73 (d, 1H, J = 11.2 Hz, PhCHH), 4.68 (d, 1H, J = 10.8 Hz, PhCHH), 4.18 (ddt, 
1H, J1 = 1.6 Hz, J2 = 5.2 Hz, J3 = 7.6 Hz, CHH-CH=CH2), 4.06 (dd, 1H, J2,3 = 3.2 Hz, J3,4 = 9.2 Hz, 
H-3), 4.00 (ddt, 1H, J1 = 1.6 Hz, J2 = 5.2 Hz, J3 = 7.6 Hz, CHH-CH=CH2), 3.86-3.80 (m, 1H, H-5), 
3.51 (t, 1H, J3,4 = 9.2 Hz, H-4), 2.20 (s, 3H, CH3CO), 1.38 (d, 3H, J5,6 = 6.4 Hz, H-6). 
13CNMR 
(CDCl3, 100 MHz): δ = 170.43, 138.66, 135.64, 133.64, 133.45, 132.93, 128.40, 128.14, 127.93, 
127.70, 126.84, 126.14, 126.01, 125.87, 117.81, 96.99 (C-1), 80.18 (C-4), 78.17 (C-3), 75.47, 
71.82, 69.08 (C-2), 68.06, 67.82 (C-5), 21.31, 18.10. [α]D25 = -52.14˚ (c 1.4, CHCl3).  
 
Allyl 2,4-di-O-benzyl-3-O-naphthylmethyl-α-rhamnopyranoside [29]. 
To a solution of compound 28 (5 g, 11.50 mmol) in DMF (115 mL) at 0°C, NaH (552 mg, 23 
mmol) was added. Benzyl bromide (2.7 mL, 23 mmol) was introduced dropwise. The mixture was 
stirred for 2h at room temperature, then concentrated to the minimum amount of solvent (~25 mL) 
and cooled at 0°C. H2O (50 mL) was added slowly and the product was extracted with DCM (40 
mL for five times). Organic layers were unified and washed with brine (100 mL), dried with 
Na2SO4, concentrated under vacuum and purified by flash chromatography (hexane/AcOEt 70:30) 
to afford compound 29 in 95% yield.  
1HNMR: (CDCl3, 400 MHz): δ = 7.9-7.72 (m, 4H, Ph-Nap), 7.54-7.28 (m, 18H, Ph), 5.90-5.79 (m, 
1H, CH2-CH=CH2), 5.25-5.14 (m, 2H, CH2-CH=CH2), 5.01 (dd, 1H), 4.89-4.59 (m, 7H, PhCHH, 
H-1, H-2), 4.15 (bs, 1H, H-3), 4.01-3.91 (m, 2H, CHH-CH=CH2, H-5), 3.79-3.65 (m, 2H, CHH-
CH=CH2, H-4), 1.38 (d, 3H, J5,6 = 6.4 Hz, H-6).  
 
Allyl 2,4-di-O-benzyl-α-rhamnopyranoside [30]. 
To a solution of compound 29 (5.73 g, 14.90 mmol) in MeOH/DCM 4:1 (30 mL) DDQ (6.76 g, 
29.8 mmol) freshly crystallized from CHCl3 was added. The mixture was stirred for 2h, then 
quenched with a solution of 15% NaHCO3 (15 mL). Product 30 was extracted three times with 
DCM (25 mL). Organic layers were unified and washed with H2O (35 mL) and brine (35 mL), dried 
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with Na2SO4 and concentrated under reduced pressure. The mixture was purified by flash 
chromatography (hexane/AcOEt 90:10→60:40) to afford compound 30 in 82% yield.  
1HNMR: (CDCl3, 400 MHz): δ = 7.42-7.29 (m, 10H, Ph), 5.92-5.83 (m, 1H, CH2-CH=CH2), 5.27 
(dt, 1H, J1= 1.6 Hz, J2= 2.8 Hz, CH2-CH=CHH), 5.19 (dt, 1H, J1= 1.6 Hz, J2= 2.8 Hz, CH2-
CH=CHH), 4.93 (d, 1H, J = 11.2 Hz, PhCHH), 4.88 (d, 1H, J1,2 = 1.2 Hz, H-1), 4.77 (d, 1H, J = 
11.6 Hz, PhCHH), 4.68 (d, 1H, J = 11.2 Hz, PhCHH), 4.61 (d, 1H, J = 11.6 Hz, PhCHH), 4.16 (ddt, 
1H, J1 = 1.6 Hz, J2 = 5.2 Hz, J3 = 7.6 Hz, CHH-CH=CH2), 4.01-3.93 (m, 2H, CHH-CH=CH2, H-3), 
3.77 (dd, 1H, J1,2 =1.2 Hz, J2,3 = 3.6 Hz, H-2), 3.75-3.69 (m, 1H, H-5), 3.55 (t, 1H, J3,4 = 10 Hz, H-
4), 1.92 (bs, 1H, OH), 1.35 (d, 3H, J5,6 = 6.4 Hz, H-6). 
13CNMR (CDCl3, 100 MHz): δ = 127.75, 
133.53, 117.23, 95.79 (C-1), 81.80 (C-4), 78.49 (C-2), 74.51, 72.60, 71.63 (C-3), 67.84, 67.19 (C-
5), 18.36 (C-6).  
 
2-O-acetyl-4-O-benzyl-3-O-naphthylmethyl-α-rhamnopyranosyl trichloroacetimidate [32]. 
A solution of compound 28 (5.37 g, 11.2 mmol) in THF (112 mL) containing 1,5-
cyclooctadienebis(methyldiphenylphosphine)-Iridium(I)-hexafluorophosphate (946.4 mg, 1.12 
mmol) was degassed for 1h, then hydrogen was flown for 10 min. The mixture was stirred for 30 
min, when 1HNMR showed isomerization of the double bond. Water (55 mL) and I2 (5.66 g, 22.4 
mmol) were added. The mixture was stirred for 15 min, then  10% aq. NaS2O3 (80 mL) was added 
and the product was extracted with DCM (120 mL for 3 times). Organic layers were unified, 
washed with 5% NaHCO3 (150 mL), H2O (150 mL) and brine (150 mL), then dried with Na2SO4 
and concentrated under vacuum. The deallyled intermediate was purified on silica gel 
(hexane/AcOEt 80:20→60:40) to afford 4.05g of foregoing product, which was dissolved in DCM 
(90 mL), then CCl3CN (5.5 mL, 55.67 mmol) and DBU (0.41 mL, 2.78 mmol) were added. The 
mixture was stirred for 3h, concentrated under vacuum and purified by flash chromatography 
(hexane/AcOEt + 1% TEA 70:30). Compound 32 was recovered in 85% yield after two steps. The 
insertion of trichloroacetimidate was confirmed by 1HNMR and the compound was immediately 
used in the next step to preserve the trichloroacetimidate from hydrolysis. 
1HNMR: (CDCl3, 400 MHz): δ = 8.65 (s, 1H, NH), 7.85-7.75 (m, 4H, Ph-Nap), 7.51-7.47 (m, 3H, 
Ph-Nap), 7.38-7.31 (m, 5H, Ph), 6.20 (d, 1H, J1,2 = 1.6 Hz, H-1), 5.53 (dd, 1H, J1,2 = 2.0 Hz, J2,3 = 
3.2 Hz, H-2), 4.99 (d, 1H, J = 10.0 Hz, PhCHH), 4.91 (d, 1H, J = 10.8 Hz, PhCHH), 4.76 99 (d, 1H, 
J = 11.2 Hz, PhCHH), 4.69 99 (d, 1H, J = 10.8 Hz, PhCHH),4.06 (dd, 1H, J2,3 = 2.4 Hz, J3,4 = 9.2 
Hz, H-3), 3.99-3.92 (m, 1H, H-5), 3.57 (t, 1H, J3,4 = 9.2 Hz, H-4), 2.23 (s, 3H, CH3CO), 1.38 (d, 
3H, J5,6 = 6.0 Hz, H-6).  
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3-(benzyloxycarbonyl)-3-N-benzyl-aminopropyl (2-O-acetyl-4-O-benzyl-3-O-naphthylmethyl-
α-rhamnopyranosyl)-(1-3)-2,4-di-O-benzyl-α-rhamnopyranoside [33]. 
To a stirred solution of acceptor 22 (1.86 g, 2.97 mmol) and donor 32 (1.29 g, 2.23 mmol) in DCM 
(29 mL) containing activated 4 Å molecular sieves (1.86 g), TMSOTf (53.75 μL, 0.297 mmol) was 
added at 0°C. The reaction was stirred at 0°C for 30 min. After neutralization with TEA, the 
mixture was concentrated and purified by flash chromatography (hexane/AcOEt 80:20) to afford 
product 33 in 85% yield. 
1HNMR: (CDCl3, 400 MHz): δ = 7.79-7.73 (m, 3H, Ph-Nap), 7.68-7.63 (m, 1H, Ph-Nap), 7.44-7.40 
(m, 3H, Ph-Nap), 7.38-7.19 (m, 25H, Ph), 5.56 (dd, 1H, J1,2 = 1.6 Hz, J2,3 = 3.2 Hz, H-2
II), 5.18 (s, 
2H, CH2Cbz), 5.11 (d, 1H, J1,2 = 1.2 Hz, H-1
II), 5.00 (d, 1H, J = 10.8 Hz, PhCHH), 4.84 (d, 1H, J = 
11.6 Hz, PhCHH), 4.77 (d, 1H, J = 10.8 Hz, PhCHH), 4.69-4.34 (m, 8H, PhCHH, PhCH2, H-1
I), 
4.08-4.01 (m, 2H, H-3I, H-3II), 3.90-3.84 (m, 1H, H-5II), 3.71-3.56 (m, 4H, O-CHH-CH2-CH2-NH, 
H-2I, H-4I, H-5I), 3.38-3.23 (m, 3H, O-CHH-CH2-CH2-NH, O-CH2-CH2-CH2-NH), 2.13 (s, 3H, 
CH3CO), 1.76 (bs, 2H, O-CH2-CH2-CH2-NH), 1.29 (d, 3H, J5,6 = 6.0 Hz, H-6
I), 1.26 (d, 3H, J5,6 = 
6.4 Hz, H-6II). 13CNMR (CDCl3, 100 MHz): δ = 170.11, 138.81, 138.14, 137.78, 136.74, 135.51, 
133.25, 132.95, 128.59, 128.40, 128.29, 128.09, 127.90, 127.65, 127.35, 126.85, 126.13, 125.96, 
125.82, 99.28 (C-1II), 97.56 (C-1I), 80.91 (C-4I), 80.03 (C-4II), 77.84 (C-2I), 77.74 (C-3I), 77.52 (C-
3II), 75.22, 72.67, 71.82, 69.08 (C-2II), 68.39 (C-5II), 68.21 (C-5I), 67.22, 65.07, 28.37, 21,16, 18.12. 
ESI [M+Na]+= 1024.47. [α]D25 = -49.61˚ (c 1.3, CHCl3).  
 
3-(benzyloxycarbonyl)-3-N-benzyl-aminopropyl (4-O-benzyl-3-O-naphthylmethyl-α-
rhamnopyranosyl-(1-3)-2,4-di-O-benzyl-α-rhamnopyranoside [34]. 
Compound 33 (1.13 g, 1.08 mmol) was dissolved in DCM (10 mL) and a solution 0.1M of 
NaOMe/MeOH was added until pH 9. The mixture was stirred overnight, then neutralized with 
Amberlite (H+ form), filtered and concentrated to afford product 34 in 95% yield. 1HNMR 
confirmed the disappearance of signal at 2.13 ppm.  
 
Allyl (2-O-acetyl-4-O-benzyl-3-O-naphthylmethyl-α-rhamnopyranosyl)-(1-3)-2,4-di-O-benzyl-
α-rhamnopyranoside [35]. 
To a stirred solution of acceptor 30 (2 g, 5.20 mmol) and donor 32 (3.6 g, 6.24 mmol) in DCM (52 
mL) containing activated 4 Å molecular sieves (2 g), TMSOTf (94.11 μL, 0.520 mmol) was added 
at 0°C. The reaction was stirred at 0°C for 30 min. After neutralization with TEA, the mixture was 
concentrated and purified by flash chromatography (hexane/AcOEt 90:10→70:30) to afford product 
35 in 72% yield. 
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1HNMR: (CDCl3, 400 MHz): δ = 7.78-7.71 (m, 3H, Ph-Nap), 7.68-7.63 (m, 1H, Ph-Nap), 7.46-7.40 
(m, 3H,Ph-Nap), 7.39-7.21 (m, 15H, Ph), 5.90-5.80 (m, 1H, CH2-CH=CH2), 5.56 (dd, 1H, J1,2 = 2.0 
Hz, J2,3 = 3.2 Hz, H-2
II), 5.24 (dt, 1H, J1= 1.6 Hz, J2= 2.8 Hz, CH2-CH=CHH), 5.16 (dt, 1H, J1= 1.6 
Hz, J2= 2.8 Hz, CH2-CH=CHH), 5.13 (d, 1H, J1,2 = 1.2 Hz, H-1
II), 4.99 (d, 1H, J = 11.2 Hz, 
PhCHH), 4.85-4.76 (m, 3H, PhCHH, H-1I), 4.67-4.56 (m, 5H, PhCHH), 4.16-4.10 (m, 2H, CHH-
CH=CH2, H-3
I), 4.04 (dd, 1H, J2,3 = 3.6 Hz, J3.4 = 9.2 Hz, H-3
II), 3.95-3.85 (m, 2H, CHH-CH=CH2, 
H-5II), 3.75-3.67 (m, 2H, H-2I, H-5I), 3.60 (t, 1H, J3.4 = 9.0 Hz, H-4
I), 3.47 (t, 1H, J3.4 = 9.2 Hz, H-
4II), 2.12 (s, 3H, CH3CO), 1.33-1.28 (m, 6H, H-6
I, H-6II). 13CNMR (CDCl3, 100 MHz): δ = 169.92, 
135.39, 133.81, 128.39, 128.30, 128.10, 127.92, 127.86, 127.84, 127.68, 127.67, 127.63, 127.53, 
126.85, 126.12, 125.95, 125.83, 117.00, 99.34 (C-1II), 96.80 (C-1I), 80.97 (C-4I), 80.00 (C-4II), 
77.85 (C-3I), 77.77 (C-3II), 77.55 (C-2I), 75.24, 75.16, 72.71, 71.81, 69.08 (C-2II), 68.37 (C-5II), 
68.18 (C-5I), 67.71, 21.03, 18.02 (C-6I), 17.94 (C-6II). ESI: [M+Na]+= 825.99. [α]D25 = +34.66˚ (c 
1.5, CHCl3).  
 
(2-O-acetyl-4-O-benzyl-3-O-naphthylmethyl-α-rhamnopyranosyl)-(1-3)-2,4-di-O-benzyl-α-
rhamnopyranosyl trichloroacetimidate [36]. 
A solution of compound 35 (3 g, 3.74 mmol) in THF (38 mL) containing 1,5-
cyclooctadienebis(methyldiphenylphosphine)-Iridium(I)-hexafluorophosphate (316 mg, 0.374 
mmol) was degassed for 1h, then hydrogen was flown for 10 min. The mixture was stirred for 30 
min, when 1HNMR showed isomerization of the double bond. Water (16 mL) and I2 (1.8 g, 7.48 
mmol) were added. The mixture was stirred for 20 min, then partitioned with 10% NaS2O3 (15 mL) 
and DCM (35 mL for 3 times). Organic layers were unified, washed with 5% NaHCO3 (45 mL), 
H2O (45 mL) and brine (45 mL), then dried with Na2SO4 and concentrated under vacuum. The 
deallyled intermediate was purified on silica gel (hexane/AcOEt 70:30) to afford 2.5g of foregoing 
product, which was dissolved in DCM (32 mL), then CCl3CN (1.97 mL, 19.67 mmol) and DBU 
(0.49 mL, 3.27 mmol) were added. The mixture was stirred for 5h, concentrated under vacuum and 
purified by flash chromatography (hexane/AcOEt + 1% TEA 70:30). Compound 36 was recovered 
in 85% yield after two steps. The insertion of trichloroacetimidate was confirmed by 1HNMR and 
the compound was immediately used in the next step to preserve the trichloroacetimidate from 
hydrolysis. 
1HNMR: (CDCl3, 400 MHz): δ = 8.56 (s, 1H, NH), 7.80-7.66 (m, 4H, Ph-Nap), 7.47-7.41 (m, 3H, 
Ph-Nap), 7.38-7.22 (m, 15H, Ph), 6.28 (d, 1H, J1,2 = 1.6 Hz, H-1
I), 5.58 (dd, 1H, J1,2 = 2.0 Hz, J2,3 = 
3.2 Hz, H-2II), 5.14 (s, 1H-H-1II), 4.99 (d, 1H, J = 11.2 Hz, PhCHH), 4.87 (d, 1H, J = 10.8 Hz, 
PhCHH), 4.81-4.57 (m, 6H, PhCHH), 4.18 (m, 2H, J2,3 = 2.8 Hz, J3.4 = 9.2 Hz H-3
I,), 4.01 (dd, 1H, 
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J2,3 = 3.6 Hz, J3.4 = 9.2 Hz, H-3
II), 3.95-3.89 (m, 2H, H-2I, H-5II), 3.83-3.76 (m, 1H, H-5II), 3.71 (t, 
1H, J3.4 = 9.0 Hz, H-4
I), 3.47 (t, 1H, J3.4 = 9.2 Hz, H-4
II), 2.13 (s, 3H, CH3CO), 1.36 (s, 3H, J5,6 = 
6.4 Hz, H-6I), 1.24 (s, 3H, J5,6 = 6.0 Hz, H-6
I). 
 
3-(benzyloxycarbonyl)-3-N-benzyl-aminopropyl (2-O-acetyl-4-O-benzyl-3-O-naphthylmethyl-
α-rhamnopyranosyl)-(1-3)-(2,4-di-O-benzyl-α-rhamnopyranosyl)-(1-2)-(4-O-benzyl-3-O-
naphthylmethyl-α-rhamnopyranosyl)-(1-3)-2,4-di-O-benzyl-α-rhamnopyranoside [37]. 
To a stirred solution of disaccharide acceptor 34 (1.27 g, 1.26 mmol) and disaccharide donor 36 
(1.36 g, 1.51 mmol) in DCM (12.6 mL) containing activated 4 Å molecular sieves (1 g), TMSOTf 
(22.8 μL, 0.126 mmol) was added at 0°C. The reaction was stirred at 0°C for 1h. After 
neutralization with TEA, the mixture was concentrated and purified with Biotage SNAP 50g 
column (hexane/AcOEt 0→100%) to afford tetrasaccharide 37 in 87% yield. 
1HNMR: (CDCl3, 400 MHz): δ = 7.79-7.60 (m, 4H, Ph-Nap), 7.46-7.12 (m, 46 H, Ph-Nap, Ph), 
5.58 (dd, 1H, J1,2 = 1.6 Hz, J2,3 = 3.2 Hz, H-2
IV), 5.17 (s, 2H, CH2Cbz), 5.13 (d, 1H, J1,2 = 1.6 Hz, 
H-1IV), 5.08 (d, 1H, J1,2 = 1.6 Hz, H-1
III), 5.02 (d, 1H, J1,2 = 1.6 Hz, H-1
II), 4.95 (dd, 1H, J1 = 4.4 
Hz, J1 = 10.8 Hz, PhCH2), 4.85-4.51 (m, 14H, PhCH2, H-1
I), 4.48-4.34 (m, 5H, PhCH2), 4.15 (dd, 
1H, , J2,3 = 3.2 Hz, J3.4 = 9.6 Hz, H-3
III), 4.03-3.93 (m, 4H, H-2II, H-3II, H-3IV, H-5III) 3.89-3.67 (m, 
5H, H-2III, H-2I, H-3I, H-5II, H-5IV), 3.66-3.52 (m, 3H, O-CHH-CH2-CH2-NH, H-4
III, H-5I), 3.51-
3.40 (m, 3H, H-4II, H-4I, H-4IV), 3.37-3.20 (m, 3H, O-CHH-CH2-CH2-NH, O-CH2-CH2-CH2-NH), 
2.11 (s, 3H, CH3CO), 1.76 (bs, 2H, O-CH2-CH2-CH2-NH), 1.27 (s, 3H, J5,6 = 6.4 Hz, H-6
IV), 1.23 
(s, 3H, J5,6 = 6.4 Hz, H-6
III), 1.18 (s, 3H, J5,6 = 6.0 Hz, H-6
I), 1.12 (s, 3H, J5,6 = 6.0 Hz, H-6
II). 
13CNMR (CDCl3, 100 MHz): δ = 170.07, 138.86, 138.76, 138.34, 138.18, 138.05, 137.80, 135.62, 
135.49, 133.32, 133.24, 133.05, 129.99, 128.68, 128.65, 128.46, 128.40, 128.37, 128.31, 128.26, 
128.16, 127.99, 127.95, 127.81, 127.80, 127.74, 127.68, 127.62, 127.60, 127.46, 127.40, 126.91, 
126.65, 126.21, 126.02, 125.98, 125.90, 125.89, 100.90, 99.25, 99.02, 97.45, 81.05, 80.78, 80.54, 
80.02, 79.78, 78.66, 78.19, 78.09, 77.89, 76.70, 75.40, 75.28, 75.24, 75.09, 72.64, 72.25, 71.91, 
69.10, 69.83, 69.84, 68.30, 68.18, 67.27, 65.12, 43.84, 28.35, 21.11, 18.19, 18.04, 18.02, 8.01. ESI 
[M+Na]+= 1768.89. [α]D25 = -53.40˚ (c 1.0, CHCl3).  
 
3-(benzyloxycarbonyl)-3-N-benzyl-aminopropyl (2-O-acetyl-4-O-benzyl-α-rhamnopyranosyl)-
(1-3)-(2,4-di-O-benzyl-α-rhamnopyranosyl)-(1-2)-(4-O-benzyl-α-rhamnopyranosyl)-(1-3)-2,4-
di-O-benzyl- α-rhamnopyranoside [38]. 
To a solution of compound 37 (1.91 g, 1.09 mmol) in MeOH/DCM 4:1 (11 mL) DDQ (989 mg, 
4.36 mmol) freshly crystallized from CHCl3 was added. The mixture was stirred for 6h, then 
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quenched with a solution of 15% NaHCO3 (5 mL). Product 37 was extracted three times with DCM 
(10 mL). Organic layers were unified and washed with H2O (10 mL) and brine (10 mL), dried with 
Na2SO4 and concentrated under reduced pressure. The mixture was purified with Biotage SNAP 
50g column (hexane/AcOEt 0→100%). Yield = 78%.  
1HNMR: (CDCl3, 400 MHz): δ = 7.39-7.22 (m, 40H, Ph), 5.26 (dd, 1H, J1,2 = 1.6 Hz, J2,3 = 3.2 Hz, 
H-2IV), 5.18 (s, 2H, CH2Cbz), 5.13 (s, 1H, H-1
III) 5.09 (s, 1H, H-1IV) 4.96 (d, 1H, J1,2 = 1.6 Hz, H-
1II) 4.86-4.77 (m, 3H, PhCHH), 4.73-4.53 (m, 12H, PhCHH, H-1I), 4.15-4.09 (m, 2H, H-3II, H-3IV), 
4.02-3.97 (m, 2H, H-3I H-3III), 3.90 (bs, 1H, H-2III), 3.87-3.77 (m, 4H, H-2II, H-5I, H-5II, H-5IV), 
3.69 (bs, 1H, H-2I), 3.65-3.51 (m, 4H, O-CHH-CH2-CH2-NH, H-4
II, H-4III, H-5III), 3.38-3.20 (m, 
5H, O-CHH-CH2-CH2-NH, O-CH2-CH2-CH2-NH, H-4
I, H-4IV) 2.11 (s, 3H, CH3CO), 1.77 (bs, 2H, 
O-CH2-CH2-CH2-NH), 1.30 (s, 3H, J5,6 = 6.4 Hz, H-6
IV), 1.23 (s, 3H, J5,6 = 6.4 Hz, H-6
I), 1.20 (s, 
3H, J5,6 = 6.0 Hz, H-6
III), 1.15 (s, 3H, J5,6 = 6.0 Hz, H-6
II). 13CNMR (CDCl3, 100 MHz): δ = 170.55, 
139.53, 138.39, 138.14, 138.12, 137.91, 137.74, 128.58, 128.44, 128.41, 128.37, 128.36, 127.86, 
127.81, 127.75, 127.72, 127.67, 127.60, 100.55, 99.67, 98.57, 97.42, 82.34, 81.50, 80.96, 80.57, 
79.27, 78.12, 77.67, 75.00, 74.81, 72.67, 72.57, 72.35, 71.39, 70.42, 68.83, 68.15, 67.93, 67.92, 
67.19, 65.21, 20.94, 18.13, 18.12, 18.03, 17.96. ESI: [M+Na]+= 1488.97. [α]D25 = -30.28˚ (c 2.5, 
CHCl3).  
 
1,3,4,6-tetra-O-acetyl-2-deoxy-2-phthalimido-β-D-glucopyranose [43]  
D-Glucosamine hydrochloride (50g, 231.8 mmol) was dissolved in MeOH (500 mL). The solution 
was cooled down to 0°C and NaOMe (13.6 g, 251 mmol) was added. The mixture was stirred for 
10min, then phthalic anhydride (20 g, 135.0 mmol) was introduced slowly. After 20min at 0°C, 
TEA (25 mL) was added and the mixture was stirred overnight at room temperature.  
The solution was cooled down to 0°C, phthalic anhydride (20 g, 135.0 mmol) was added slowly and 
the mixture was stirred overnight at room temperature. 
The reaction was co-evaporated with toluene for three time. The crude was dissolved in pyridine 
(350 mL), cooled down to 0°C and acetic anhydride (150mL) was added slowly. The reaction was 
stirred overnight at room temperature. The mixture was concentrated under vacuum and partionated 
from CHCl3 (300 mL) and HCl 5% (120 mL). The organic layer was washed with brine (120 mL), 
concentrated, dried with Na2SO4 and purified by flash chromatography (hexane/AcOEt 60:40). The 
product 43 was obtained in α/β mixture (40% α-anomer) in yield = 47%.  
1HNMR: (CDCl3, 400 MHz): δ = 7.82-7.76 (m, 2H, Phth), 7.71-7.67 (m, 2H, Phth), 6.44 (d, 1H, J1,2 
= 9.2 Hz, H-1), 5.82 (dd, 1H, J1,2 = 9.2 Hz, J2,3 = 10.8 Hz, H-2), 5.14 (t, 1H, J3,4 = 10.0 Hz, H-4), 
4.40 (dd, 1H, J2,3 = 10.7 Hz, J3,4 = 10.2 Hz, H-3), 4.29 (dd, 1H, J5,6 = 4.0 Hz, J6,6 = 12.0 Hz, H-6a), 
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4.05 (dd, 1H, J5,6 = 4.0 Hz, J6,6 = 12.0 Hz, H-6b), 3.97-3.94 (m, 1H, H-5), 2.04 (s, 3H, CH3CO), 
1.97 (s, 3H, CH3CO), 1.92 (s, 3H, CH3CO), 1.79 (s, 3H, CH3CO). 
 
Characterization in agreement to D. Bednarcyk et al. Carbohydrate Research, 2013, 367, 10-17. 
 
p-Methoxyphenyl 3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-β- D-glucopyranoside [44]. 
Compound 43 (17 g, 35.6 mmol) was dissolved in DCM (60.0 mL) at 0°C with 4Å activated 
molecular sieves (40 g) and stirred for 10 min under nitrogen. Para-methoxyphenol (25 g, 201.4 
mmol) and BF3·Et2O (24 mL, 194.5 mmol) were added at 0°C. After 1 h, the mixture was allowed 
to warm up to room temperature. Stirring was continued for further 24 h. TEA was added, solid was 
filtered off and the solvent removed at reduced pressure. The crude was purified with Biotage 
SNAP 100g column (hexane/AcOEt (0→100%); yield = 89%. 
1HNMR (400 MHz, CDCl3): δ = 7.80-6.66 (m, 8H, Ar), 5.81 (m, 2H, H-1, H-3) , 5.19 (t, 1H, J3,4 = 
9.7 Hz, H-4), 4.50 (dd, 1H, J1,2 = 8.6 Hz, J2,3 = 10.6 Hz, H-2), 4.29 (dd, 1H, J5,6 = 5.3 Hz, J6,6 = 
12.3 Hz, H-6a) , 4.16 (dd, 1H, J5,6 = 1.9 Hz, J6,6 = 12.3 Hz, H-6b), 3.90-3.86 (m, 1H, H-5), 3.66 (s, 
3H, OCH3), 2.04 (s, 3H, CH3CO), 1.98(s, 3H, CH3CO), 1.82 (s, 3H, CH3CO), 
13CNMR (100 MHz, 
CDCl3): δ = 134.4-114.4 (C-Ar), 97.5 (C-1), 72.0 (C-5), 70.7 (C-3), 68.9 (C-4), 62.0 (C-6), 55.6 
(OCH3), 54.5 (C-2), 20.8, 20.7, 20.5. ESI MS m/z [M+Na]+ = 564.14. [α]D25 = +63.04˚ (c 1.3, 
CHCl3).  
 
p-Methoxyphenyl 4,6-O-benzylidene-2-deoxy-2-phthalimido-β- D-glucopyranoside [45].  
Sodium methoxide (until pH 9) was added to a stirred mixture of compound 44 (18.0 g, 35.6 mmol) 
in methanol (40 mL). After 20 hours the reaction was quenched with Dowex 50WX2. After the 
filtration of the resin, the filtrate was evaporated under reduced pressure. 
To the crude material acetonitrile (30 mL), benzaldehyde dimethyl acetal (6.9 mL, 68 mmol) and 
para-toluenesulfonic acid (0.470 g, 2.73 mmol) were added. After 3 h the reaction was quenched 
with triethylamine (4.7 mL), and the mixture was evaporated under reduced pressure. The crude 
was purified by flash chromatography (hexane/AcOEt 50:50) to afford 45 in, 84 % yield 
1HNMR (400 MHz, CDCl3) δ 7.95-6.77(m, 13H, H-Ar), 5.84 (d, 1H, J1,2 = 8.5 Hz, H-1), 5.62 (s, 
1H, PhCH), 4.74 (dd, 1H, J2,3 =8.5 Hz, J3,4 = 10.3 Hz, H-3), 4.54 (dd, 1H, J1,2 =8.5 Hz, J2,3 = 10.7 
Hz, H-2), 4.44 (dd, 1H, J5,6 = 4.5 Hz, J6,6 = 10.7 Hz, H-6a), 3.90 (t, 1H, J6,6 = 9.8 Hz, H-6), 3.81-
3.66 (m, 5H, H-4, H-5, OCH3).
13CNMR (100 MHz, CDCl3): δ = 134.4-112.8 (C-Ar), 102.07 
(CHPh), 98.10 (C-1), 82.04 (C-4), 68.69 (C-3), 68.63 (C-6), 66.32 (C-5), 56.47 (C-2), 55.70 
(OCH3). [α]D25 = +64.10˚ (c 1.2, CHCl3). 
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3-O-benzyl-4,6-O-benzylidene-2-deoxy-2-phthalimido-β- D -glucopyranosil 
trichloroacetimidate [46]. 
Sodium hydride (285 mg, 11.91 mmol) was added to a stirred solution of compound 45 (5 g, 9.93 
mmol) in DMF (20 mL) at 0°C under argon. After 15 min benzyl bromide (2.08 mL, 13.90 mmol) 
was added, and the mixture was allowed warming to room temperature. After 2 h methanol (15 mL) 
was added, and the mixture was evaporated under reduced pressure. The product was dissolved in 
AcOEt (30 mL) and washed with NaHCO3 (15 mL) and brine (15 mL), dried with Na2SO4 and 
evaporated under reduced pressure. The crude was purified with Biotage SNAP 50g column 
(hexane/AcOEt 0→100%) to afford 46 in 82% yield.  
1HNMR (400 MHz, CDCl3): δ = 7.78- 6.74 (m, 18H, H-Ar), 5.77 (d, 1H, J1,2 = 7.9 Hz, H-1), 5.68 
(s, 1H, CHPh), 4.86 (d, 1H, J = 12.4 Hz, CHHPh), 4.57 (d, 1H, J = 12.4 Hz, CHHPh), 4.53-4.48 (m, 
2H, H-3, H-2), 4.45 (dd, 1H, J5,6  = 4.9, J6,6 =  10.4 Hz, H-6a), 3.98-3.88 (m, 2H, H-4, H-6), 3.80-
3.74 (m, 1H, H-5), 3.73 (s, 3H, OCH3). 
13CNMR (100 MHz, CDCl3): δ = 134.00-114.53 (C-Ar), 
101.40 (CHPh), 98.00 (H-1), 83.00 (C-4), 74.20 (CH2Ph), 74.51 (C-3), 68.74 (C-6), 55.74 (C-2), 
66.30 (C-5), 55.60 (OCH3). ESI MS m/z [M+Na]
+ = 616.18. [α]D25 = +65.17˚ (c 1.1, CHCl3). 
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3-O-benzyl-4,6-O-benzylidene-2-deoxy-2-phthalimido-α,β-D-glucopyranosyl 
trichloroacetimidate [41].  
Cerium ammonium nitrate (9.1 g, 16.68 mmol) was added to a stirred solution of compound 46 (4.9 
g, 8.34 mmol) in acetonitrile/H2O 4:1 (80 mL) at 0°C. After 3 h, TLC (hexane/AcOEt 60:40) 
showed the disappearance of the starting material and the formation of one major spot. The reaction 
was washed with a solution of 10% NaHCO3 (40 mL two times) and brine (40 mL) and the 
combined organic phases were dried with Na2SO4 and evaporated under reduced pressure. The 
crude (3.65 g, 7.50 mmol) was dissolved in DCM (35 mL) and CCl3CN (4.51 mL, 45.0 mmol) and 
DBU (0.335 mL, 2.25 mmol) were added. The mixture was stirred for 2h, then concentrated under 
reduced pressure and the crude was purified by flash chromatography (hexane/AcOEt 60:40) to 
afford 41 in 70% yield in 1:2 α/β ratio. The presence of trichloroacetimidate was confirmed by 
1HNMR and the product 41 was immediately used in the next step to preserve trichloroacetimidate 
from the hydrolysis.  
1HNMR (400 MHz, CDCl3): δ = 8.5 (s, 1H, NH) 7.62-6.80 (m, 14H, H-Ar), 6.42 (d, 1H, J1,2 = 8.4 
Hz, H-1β), 6.30 (d, J1,2 =3.8 Hz, H-1α), 5.60 (s, CHPhα), 5.57 (s, 1H, CHPhβ), 5.46 (t, H-3α) , 4.95 
(d, 1H, J = 11.1 Hz, CHHPhα), 4.75 (d, 1H, J = 12.4 Hz, CHHPhβ), 4.62 (d, 1H, J = 11.1 Hz, 
CHHPhα), 4.56 (dd, H-2α), 4.94-4.36 (m, H-2β, H-3β, CHHPhβ, H-6aβ), 4.31 (dd, H-6aα), 4.18-4.12 
(m, H-5α), 3.86-3.76 (m, H-4α, H-6bα, H-4β, H-5β, H-6bβ). 
 
3-(benzyloxycarbonyl)-3-N-benzyl-aminopropyl [(3-O-benzyl-4,6-O-benzylidene-2-deoxy-2-
phthalimido-β-D-glucopyranosyl)]-(1-3)-(2-O-acetyl-4-O-benzyl-α-rhamnopyranosyl)-(1-3)-(2,4-di-
O-benzyl-α-rhamnopyranosyl)-(1-2)-[(3-O-benzyl-4,6-O-benzylidene-2-deoxy-2-phthalimido-β-D-
glucopyranosyl)]-(1-3)-(4-O-benzyl-α-rhamnopyranosyl)-(1-3)-2,4-di-O-benzyl-α-rhamnopyranoside 
[42].  
To a stirred solution of tetrasaccharide acceptor 38 (367 mg, 0.250 mmol) and monosaccharide 
donor 41 (633 mg, 1.002 mmol) in DCM (2.5 mL) containing activated 4 Å molecular sieves (200 
mg), TMSOTf (11.13 μL, 0.050 mmol) was added at 0°C. The reaction was stirred at 0°C for 6h. 
After neutralization with TEA, the mixture was concentrated and purified with Biotage SNAP 50g 
column (toluene/AcOEt 0→100%) and with a second Biotage SNAP 25g column (hexane/AcOEt 
0→100%) to afford the hexasaccharide 42 in 47% yield. 
1HNMR (400 MHz, CDCl3): δ = 7.58-6.66 (m, 68H, Ph), 5.53 (s, 1H, H-1, Rha), 5.41 (bs, 1H, H-
2IV, Rha), 5.38 (d, 1H J1,2 =7.2 Hz, H-1, GlcN), 5.33 (d, 1H, J1,2 =7.2 Hz, H-1, GlcN), 5.23 (s, 1H, 
H-1, Rha), 2.65 (s, 2H, CH2Cbz), 5.03-4.95 (m, 3H, H-1, Rha, PhCHH), 4.87 (s, 1H, H-1, Rha), 
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4.81-4.58 (m, 7H, PhCHH), 4.49-3.84 (m, 22H, PhCHH, HRha, HGlcN), 3.79-3.47 (m, 11H, O-
CHH-CH2-CH2-NH, HRha, HGlcN), 3.41-3.14 (m, 8H, O-CHH-CH2-CH2-NH, O-CH2-CH2-CH2-
NH, HRha, HGlcN), 2.12 (s, 3H, CH3CO), 1.72 (bs, 2H, O-CH2-CH2-CH2-NH), 1.24-1.14 (m, 9H, 
H-6, Rha), 0.95 (d, J5,6 = 6.0 Hz, H-6, Rha). 
13CNMR (100 MHz, CDCl3): δ = 133.54, 133.39, 
128.72, 128.53, 128.45, 128.27, 128.25, 128.14, 127.98, 127.97, 127.84, 127.71, 127.33, 127.28, 
127.22, 126.47, 126.26, 126.22, 101.26, 100.92, 100.61, 99.03, 98.74, 98.02, 82.91, 82.67, 82.47, 
82.32, 79.64, 79.60, 79.59, 79.55, 79.53, 79.51, 77.21, 77.01, 74.55, 74.30, 74.31, 74.02, 68.72, 
68.07, 68.06, 68.05, 68.04, 65.45, 65.07, 56.09, 55.87, 20.74, 18.13, 17.97, 17.88, 17.84. 
MALDI: [M+Na]+= 2322.13. [α]D25 = -20.86˚ (c 1.1, CHCl3). 
 
3-aminopropyl [(2-deoxy-2-acetamido-β-D-glucopyranosyl)]-(1-3)-(α-rhamnopyranosyl)-(1-3)-(α-
rhamnopyranosyl)-(1-2)-[(2-deoxy-2-acetamido-β-D-glucopyranosyl)]-(1-3)-(-L-
rhamnopyranosyl)-(1-3)-α-L-rhamnopyranoside [3].  
Compound 42 (282 mg, 0.118 mmol) was dissolved in EtOH (4 mL) and etylendiamine (400 μL) 
was added. The solution was stirred overnight at 100°C. HP-TLC (toluene/AcOEt 60:40 + 0.1% 
TEA) showed the disappearance of starting material and the formation of main spot (Rf = 0.5).  the 
solvent was co-evaporated with toluene, then the crude was dissolved in pyridine (2 mL) and cooled 
at 0°C. Acetic anhydride (2 mL) was added slowly and the solution was stirred overnight at room 
temperature. The TLC (hexane/AcOEt 70:30) showed the formation of a main spot (Rf = 0.4). The 
solvent was co-evaporated with toluene and purified with Biotage SNAP 25g column 
(hexane/AcOEt 0→100%). The foregoing product (257 mg, 0.115 mmol) was dissolved in MeOH 
(2 mL) and NaOMe was added until pH 9. The mixture was stirred for 5h, then neutralized with 
Amberlite (H+ form), filtered and concentrated under reduced pressure. The intermediate (114 mg) 
was hydrogenated (H2 pressure: 3 bar) in H2O/EtOH 4:1 (3 mL) in the presence of 10% Pd/C (100 
mg). The reaction was stirred at room temperature for 2 weeks, when 1HNMR showed the 
disappearance of aromatic signals. The mixture was filtered through a celite pad, concentrated 
under vacuum, then lyophilized to afford product 3 in 40% yield after three steps. 
1HNMR (400 MHz, CDCl3): δ = 5.18 (s, 1H, H-1III, Rha), 5.07 (s, 1H, H-1II, Rha), 5.02 (s, 1H, H-
1IV, Rha), 4.76 (s, 1H, H-1I, Rha), 4.71 (d, 1H, J1,2 =7.2 Hz ,H-1, GlcN), 4.69 (d, 1H, J1,2 =7.2 Hz 
,H-1, GlcN), 4.29, 4.26 (m, 2H, H-2II, H-2IV, Rha), 4.07 (bs, 1H, H-2III, Rha), 3.99-3.89 (m, 4H, H-
3II, H-3IV, Rha, H-6I, H-6II, GlcNAc), 3.83-3.67 (m, 8H, HRha, HGlcNAc), 3.57-3.42 (m, 8H, O-
CHH-CH2-CH2-NH, HRha, HGlcNAc), 3.21-3.05 (m, 3H, O-CHH-CH2-CH2-NH, O-CH2-CH2-
CH2-NH), 2.02 (s, 3H, CH3NH), 2.01 (s, 3H, CH3NH), 1.80 (bs, 2H, O-CH2-CH2-CH2-NH), 1.30-
1.25 (m, 12H, H-6, Rha).  
83 
 
 
Characterization in agreement to M. Johnson, M. Pinto, J. Am. Chem. Soc., 2002, 124, 15368-
15374. 
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